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CHAPTER 1 
INTRODUCTION 

INTRODUCTION 
Most haematological malignancies originate from immunocompetent cells 
and are as such associated with an Impaired host defence. This Impairment 
will be Increased by aggressive chemotherapy, radiotherapy and bone 
marrow transplantat ion (1-3). These treatment modalities often require 
disruption of the integument for access of the bloodstream, induce 
granulocytopenia, and damage the mucosal barrier, especially In the 
oropharynx and the remainder of the gastrointestinal t ract , and the 
respiratory tract. Furthermore, severe thrombocytopenia, as a result of bone 
marrow invasion a n d / o r bone marrow ablative therapy, may lead to 
haemorrhagic complications, which potentially Increase the organ damage. 
Moreover, patients who receive an allogeneic bone marrow transplantation 
will be subjected to a longstanding Impairment of both humoral and cellular 
Immunity (4-7). 
CONSEQUENCE OF IMPAIRED IMMUNITY". Infection still const i tutes a 
major problem in patients treated for a haematological malignancy and a 
high morbidity and mortality must be anticipated (8-11). Improvement of the 
survival of these patients Is at least partly due to better supportive therapy 
such as tlje availability of donor bloodproducts and enhanced knowledge of 
possible infectious complicat ions. Better diagnostic facilities and 
antimicrobial agents have allowed the employment of a more aggressive 
antltumour strategy. Fever will occur in approximately 80 percent of patients 
with a granulocytopenia of more than seven days. Diagnostic facilities for 
Infections have been Improved, but are still Inadequate to ascertain the cause 
of fever in many cases. About 30-40% of the patients will experience fever of 
unknown origin, in 20-30% bacteraemia will be detected and in the 
remaining 20-40% localised Infection will be diagnosed, mainly affecting the 
skin, soft tissues and lower respiratory tract (12). The spectrum of pathogens 
causing bacteraemia is changing: the incidence of Gram-positive Infections 
has Increased over the past decade as a result of several factors (10, 13) 
including selective oral antibacterial prophylaxis (14-16), the use of 
indwelling catheters (17-21) and intensification of cytostatic therapy 
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resulting In extensive mucosal damage (22. 23). Escherichia coli. Klebsiella 
spec ies a n d Pseudomonas aeruginosa remain the predominant Gram-
negative pathogens, whereas filamentous fungi and yeasts are a difficult to 
diagnose common cause of subsequent Infections which are frequently 
refractory to therapy (24). 
FEVER Fever cüone is the most frequent presenting sign of an infection. 
Typically, the low number of granulocytes is responsible for a limited 
Inflammatory response resulting in mute other symptoms and signs of 
infection (25). Since there is no reliable way to distinguish fever of an 
infectious origin from that due to other causes, it is mandatoiy to administer 
broad-spectrum antibiotics as soon as a rise in body temperature has been 
registered In order to prevent early mortality from a possible Gram-negative 
infection. 
EMPIRIC THERAPY. The so-called empiric therapy of the febrile granulocy-
topenic patient is still a generally accepted strategy which was proposed in 
1971 by Schlmpff et al (26). For the past two decades, combination of a ß-
lactam antibiotic and an aminoglycoside at first sign of infection in the 
neutropenic patient has been the cornerstone of empiric antimicrobial 
therapy (27-29). These combinations have obtained popularity because of the 
extended spectrum, the bactericidal activity, and synergism. Such an 
approach produced a clinical response rate of approximately 75%. Although 
over 170 trials, Including large numbers of patients and numerous different 
regimens, have been performed, no particular combination has been shown 
to be consistently superior. Moreover, three-drug regimens have not proved 
to be more effective than two-drug schedules (30). The results of the various 
studies, however, are often difficult to compare because the definitions of 
infections and criteria for outcome may vary widely (31-33). However, the 
traditional combinations carry severed drawbacks such as the suboptimal 
efficacy of the aminoglycosides in severe granulocytopenia (34) and the 
potential toxicity to the ear (35) and kidney (36), which is Important in view 
of the increasing employment of drugs with similar toxicity like cyclosporin 
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A, cisplatlnum and amphotericin B. The double ß-lactam combinations have 
decreased the risks of oto- and nephrotoxicity, yet they suffered from their 
own adverse events; ß-lactams may be bone marrow suppressive, they may 
act antagonistically against certain Gram-negative bacilli, and emergence of 
resistance during therapy was reported. The huge sodium contents may be a 
disadvantage, especially in elderly people, and, finally, the costs are high. 
During the last few years the option of monotherapy h a s reattracted 
attention. The efficacy of monotherapy was comparable to that of standard 
antibiotic regimens. Most trials exploring the potential of single agents for 
this purpose have used ceftazidime in the single agent arm (8, 37-41), followed 
by imipenem (42-44). In fact, the first trial on the feasibility of empiric 
therapy with a modem antibacterial agent as monotherapy was performed at 
our institute (45); the favourable results fostered a subsequent series of 
prospective, randomised studies assessing the options and limitations of this 
approach (46). A recently published meta-analysis on the efficacy of 
ceftazidime as a single agent in comparison with combination regimens 
corroborates that a significant diiTerence between these strategies is unlikely 
(47). 
POSSIBILITIES FOR AN INDIVIDUAL APPROACH. Inter-hospital variations 
have to be kept in mind when a basic empiric regimen Is selected. While local 
situations have been accepted as a modus for individualisation, presenting 
symptoms of infection in a patient have not gained acceptance so far. 
Probably it is not correct to consider the neutropenic patients with fever as a 
homogeneous group (48). Patients with a clinically and/or microbiologically 
documented infection run a risk different from patients with fever of 
unknown origin. Independent of the empiric regimen chosen, the highest 
mortality will occur among patients with respiratory infections and patients 
presenting with shock. Patients with a pneumonia have consistently had 
substantiaUy lower response rates than patients with other sites of infection 
(49, 50). It is frequently necessary to add antibiotics to an empiric regimen in 
cases with a documented infection. Such additions should not be considered 
automatically, but ought to be guided by the clinical circumstances (33). Since 
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Gram-negative organisms still dominate infections associated with 
hypotension and the lower respiratory tract, combination of a β -lactam 
antibiotic and an adequately dosed aminoglycoside may result in faster 
defervescence, b u t th i s hypothesis is not substant ia ted by adequate 
investigations. Urinary tract infections are dominated by Gram-negative 
organisms and they usually respond very well to the Initial antibiotics. 
Streptococci are the prevalent pathogens in the upper respiratory tract; in 
very severe cases early addition of penicillin or a llncosamlde may result In 
less morbidity (22. 23). A particular, rapidly growing group is that of the 
catheter associated infections (19, 20). A glycopeptide containing regimen 
may be of benefit in patients where coagulase-negative staphylococci, 
methiclllln-resistant Staphylococcus aureus. Corynebacterium species, and 
α-hemolytic streptococci are frequent causes of fever. Two opinions prevail 
a s to their inclusion in the initial regimen. One contends that a drug like 
vancomycin can be added later if Gram-positive bacteria are Isolated or If no 
response is accomplished. The second opinion claims that addition from the 
start will provide earlier effective treatment. Support for both approaches is 
found in the literature (51-53). If there is reason to suspect methicillln 
resistant S.aureus, vancomycin or teicoplanln should be Included in the 
Initial regimen. Indiscriminate use of glycopeptldes does not contribute to 
the chances of cure for the patient and should be avoided. The potential 
toxicity is not insignificant and they remain expensive antibiotics. 
RESPONSE TO EMPIRIC THERAPY. In fact empiric antibiotic therapy is the 
most straightforward part of the antibiotic management of these patients. 
Approximately 70% of the pyrexial episodes, whether infection is 
subsequently documented or not, will respond rapidly and completely to 
antibiotics ( 8. 9. 37, 43, 54-56). The earlier the empiric therapy is started the 
lower the likelihood that an infection will be documented. On the other hand, 
it is also logical to believe that very early therapy might be more effective, as 
it is directed against the initial stages of infections with relatively low 
bacter ia l Inocula. For p a t i e n t s who have a s h o r t d u r a t i o n of 
granulocytopenia, the initial regimen may well suffice for the entire 
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treatment period. For patients who remain granulocytopenic for more t h a n 
one week, additions or modifications of therapy are required with a 
frequency proportional to the length of the granulocytopenia (57). 
INADEQUATE RESPONSE TO EMPIRIC THERAPY. Patients who remain 
febrile despite antibacterial therapy pose a difficult diagnostic and 
therapeutic challenge (33). These patients may have undetected bacterial 
infections that are resis tant to therapy or infections by non-bacterial 
pathogens. If fever persists after broad-spectrum antibacterial therapy for 72 
hours with no clinical or laboratory evidence of a bacterial infection, it is 
unlikely to be due to a Gram-negative organism. Drug or transfusion related 
fever may also occur. Aggressive diagnostic manoeuvres are necessary if 
fever is associated with a deteriorating clinical condition in order to obtain 
objective parameters for the selection of further or other antibiotics. 
Treatment failures are most frequently encountered in pat ients with 
polymicrobial Infections, skin and soft tissue Infections, including Hickman 
line associated infections, in pneumonia and in unremitting underlying 
disease (48). 
Empiric institution of antifungal therapy may be warranted, especially in 
patients on corticosteroids expected to be granulocytopenic for more than a 
week and known to be colonized with fungi (11, 58-60). The exact point at 
which empiric antifungal therapy should be started in the patients with 
persisting fever and granulocytopenia remains uncertain. A chest X-ray 
should be performed in an attempt to Identify a focus of infection. The 
immunocompromised patient with persisting or new pulmonary infiltrates 
represents a diagnostic and therapeutic dilemma. Appropriate management 
is dependent upon distinguishing between opportunistic Infection and other 
causes . Bacteria, viruses, fungi, yeasts, and protozoa are all potential 
pathogens. Moreover, evaluation is complicated by the patient 's altered 
inflammatory response (25) and infiltrates may have a non-infectious 
aetiology including haemorrhage (61), leukaemlc infiltration (62), toxicity 
from antileukaemlc chemotherapy (63, 64), or irradiation (65). Furthermore, 
the infiltrate may represent an early indicator of granulocyte recovery with 
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leukocyte Infiltration into previous sites of Infection. Patients who develop 
infiltrates in conjunction with bone marrow recovery usually do well, but 
when a new local Infiltrate appears and progresses in patients who remain 
granulocytopenic, a fungal aetiology is most likely. A similar consideration 
pertains to patients who present with diffuse infiltrates without significant 
hypoxaemia. Fungal Infections account for 20-30% of all fatal infections in 
patients with acute leukaemia (66). It is the second, third and fourth episodes 
of fever, not unusually caused by fungi, that account for the high overall 
mortality of episodes of fever associated with neutropenia. Although empiric 
antimicrobial therapy with or without subsequen t modifications is 
necessary, the inappropriate prescribing of antibiotics is of concern. In a 
retrospective study the paramount rationale for changes in antibiotics was 
persistent fever (67); pat ients who had a microbiologically documented 
infection did not receive more antibiotics than individuals with fever alone. 
The number of antibiotics administered to patients did not correlate with 
improved survival, bu t in fact was associated with significantly more 
adverse reactions. 
SUMMARY. In summary it may be stated tha t many aspects of the 
management of infectious complications in the patient with susta ined 
granulocytopenia and fever remain unsettled. The options for the treatment 
of bacterial infections have become better with the availability of powerful 
antibiotics, but there is no consensus as yet on how and where to fit them into 
the t reatment schedules. Local c i rcumstances and a more individual 
approach of the febrile granulocytopenic patient, accounting for prognostic 
and complicating factors, may become of increasing Importance thereby 
abandoning the concept that one treatment scheme will fit any patient or 
institution. Invasive fungal and generalized viral Infections remain highly 
problematic. Accurate and early diagnoses are very difficult to make, the 
pathophysiology Is poorly understood, and the possibilities for effective 
treatment are limited. Efforts should be made to upgrade the diagnostic 
methods in order to obtain a reliable diagnosis as early as possible. While 
empiric therapy has become the standard of initial infection management of 
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the neutropenic patient, it is important to recognize the differences between 
patients and centres. The keys to successful patient management are 
meticulous attention to clinical details, repeated examinations, thoughtful, 
continuous consideration of the microbiologic data and recognition of 
Institutional trends. Therefore It was decided to address some of the still 
controversial issues mentioned In this short survey, mainly focusing on the 
putative differences between monotherapy with ceftazidime as a single agent 
and combination of an aminoglycoside and ^- lactams in the treatment of 
presumed bacteraemias and clinically documented Infections, the options 
and limitations of glycopeptldes, and the Impact and consequences of 
localised Infections, notably pulmonary infiltrates. 
17 
REFERENCES 
1. Bodey GP, Bolivar R, Fainstein V. Infectious complications in leukemic 
patients. SeminHematol 1982; 19:193-226. 
2. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med 
1986; 81:243-248. 
3. Armstrong D. Empiric therapy for the immunocompromised host. Rev 
Infect Dis 1991: 13 (suppl 9):S763-9). 
4. Winston DJ, SchiiTman G, Wang DC et aL Pneumococcal Infection after 
h u m a n bone marrow transplantation. Ann Intern Med 1979; 91 : 835-
841. 
5. Al-Eid MA, Tutchka PJ, Wagner HN JR, Santos GW, Tsan MF. 
Functional asplenia in patients with chronic graft-versus-host disease: 
consise communication. J Nucl Med 1983; 24: 1123-1126. 
6. Aucouturier P, Barra A, Intrator L. et al Long lasting IgG subclass and 
antibacterial polysaccharide antibody deficiency after allogeneic bone 
marrow transplantation. Blood 1987; 70: 779-785. 
7. Wingard J R Advances in the management of infectious complications 
after bone marrow transplantat ion. Bone Marrow Transplantat ion 
1990; 6: 371-383. 
8. Pizzo PA, H a t h o m JW. Hiemenz J , Browne M, Cotton D et al. A 
randomised trial comparing ceftazidime alone with combination 
antibiotic therapy in cancer patients with fever and neutropenia. N Engl 
J Med 1986; 315: 552-558. 
9. The EORTC International Antimicrobic Therapy Cooperative Group. 
Ceftazidime combined with a short or long course of amikacin for 
empirical therapy of Gram-negative bacteremia in cancer patients with 
granulocytopenia. N Engl J Med 1987; 317:1692-1698. 
10. Whlmbey E, Kiehn TE.Brannon P, Blevlns A, Armstrong D. Bacteremia 
and fungemia in patients with neoplastic disease. Am J Med 1987; 
82:723-730. 
11. Degregorio MW, Lee WMF, Linker CA, Jacobs RA, Ries CA. Fungal 
infection In patients with acute leukemia. Am J Med 1982; 73:543-548. 
12. Klastersky J , Zinner SH, Calandra Τ, Gaya Η, Glauser MP et al. Empirie 
antimicrobial therapy for febrile granulocytopenic cancer patients: 
lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988; 24 (suppl 
l):S35-45. 
13. Karp JE, Dick JD, Angelopulos C, Charache P, Green L et al. Empiric use 
of vancomycin during prolonged treatment-induced granulocytopenia. 
Am J Med 1986; 81:237-242. 
14. Sleyfer DTh, Mulder NH, De Vries-Hosperen HG et al Infection 
prevention in granulocytopenic patients by selective decontamination 
of the digestive tract. Eur J Cancer 1980; 16:859-869. 
15. Karp J E . Merz WG, Hendricksen С, Laughon В, Redden Τ et al. Oral 
norfloxacin for prevention of Gram-negative bacterial infection in 
patients with acute leukemia and granulocytopenia. Arm Intern Med 
1987; 106:1-7. 
16. Brun-Bulsson C, Legrand Ρ, Rauss A, Richard C, Monravers F et al. 
Intestinal decontamination for controle of nosocomial mult irestant 
Gram-negative bacilli. Ann Intern Med 1989; 110:873-881. 
17. Lowder JN, Lazarus HM, Herzig RH. Bacteraemias and fungaemias in 
oncologic patients with central venous catheters: changing spectrum of 
infection. Arch Inter Med 1982; 142, 1456-1459. 
18 
18. Press OW, Ramsey PG, Larson EB. Hefer A, Kickman RD. Hickman 
catheter Infections In pat ietns with malignancies. Medicine 1984; 
63:189-200. 
19. J o h n s o n PR, Decker MD, Edwards KM, Schaffner W, Wright PF. 
Frequency of Broviac catheter infections in pediatric oncology patients. 
J Infect Dis 1986; 154, 570-578. 
20. Benezra D, Klehn TE, Gold JWM, Brown AE, Tumbull ADM, Armstrong 
D. Prospective study of infection in indwelling central venous catheters 
using quantitative blood cultures. Am J Med 1988; 85:495-498. 
21 . Dickinson, G. M., and A. L. Blsno. Infections associated with indwelling 
devices: concept of pathogenesis ; Infections associa ted with 
Intravascular devices. Antimicrob. Agent Chemother. 1989; 33:597-601. 
22. Cohen J , Donnelly JP . Worsley AM, Catovsky D. Goldman JM, Galton 
DAG. Septicaemia caused by viridans streptococci in neutropenic 
patients with leukaemia. Lancet 1983; 11:1452-1454. 
23. Kem W, Kurrle E, Vanek E. High risk of streptococcal septicemia after 
high dose arablnoside treatment for acute myelogenous leukemia. Kiln 
Wochenschrift 1987; 65:773-780. 
24. Wade J C . Antibiotic therapy for the febrile granulocytopenic cancer 
patient: combination vs. monotherapy. Rev Infect Dis 1989; 11 (suppl 7): 
S1572-1581. 
25. Sickles EIA, Green WH. Wiemlk PH. Clinical presentation of Infections 
in granulocytopenic patients. Arch Intern Med 1975; 135:715-9. 
26. Schimpff S. Satterlee W, Young VM. Serpik A. Empiric therpay with 
carbenicillln and gentamycin for febrile patients with cancer and 
granulocytopenia. N Engl J Med 1971; 284:1061-1065. 
27. Sculler JP , Klastersky J . Significance of serum bactericidal activity in 
Gram-negative baclllary bacteremia in pat ients with and without 
granulocytopenia. Am J Med 1984; 76:429-35. 
28. Klastersky J . Concept of empiric therapy with antibiotic combinations. 
Am J Med 1986; 80 (suppl 5C):2-11. 
29. De Jong CA, Joshi JH, Newman KA, Moody MR, Wharton R, Standford 
HC, Schimpff SC. Antibiotic synergism and response In Gram-negative 
bacterenia In granulocytopenic patients. Am J Med 1986; 80 (suppl 
50:96-111. 
30. Hughes WT, Armstrong D, Bodey GP. Feld R, Mandell GL et aL Guidelines 
for the use of antimicrobial agents in neutropenic pat ients with 
unexpained fever. J Infect Dis 1990; 161:381-396. 
31. Pater JL, Weir L. Reporting the results of randomised trials of empiric 
antibiotics In febrile neutropenic patients: a critical survey. J Clin 
Oncol 1986; 4:346-352. 
32. Elliott CR, Pater JL. The effect of different measures of outcome on the 
resits of studies of empiric antibiotic therapy in febrile neutropenic 
patients. Clin Invest Med 1988; 11:327-330. 
33. Donnelly JP . For debate. Assessment and reporting of clinical trials of 
empirical therapy in neutropenic patients. J Antimicrob Chemother 
1991; 27:377-387. 
34. Bodey GP. Infection In cancer patients: a continuing association. Am J 
Med 1986; 81(suppl 1A): 11-26. 
35. Gatell JM, Ferran F, Araujo V, Bonet M, Sorlano E, Traserra J , 
SanMlguel JG. Univariate and multivariate analyses of risk factors 
p r e d i s p o s i n g to aud i to ry toxici ty In p a t i e n t s receiving 
aminoglycosides. Antimicrob Agents Chemother 1987; 31:1383-1387. 
36. Meyer RD. Risk factors and comparison of clinical nephrotoxicity of 
aminoglycosides. Am J Med 1986; 80 (suppl 6B): 119-124. 
19 
37. Ramhai R Kram.er BS, Rand KH, Wiener K, Shands J. Early results of a 
comparative trial of ceftazidime versus cephalotln, carbenicillin, and 
gentamycln In the treatment of febrile granulocytopenic patients. J 
Antlmlcrob Chemother 1983; 12 (Suppl A):S81-88. 
38 Reilly JT, Brada JT, Belllnham AJ, Bennet С. Ceftazidime compared to 
tobramycin and ticarcillln In Immunocompromised haematological 
patients. J Antlmlcrob Chemother 1983; 12(suppl A):S89-92. 
39. Donnelly JP, Marcus RE, Goldman JM, Cohen J, Worsley AM et cd. 
Ceftazidime as first-line therapy for fever In acute leukaemia. J Infect 
1985; 11:205-215. 
40. Granowetter L, Wells H, Lange В. Ceftazidime with or without 
vancomycin vs. cephalotln, carbenicillin and gentamycln as the Initial 
therapy of the febrile neutropenic pediatric cancer patient. Pediatr 
Infect Dis 1988; 7:165-70. 
41. Hathom JW. Empirical antibiotics for febrile neutropenic cancer 
patients. Eur J Cancer Clin Oncol 1990; 25 (suppl 2):S43-51. 
42. Liang R, Yung R, Chu E, Vhau P-K, Chan TK et αί. Ceftazidime versus 
Imlpenem-cllastin as initial monotherapy for febrile neutropenic 
patients. Antlmlcrob Agents Chemother 1990; 34:1336-13341. 
43. Winston DJ, Ho WG, Young LS, Hewitt WL. Gale RP. Piperacillin plus 
amikacin therpay ν carbenicillin plus amikacin therapy in febrile, 
granulocytopenic patients. Arch Intern Med 1982; 1663-1667. 
44. Rolston KVI, Berkey P, Bodey GP, Analssie EJ. Khardori NM et al A 
comparison of Imipenem to ceftazidime with or without amikacin as 
empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 
152:283-291. 
45. De Pauw BE. Kauw F. Muytjens Η. Williams KJ, Bothof TH. Randomised 
study of ceftazidime versus gentamicln plus cefotaxime for Infection in 
severe granulocytopenic patients. J Antlmlcrob Chemother 1983; 
12(supplA):93-99. 
46. Verhagen CAHHVM. Treatment of bacteriological infections in 
neutropenic patients with special emphasis on ceftazidime 
monotherapy. Thesis; Gent 1987. 
47. Sanders JW. Powe NR, Moore RD. Ceftazidime monotherapy for empiric 
treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 
1991; 164:907-916. 
48. De Pauw BE, Donnelly JP, Verhagen С, Nováková IRÒ. Van Der Meer 
JWM. Towards individually tailored empiric antibiotic therapy In 
febrile granulocytopenic patients. Neth J Med 1990; 37:111-119. 
49. Fainstein V. Bodey GP. Bolivar R. Eltlng L, McCredle KB et al. 
Moxalactam plus ticarcillln of tobramycin for treatment of febrile 
episodes In neutropenic cancer patients. Arch Intern Med 1984; 
144:1766-1770. 
50. Jones PG, Rolston KVI, Fainstein V, Eltlng L, Walters RS et al. 
Aztreonam therapy in neutropenic patients with cancer. Am J Med 
1986; 81:243-248. 
51. Rubin, M., J. W. Hathom, D. Marshall, J. Gress, S. M. Steinberg, and P. 
A. Pizzo. Gram-positive infections and the use of vancomycin In 550 
episodes of fever and neutropenia. Ann Intern Med. 1988; 108:30-35. 
52. Shennep JL, Walter TH, Roberson PK, Blankenship KR. Baker DK et aL N 
Engl J Med 1988; 319:1053-1058. 
53. European Organisation for Research and Treatment of Cancer (EORTC) 
International Antimicrobial Therapy Group and the National Institute 
of Canada Clinical Trials Group. Vancomycin added to empirical 
20 
combination antibiotic therapy for fever In granulocytopenic cancer 
patients. J Infect Dis 1991; 163:951-958. 
54. De Pauw BE, WllHans К, De Neef J, Bothof Τ, De Witte Τ, Holdrlnet R et 
aL A randomized prospective study of ceftazidime plus flucloxaclllin In 
the empirle t reatment of febrile episodes In severly neutropenic 
patients. Antlmlcrob Agents Chemother 1985; 28:824-828. 
55. Kramer BS, Ramphal R, Rand КН. Randomized comparison between two 
ceftazldlme-contalnlng reg imens a n d cephalot ln-gentamycln-
carbenlclllln In febrile granulocytopenic cancer patients. Antlmlcrob 
Agents Chemother 1986; 30:64-68. 
56. Analssle EJ, Falnsteln V, Bodey GP, Rolston K, Eltlng L, Kantarljan H et 
al. Randomised trial of beta-lactam regimens In febrile neutropenic 
cancer patients. Am J Med 1988; 84:581-589. 
57. Pizzo PA. After empiric therapy: what to do until the granulocyte count 
comes back. Rev Infect Dis 1987; 9:214-219. 
58. Pizzo PA, Roblchaud KJ, Wltebsky FG. Empiric antibiotic and fungal 
therapy for cancer patients with prolonged fever and granulocytopenia. 
Am J Med 1982; 72:102-111. 
59. Holleran WM, Wilbur JR. DeGregorio MW. Empiric amphotericin В 
therapy in patients with acute leukemia. Rev Infect Dis 1985; 7:619-624. 
60. EORTC Internat ional Antimicrobial Therapy Cooperation Group. 
Empiric antifungal therapy in febrile granulocytopenic patients. Am J 
Med 1989; 86:668-672. 
61. Robblns RA, Linder J , Stahl MG et aL Diffuse alveolar hemorrhage in 
autologous bone marrow transplant recipients. Am J Med 1989; 87:511-
518. 
62. Kowalski R, Hansen-Flaschen J , Lodato R, Pietra G. Localized leukemic 
pulmonary Infiltrates. Chest 1990; 97:674-678. 
63. Twohlng KJ, Mathay RA. Pulmonary effects of cytotoxic agents other 
than bleomycin. Clin Chest Med 1990; 11:11-31. 
64. Mann H, Ward JH, Samlwskl WE. Vascular leak syndome associated 
with lnterleukln-2: chest radiographic manifestations. Radiology 1990; 
176:191. 
65. Van Dijk J , Keane TJ, Kan S. et al. Radiation pneumonitis following 
large single dose Irradiation: A réévaluation based on absolute dose to 
lung. Int J Radiât Oncol Biol Phys. 1981; 461. 
66. Bodey G, Bueltmann B, Duguld W, Gibbs D, Hanak H et al. Fungal 
Infections In cancer patients: An international autopsy survey. Eur J 
Clin Microbiol Infect Dis 1992; 11:99-109. 
67. O'Hanley P, Easaw J Rugo H, Easaw S. Infectious disease management of 
adult leukemic patients undergoing chemotherapy: 1982 to 1986 
experience at Stanford University Hospital. Am J Med 1989; 87:605-613. 
21 

CHAPTER 2 
OUTLINE OF INVESTIGATION 

OUTLINE OF INVESTIGATION 
This thes is conta ins three pa r t s . The first part evaluates possible 
alternatives of antibacterial therapy for fever in granulocytopenic patients 
with presumed bacteraemla and localised Infections. The entry criteria for 
the trials were varied in order to assess whether patients with different 
presenting symptoms of Infection could benefit from an individually tailored 
approach. Furthermore, the efficacy and safety of a novel glycopeptide, 
teicoplanin, as a supplement to the standard basic regimen of ceftazidime 
monotherapy was assessed. The second part consists of a survey of the 
occurrence and classification of the various types of Infection in the febrile 
granulocytopenic patient. Finally, the third part focusses on the value and 
Implications of radiological examination of the chest In lower respiratory 
infections. 
CHAPTER 3 describes the resul ts of a prospectively randomised s tudy 
comparing the safety and efficacy of ceftazidime alone with that of a 
combination of piperacillin and amikacin In febrile granulocytopenic 
patients with presumed bacteraemla without a presenting clinical focus of 
infection. This category of Infections is dominated by streptococci when 
prophylactic antibacterials are used. The hypothesis was that piperacillin, a 
drug with better intrinsic activity against these organisms, would offer a 
protection superior to that of ceftazidime. 
CHAPTER 4 reports on the resul ts of rescue treatment with the novel 
glycopeptide teicoplanin for pat ients with presumed persist ing Gram-
positive infections not responding to ceftazidime alone or to combinations 
with amikacin. The study was also designed to serve as a phase II study of 
teicoplanin with special attention to toxicity and serumlevels. 
CHAPTER 5 contains the data obtained from the second prospective study. As 
the results of piperacillin in the treatment of Gram-positive infections 
remained below expectation in the previous trial, it was decided to assess the 
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potential of teicoplanin, which had shown to be a promising alternative for 
vancomycin, for th is purpose. Febrile granulocytopenic pat ients with 
presumed bacteraemla were randomly allocated to treatment with either 
ceftazidime alone or to the combination of ceftazidime. Using this strategy 
also the impact of the use of a glycopeptlde up front could be assessed. This 
issue seemed to be relevant in view of the increasing Incidence of coagulase-
negative staphylococci In association with Hickman catheters. 
CHAPTER 6 discloses the results of the third prospectively randomised study 
in granulocytopenic patients with fever and a clinical focus of infection with 
or without concomitant bacteraemla. Previous studies performed at our 
institute had learned that patients with a localised infection responded 
slower and required more additional antibiotics. Moreover, In spite of the 
overall Increasing Incidence of Gram-positive Infections, Gram-negative 
microorganisms were shown to remain the prevalent pathogens In patients 
with a focus, particularly In the lower respiratory tract. Therefore we 
designed a prospective randomised study to assess the putative benefit or 
possible hazards of the addition of an aminoglycoside, amikacin, to 
ceftazidime In the empiric treatment of febrile granulocytopenic patients 
with a clinical focus of Infection at onset of fever. 
CHAPTER 7 is dedicated to the phenomenon of localised infections In the 
febrile neutropenic patient. This subject has gained hitherto relatively 
limited attention in the literature. Different foci of Infection are related with 
different causative pathogens and therefore it is questionable whether one 
and the same empiric regimen will suit every challenge optimally. The onset 
and evolution of the localised Infections In 300 febrile episodes in 210 
granulocytopenic patient was Investigated. Particular attention was paid to 
those clinical foci which emerged later during the febrile episode. The 
purpose of the analysis was to derive data which may be indicative for their 
aetiology, microbiological origin and prognosis in order to enable a more 
individually tailored antibiotic therapy in the future. 
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CHAPTER 8 addresses the problem of occurrence of a pulmonary Infiltrate 
before or during antibiotic therapy, since this phenomenon appeared to be 
related to a dismal prognosis In previous studies. Radiological examination 
of the chest Is an easy and inexpensive diagnostic tool which can be 
performed whenever required. Consequently, it is usually one of the first 
steps in the work-up of a granulocytopenic patient with persisting signs and 
symptoms of infection. The yield of this diagnostic procedure is sometimes 
questioned, but it is doubtful whether the information offered is always 
optimally used. The radiological patterns encountered on a chest X-ray vary 
widely and this could offer a clue to a possible aetiology. As Investigations 
which correlate the results of chest X-ray with clinical findings are very 
scarce, we decided for this purpose to review all chest X-rays made in febrile 
patients with a haematological malignancy who were admitted to our 
institution during the period 1985-1989. 
CHAPTER 9 is similar, but the review has been extended to pulmonary 
Infiltrates emerging on chest X-rays In bone marrow transplant recipients. 
This group of patients was assessed separately because, next to 
granulocytopenia, specific factors such as the presence of grañ-versus-host 
disease, a decreased humoral and cellular Immunity and tissue damage due to 
Irradiation and high dosed chemotherapy could have Influenced the clinical 
and radiological picture. Particular attention was paid to the impact of 
pulmonary Infiltrates on morbidity and mortality. 
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ABSTRACT 
Sixty nine febrile granulocytopenic episodes without an initial focus of 
infection were assessed for empiric t reatment ei ther with high-dose 
amikacin plus piperacillin or ceftazidime. Ninety percent of patients in each 
group survived the granulocytopenic episode; 15 episodes (44 ± 17%) treated 
with the combination and 23 (66 ± 16%) given ceftazidime responded without 
any modification of initial therapy and half defervesced within 72 hours . 
Persistent fever was the most frequent reason for altering treatment which 
was done empirically in 90% of cases, bu t two-thirds of patients required 
further treatment modification. An infectious focus mainly involving the 
lung developed during granulocytopenia in 21 patients (30%), of which 17 
occurred during antimicrobial therapy. Only one infection was shown to be 
due to bacteria, while seven were due to fungi. Amikacin levels were similar 
to those expected following a normal dose (mean peak of 34.7 and mean 
trough of 12.6 mg/1). Therapy with the combination resulted in a higher 
serum creatinine (P<0.001) and a lower potassium level (P<0.001) in 
comparison with monotherapy. Potassium supplementation was required in 
45% of patients given the combination compared with only 4% of those 
treated with ceftazidime. While both regimens appeared to be equally 
effective a s initial therapy, the need for modification was high in both 
patient groups. Monotherapy being both simpler to administer and less toxic 
seems therefore to be the logical choice although the period of empiric 
therapy must be fully exploited in order to improve diagnosis and therefore 
antimicrobial management. 
INTRODUCTION 
The febrile granulocytopenic patient requires prompt administrat ion of 
broad-spectrum empiric antibiotics to minimize the risk of fulminant sepsis 
and early death (1). A large number of antimicrobic agents with comparable 
activity are available today. Therefore it is unlikely tha t appropriately 
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selected empiric regimens will show a significant difference In randomized 
trials (2,3,4). In view of this . Improved tolerance and greater ease of 
adminis t ra t ion seem to be more appropriate goals for investigation. 
Moreover, of those patients Initially treated with empiric antibiotics 20-40% 
will later found not to be infected (5); therefore toxicity must be minimized. 
We decided to assess the possible renal side effects and the efficacy of a 
putatively non-toxic regimen (2,4,6,7,8) in comparison with a s tandard 
combination of an aminoglycoside and a Jî-lactam antibiotic. 
Patients presenting with an Infective focus might be expected to respond 
suboptimal particularly those with skin and soft tissue Infections which are 
mainly caused by Gram-positive organisms (9) and respiratory tract 
infections in which fungi play a major role (10). Furthermore these patients 
frequently require additional antibiotics, which complicate the assessment 
of side effects of empiric therapy. Therefore for this study we selected a 
homogeneous population of febrile, granulocytopenic patients presumed to 
suffer from bacteremia or septicemia. The protocol was approved by the 
ethics committee (CEOM 1986-919) 
PATIENTS AND METHODS 
Adults (15 years or over) who were granulocytopenic (< 0.5 χ 109/1) following 
c h e m o t h e r a p y for mal ignancy (mainly leukemia), febrile (axillary 
t e m p e r a t u r e >38 0 С for two or more hours), without a defined focus of 
infection were eligible for the study provided they gave their informed 
c o n s e n t . Pat ient s could not re-enter the s tudy during the same 
granulocytopenic phase. Allergy to ^- lactams, concurrent intravenous 
antimlcrobic therapy or end-stage underlying disease were grounds for 
exclusion as were levels of serum creatinine above 100 цтоі/ і or a creatinine 
clearance below 80 ml/min. Patients were nursed in reverse isolation and 
7 1 % received oral antimlcrobic prophylaxis with co-trlmoxazole plus 
Colistin (45%), pipemidic acid plus Colistin (15%), neomycin plus Colistin 
(4%) and ciprofloxacin (7%). These were discontinued at the onset of fever (8). 
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Pretreatment evaluation Included relevant history, physical 
examination, hematologic and biochemical profiles and a chest X-ray. Two 
venous blood samples were obtained for culture (10 ml from two separate 
veins or the same vein with an interval of 30 minutes) together with 10 ml 
blood via a Hickman catheter when present. When a patient was eligible, the 
attending physician opened a sealed envelope containing the prescribed 
treatment. These envelopes had been generated using a computer and were to 
be opened following a strict numeric sequence. Ceftazidime (2 g tds) or 
amikacin (500 mg tds) plus piperacillin (4 g qds) were given In short 
infusions. Modification of the initial treatment was permitted after 72 hours 
if there was no satisfactory response, a resistant pathogen was Isolated from 
blood, an infective focus developed or there was marked clinical 
deterioration. Treatment was continued until the patient had been free of 
fever and symptoms for four days. 
All patients were examined daily and cultures from blood and any 
clinically suspicious site were obtained while symptoms persisted. 
Hematologic profiles, serum creatinine and plasma potassium were 
determined three times a week and other biochemical parameters at least 
once a week. Serum for amikacin levels was obtained on the second or third 
day of treatment immediately before and one hour after the infusion and the 
drug was assayed by means of polarized fluorimetiy (TDx system. Abbot 
Laboratories). All Isolates were identified using standard laboratory 
techniques and susceptibility to antibiotics was determined by agar dliTusion 
using the NCCLS method (11). A strain was regarded as being resistant to the 
combination if it was resistant to both amikacin and piperacillin. 
Failure to culture organisms from blood was defined as FEVER OF 
UNKNOWN ORIGIN (FUO). BACTEREMIA was defined as being one or more blood 
samples positive for all organisms except coagulase-negative staphylococci 
and coryneforms. These organisms are associated with the skin and 
therefore to exclude contamination, two or more samples yielding the same 
organism were required. ERADICATION occurred If the original isolate was 
cleared by the initial regimen and failure to do so was termed PERSISTENCE 
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Clinical evaluation was undertaken at the end of antibacterial treatment. 
Protocol-violations, initial fever proven to be of non-bacterial etiology and 
death unrelated to infection were deemed unassessable. Patients who were 
given modifications before 72 hours of empiric therapy without obvious 
clinical deterioration, persistent bacteremia or the development of a focus 
were also considered unassessable. New fevers and other adverse events 
which occurred off-therapy but during or at the end of granulocytopenia were 
also recorded. 
The outcome of treatment was classified as follows:-
RESPONSE: the patient survived the infection and all infections symptoms 
disappeared without any change of initial therapy. 
RESPONSE AFTER MODIFICATION: the patient survived the infection but 
infectious symptoms resolved only after modification of the empiric 
regimen. 
FAILURE: the patient died due to proven or probable bacterial infection 
before or after therapy modification. 
Statistics 
Unless otherwise stated parametric tests were used for comparing either 
means or proportions (expressed as %) and are presented together with their 
respective 95% confidence intervals. 
RESULTS 
Forty-four febrile episodes occurred in 41 patients allocated to receive 
amikacin plus piperacillin compared with 46 episodes in 42 patients allotted 
to the ceftazidime treatment group (TABLE 1). Both groups were similar in 
terms of age, sex and underlying disease. Likewise, no differences were found 
with regard to the number of granulocytes at the s tar t of therapy, the 
duration of granulocytopenia, and the number of days that had elapsed 
between the onset of granulocytopenia and occurrence of fever. There were 10 
unassessable episodes in the combination group and 11 in the ceftazidime 
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TABLE 1. Demographic data 
No. of patients 
Age (years) * 
Male/female 
Underlying disease 
Acute myeloid leukemia 
Acute lymphoblastic leukemia 
Solid tumours 
Lymphoma 
Chronic myeloid leukemia (blast crisis) 
Others 
No. of febrile episodes 
Assessable episodes 
Granulocytes at the 
start of treatment (no. χ 109/l) 
<, 0.1 
0.1-0.5 
> 0.5 
Onset of fever after becoming 
granulocytopenic (days) 
Duration of first fever (days) 
Duration of granulocytopenia (days) 
Duration of initial therapy (days) a 
Total duration of antibiotic therapy (days) 
AP 
41 
41.7 ± 4.6 
22/19 
24 
4 
6 
3 
1 
3 
44 
34 
23 
β 
3 
6.2 ± 1.7 
7.1 ± 2.0 
19.5 ± 2.7 
6.4 ± 0.9 
15.3 ± 2.8 
С 
42 
43.7 ± 5.2 
22/20 
22 
7 
4 
5 
2 
2 
46 
35 
23 
10 
2 
7.5 ± 2.3 
5.8 ± 1.7 
21 ± 2.9 
9.8 ± 1.0 
12.6 ± 2.4 
AP=amikacin plus piperacillin, C=ceftazidime, * Mean ± 95% confidence interval 
a
 P<0.01 
group. Five cases In each group were unassessable because therapy was 
modified before 72 hours without there being any evidence of clinical 
deterioration though all patients were febrile. 
A non-bacterial etiology was established in four cases treated with the 
combination group. Two patients died, one due to lung infarction and 
another of intestinal hemorrhage. One patient had a lung infiltrate 
ultimately shown to be due to Ceoíríchum candídum from which he 
eventually recovered after Intensive care. A further patient had extensive 
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oral lesions consistent with candidiasis and one patient who never became 
granulocytopenic was incorrectly entered into the study. On the second day of 
ceftazidime treatment, shock developed In one patient who died of Herpes 
zoster encephalitis. Another patient given monotherapy became 
hypotensive with hemoptysis. He later died of lung hemorrhage associated 
TABLE 2 Causes of bacteremia 
Organism АР С 
Coagulase-negative staphylococci 
'Viridans' streptococci 
Coryneform 
Haemophilus influenzae 
Escherichia coll 
Klebsiella pneumoniae 
Polymicrobial 
Total 16 11 
4 
8 
1 
1 
2 
2 
4 
1 
1 
1 
2 
AP=amikacin plus piperacillin, C=ceftazidime 
with pulmonary aspergillosis. There was also one case each of graft-versus-
host disease, erroneous randomization and premature termination of the 
protocol. One further case was unassessable due to insufficient 
documentation. Therefore 34 febrile episodes In the combination group and 
35 in the monotherapy group were assessable for evaluating efficacy. These 
episodes together with those given early modifications were Included in the 
assessment of toxicity resulting In 41 and 42 cases respectively. 
Bacteremia 
Sixteen episodes of bacteremia were recorded In the combination group and 
11 episodes In the other group (TABLE 2). There were twice as many episodes 
due to Viridans' streptococci in the combination group but this was not due to 
oral prophylaxis since the regimens used were equally distributed between 
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the two treatment groups. Two polymicrobic episodes occurred In each 
treatment group (Streptococcus morbtllomm plus coagulase-negatlve 
staphylococci and Streptococcus mitts plus Streptococcus sanguis In the 
combination group and Staphylococcus aureus plus Vlridans' streptococci 
and Streptococcus milleri plus coagulase-negatlve staphylococci In the 
ceftazidime group). 
Outcome of therapy without modification 
Sixteen patients were given only combined therapy but one patient died in 
shock on day 2 before the initial regimen was modified; no pathogens were 
isolated. Thus 15 cases in the combined therapy group (44 ±17%) and 23 of 
those given monotherapy (66 ±16%) responded without the addition of other 
antibiotics (FIGURE 1), 67% and 70% respectively responding after 72 hours 
of therapy. A second fever developed in three and two cases respectively after 
stopping therapy. One patient originally treated successfully with combined 
therapy developed an abscess In the submandibular region and another 
cellulitis of the labia major. A third patient had an FUO. All three recovered 
after bone marrow regeneration. In the monotherapy group one patient 
developed a lung infiltrate of unknown origin which resolved following bone 
marrow recovery. Another patient presented with shock five days after 
stopping empiric therapy. Polymicrobic septicemia due to Staphylococcus 
aureus and Enterococcus Jaecalis was diagnosed but he died two days after 
onset despite appropriate therapy. 
Five of 16 cases (31%) with initial bacteremia responded in the 
combination group and three of seven (43%) in the monotherapy group 
whereas of patients with FUO 10 of 18 (56%) responded to combined therapy 
and 20 of 28 (71%) to monotherapy. 
Outcome of therapy after modification 
Of 18 cases treated with the combination. 15 responded only after 
modification compared with 10 of 12 cases given monotherapy. Fever 
persisted longer than 72 hours in 78% and 83% respectively the mean 
duration being 13.6 ± 7.2 versus 12.6 ± 4.8 days. Three patients in the 
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combined therapy group presented Initially with FUO. During persistent 
fever they developed lung Infiltrates and died on days 11, 13 and 20 after 
starting treatment. Aspergillus fumigatus was diagnosed In two cases and 
Geotrichum candidimi In one. Both patients from the monotherapy group 
died after changing therapy due to fungal pneumonia. One patient presented 
with septicemia due to K. pneumoniae which was cleared. Fever nevertheless 
persisted and he died eight days after onset of pneumonia caused by Candida 
albicans. The other patient sufTered persistent FUO with hypotension and 
died 10 days after onset of pneumonia due to Candida tropicatis. The 
diagnosis was confirmed at autopsy In all cases. 
Response was achieved in the combined therapy group 5.5 ±1 .8 days and 
in the monotherapy group 5.3 ± 2.8 days after the onset of fever. Persistent 
fever without any other sign of infection was the reason for changing in eight 
cases the given combined therapy. Later, three of these patients developed a 
lung infiltrate of which one was due to Aspergillus fumigatus and an abscess 
In the groin was diagnosed in another. One patient experienced fever related 
to piperacillin and persistent bacteremia with fever occurred in three cases: 
one due to 'virldans' streptococci and two to coagulase-negative staphylococci 
both resistant to piperacillin. A second fever associated with a lung infiltrate 
of unknown cause developed in three cases. Monotherapy was modified in 
two cases with new FUO and in three patients with lung infiltrate associated 
with persistent fever. Aspergillus fiimigatus was found at lobectomy in one 
patient; the cause remained unknown in two patients, one of whom also had 
a persistent coagulase-negative staphylococcal bacteremia. Five cases of 
persis tent fever were initially treated with ceftazidime for FUO. Two 
developed a lung Infiltrate both of unknown etiology. 
Irrespective of the initial regimen, the first modification was successful in 
only one-third of cases, glycopeptides being the drugs most frequently used. 
Those remaining received two or more further changes of therapy, the last 
being mainly the addition of antifungal drugs. 
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Treatment, fever and granulocytopenia 
The mean peak and trough levels for amikacin were 34.7 ±1.0 (range 26.2 to 
42.5) and 12.6 ± 0.5 (range 7.9 to 16.0) mg/1 respectively. Treatment groups 
did not differ with respect to the total duration of the antibiotic therapy or of 
fever but combined therapy was given for a significantly shorter period than 
was monotherapy (TABLE 1). There was a significant difference between those 
Amikacin + 
Piperacillin Ceftazidime 
34 35 
V \ 1 early death 0 
\ \ 3 death after 2 
\ modification 
* 1 5 response after 1 0 
modification 
15 response 2 3 
FIGURE.1 Outcome of initial therapy 
who responded and those who did so only after modification in terms of the 
mean duration of antibiotic therapy: 8.9 ± 1.7 days versus 17.6 ± 3.0 days 
respectively (P<0.001) and in the number of antibiotic-free granulocytopenic 
days: 15.6 ± 3.7 versus 7.8 ± 3.2 days respectively (P<0.01). These figures 
reflected the duration of fever in both outcome groups being 3.6 ± 0.8 and 12.0 
± 3.0 days respectively (fV:0.001). 
f 
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Advene events 
One bloodstream superinfection due to coagulase-negatlve staphylococci was 
recorded 10 days after the start of amikacin-piperacillin. Two patients given 
the combination and one given ceftazidime developed a probable drug-related 
skin rash. Serum creatinine levels Increased by 19.3 ± 31% In the 
combination group but decreased by 5.7 ± 13% In the monotherapy group 
(P<0.001. Wllcoxon test). Serum potassium levels dropped by 20.3 ±17% In 
patients given amlkacln-plperaclllln and by 1 ± 4% In the monotherapy 
group (P<0.001, Wllcoxon test). Potassium levels of <3 mmol/1 were found In 
45 ± 17% and 4 ± 7% respectively and parenteral supplementation was given 
In every case. 
DISCUSSION 
Both empirical regimens were equally effective in preventing death due to 
infection during the pancytopenic phase. Only one of seven deaths was shown 
to be caused by bacteria. Therefore failure of diagnosis rather than failure of 
the empiric antibacterial drugs accounts for the other six. Ninety percent of 
patients survived granulocytopenia but only 44% episodes in the 
combination group compared to 66 % episodes in the monotherapy group did 
so without additional antibiotics before granulocytopenia subsided. This 
difference is not significant and even if it were, our study population is too 
small to reduce the type II error to less than 20%. Neither was there any 
obvious explanation for the difference. Amikacin levels of 35 and 13 mg/1 
were admittedly lower than might have been expected for a 50% increase in 
the normal dose but were nonetheless within the therapeutic range. The 
higher rate of bacteremia in the combination group might account for the 
more frequent changes in therapy since clinicians tended to react to the 
preliminary reporting of Gram-positive cocci in initial blood cultures before 
they had been fully identified. In retrospect, this practice does not appear 
Justified since the majority of isolates were shown subsequently to be 
Viridans' streptococci which are more predictably susceptible to piperacillin 
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t h a n to ceftazidime. Also pers is tent bac teremia w a s encountered 
infrequently. Therefore resistance per se is not the explanation for the 
difference In outcome between the two regimens. 
Fever was In fact the most frequent reason for modification. In our study 
defervescence within three days occurred in two-thirds of patients who 
ultimately responded but in only 20% of those for whom therapy was 
modified. A recent EORTC study showed that persistent fever was also the 
most common reason for changing therapy. However, In their study such 
modifications were deemed a failure in marked contrast to our classlflcatlon 
(12). Refractory fever alone does not seem reasonable grounds for declaring 
early failure, nor Is it necessarily an early indication to alter empiric 
therapy. Persistent fever does appear nonetheless to characterize a group of 
patients at risk of infections due to agents other than bacteria since the 
majority developed an Infective focus, particularly a lung Infiltrate, despite 
our restrictive entry criteria. Fungal Infection was established in seven cases 
and only two survived. Furthermore, two or more additional changes 'were 
made to therapy in two-thirds of pat ients albeit ultimately including 
antifungal agents. Infection only resolved after granulocyte recovery in the 
majority of patients; therefore empiric changes with antibacterial therapy 
appear fruitless unless there is clear evidence of persistent bacteremia, a 
second fever, progressing Infection or obvious clinical deterioration. A 
substantial number of cases In which therapy was modified are likely to be 
unassessable due to their being of non-bacterial cause. Blind alteration of 
treatment also renders the outcome of treatment unassessable. Moreover, the 
risk of fungal Infection (13), and delayed marrow recovery (14) may Increase 
proportionally with the number of antibacterial agents used concurrently. 
When other potentially nephrotoxic drugs , e.g. vancomycin and 
amphotericin B, were used for modification combined therapy was 
frequently stopped because hypokalemia, a known complication of this 
combination (15), had occurred or renal dysfunction was anticipated. This 
was clearly reflected in the significantly shorter duration of combined 
t r ea tmen t . Monotherapy t h u s made pa t ien t care easier because 
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modifications could be done in a more standardized way than in the 
combination group. 
Effective early management of the febrile granulocytopenic patient can be 
achieved using either regimen although ceftazidime is simpler to administer 
and does not require monitoring and therefore would seem to be the logical 
choice. However, the period of empiric therapy must be used to Its full 
advantage especially in cases where fever persists or infection progresses. 
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ABSTRACT 
Telcoplanln at a dose of 400 mg per day was added to the initial empirical 
therapy of 65 out of 203 febrile granulocytopenic episodes. Of 53 cases 
évaluable for outcome 23 (43%) responded. Responders and non-responders 
were comparable In terms of starting telcoplanln treatment, duration of 
therapy and granulocytopenia, the number of granulocytopenic days after 
therapy was stopped and peak and trough levels of the drug. Telcoplanln was 
given most often because of persistent fever or Initial Gram-positive 
bacteraemla and only one-third of these cases responded. However, when 
telcoplanln was given because of proven or presumed Gram-positive 
infection 67% of cases were treated successfully. Patients with skin and soft 
tissue infections achieved a 78% response rate. The development of a lung 
infiltrate was the most common reason for failure to respond although in 
most Instances the aetiology was not determined. Serum levels of telcoplanln 
were predictable, giving a peak and trough concentration on the fourth day of 
30.4 ±5.0mg/land 9.8 ±1.7ing/l, respectively. Concentrations achieved In 
individual patients did not correspond to outcome. Hearing loss of 20 dB at 
800 Hz was noted in one of 15 cases and transient liver or kidney 
disturbances attributable to the drug were observed in four percent of cases. 
Telcoplanln therapy was safe but only effective when used to treat Infections 
with a high probability of being due to Gram-positive bacteria. 
INTRODUCTION 
Initial empirical therapy for fever In granulocytopenic patients is directed 
mainly against Gram-negative infections which can be rapidly fatal (1). 
About 50-70% of patients will become afebrile and asymptomatic without 
any change in treatment (2-8). Therapy will be modified in others as directed 
by the results of the diagnostic procedures during the early infection phase 
(9). Gram-positive bacteria now comprise the most common isolates from 
blood (10). In particular, bacteraemla due to coagulase-negative staphyloc-
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occl Is associated with the widespread use of Indwelling catheters (11) while 
that of 'vlridans' streptococci Is related to the Intensity of chemotherapy (12, 
13). Therefore It seems reasonable to expect that patients not responding 
adequately to Initial therapy might be treated successfully with a specific 
agent versus Gram-positive bacteria, such as vancomycin. This drug, 
however, must be infused over a period of not less than one hour and requires 
monitoring to ensure adequate but safe levels (14, 15). Telcoplanln Is a new 
glycopeptlde with comparable activity to vancomycin but which need only be 
given once daily and appears to be safe (16). We therefore wished to assess its 
efficacy and toxicity when used to supplement therapy in patients not 
responding to initial empirical treatment. The Investigation received ethics 
committee approval (CEOM 8506-3622, July 1985). 
PATIENTS AND METHODS 
Three hundred febrile episodes occurred in granulocytopenic patients in the 
period 1985-1988 and patients were stratified according to whether or not 
they presented with a clinical focus of infection. Those for which no 
Infectious focus was detectable at the onset of fever were entered Into two 
consecutive ongoing randomised trials of empirical therapy. Thus of 210 
cases, 90 were treated Initially with either the combination of amikacin and 
piperacillin or ceftazidime, while the next 120 were treated with ceftazidime 
either alone or In combination with telcoplanln. Those given telcoplanln ab 
íniíío were automatically excluded from the present study. An infectious 
focus was already present at onset of fever In 90 cases and these were treated 
with ceftazidime either alone or In combination with amikacin. 
Persistent bacteraemla, or a new episode due to Gram-positive bacteria or 
clinical signs of Gram-positive infection such as soft tissue or skin infection, 
were indications for adding telcoplanln to the Initial regimen. The drug was 
also added to the initial regimen empirically if the patient had persistent 
fever , i.e., axillary temperature > 38 0 С for at least 72 hours, and had had 
either presenting bacteraemla due to Gram-positive bacteria without 
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persistence, or fever of unknown origin. These criteria implied that a Gram-
negative bacterial aetiology was not anticipated. 
Patients under 16 years old and those known to be allergic to glycopeptides 
were Ineligible as were those with serum creatinine level of more t h a n 150 
μτηοΐ/ΐ or end-stage underlying disease. Patients who satisfied the entry 
criteria and for whom teicoplanin therapy was Indicated were enrolled after 
giving their informed consent. 
Patients were nursed in reverse isolation and received oral antimicrobial 
prophylaxis (co-trimoxazol p lus Colistin, or If this regimen was not 
tolerated, pipemldlc acid), which was stopped when Intravenous therapy was 
begun (3). Pretreatment evaluation included relevant history, physical 
examination, haematological and biochemical profile, chest X-ray and 
cultures of blood (10 ml from two separate veins plus 10 ml from Hickman 
catheter when present) and any clinically suspicious lesions. 
The dosage of ceftazidime was the same in all three tr ials (2 g 
Intravenously a s a 30-minute infusion every eight hours). Amikacin, 500 mg 
three t imes daily, and piperacillin, 4 g four t imes dally, were both 
admini s te red Intravenous ly a s rapid infusions. Teicoplanin was 
administered as a bolus iv Injection of 400 mg, twice on the first day and once 
dally thereafter. Therapy was continued until the patient had been free of 
fever and symptoms for at least two days and it was changed If the patient's 
condition deteriorated, the infection did not respond, or a resistant organism 
was isolated from blood or other lesion. All patients were examined daily, 
haematological profiles were established three times each week and those for 
biochemistry at least once a week. All isolates were Identified using standard 
laboratory techniques and susceptibility to antibiotics was determined by 
agar diffusion according to National Committee for Clinical Laboratory 
Standards (17). Peak and trough concentrations of teicoplanin (1 h after a 
dose and Immediately before a dose, respectively) were determined on days 1, 
2, 4, 7 and 10, by an agar dlifuslon method with a spore-suspension of 
Bacillus subtílís. Samples and standards ranging from 4 to 64 mg/1 were 
assayed In duplicate and the resultant zones of Inhibition were calculated by 
Interpolation from the s tandard curve. Audiometry was performed when 
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possible at the beginning of, during and after finishing treatment and 
evaluation was made only when all three measurements were available. 
FEVER OF UNKNOWN ORIGIN (FUO) was defined as a temperature of >38 0C 
in the absence of either bacteraemia or a focus of Infection. BACTERAEMIA 
was defined as the occurrence of at least one blood sample positive for any 
Gram-negative rod or a specific Gram-positive pathogen, e.g. Staphylococcus 
aureus or Streptococcus pneumoniae, bu t as two or more blood cultures 
positive for opportunistic Gram-positive cocci. 
Evaluation was performed at the end of therapy only for episodes treated 
for three or more days and each episode was evaluated for both clinical and 
microbiological outcome. Patients who became afebrile, or In whom the 
symptoms and signs of the infection improved without any change of therapy 
were deemed to have responded. Patients who died because of the infection, 
those who did not become afebrile after three days and those In whom the 
infectious focus did not Improve without any other intervention were 
classified as non-responders. Patients with persistent bacteraemia due to 
Gram-positive bacteria were also assumed not to have responded. 
The Student t-test was employed for comparing data and values were 
expressed as the mean ± the 95% confidence interval according to the 
International Committee of Medical Journal Editors (18). A P-value of <0.01 
was adopted as being significant since the t-test is sensitive to the nature of 
underlying distr ibution and the data were unlikely to be normally 
distributed. 
RESULTS 
Teicoplanln was added to the Initial empirical regimen in 65 of 203 febrile 
episodes (32%) on average 4.9 ±0.6 days after the onset of fever and therapy 
was continued for 9.0 ± 1 . 3 days. There were 59 patients of whom 50 (85%) 
suffered from acute leukaemia and their demographic data are shown In 
TABLE l. Twelve episodes were unassessable : five cases were given 
teicoplanln for less than three days and three patients were given another 
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drug concomitantly (amphotericin В In two cases and cephalothln In one 
case). A non-lnfectlous cause of fever and symptoms was established In four 
cases of which three died (cerebral haemorrhage, lung haemorrhage and 
pulmonary embolism) and one patient developed graft-versus-host disease. 
TABLE 1. Demographic and clinical data 
Number of patients 59 
Male/female 37/22 
Age (years) 
mean ± 95% confidence interval 39.2 ± 3.9 
range 17-74 
Underlying disease 
acute myeloid leukaemia 35 
acute lymphoblastic leukaemia 1 5 
lymphoma 5 
chronic myeloid leukaemia 4 
Number of febrile episodes 65 
Unassessable 12 
therapy < 3 days 5 
non-infectious cause 4 
other concomitant antimicrobial 3 
Total number of assessable episodes 53 
Number of episodes with granulocytes 
< 0.5 χ 109/l 51 
Of 53 assessable episodes. 42 were treated Initially with ceftazidime alone, 
five with ceftazidime plus amikacin and six with a combination of 
piperacillin and amikacin. After the addition of telcoplanln. the Initial 
combination therapy was replaced by ceftazidime alone In five patients 
given piperacillin plus amikacin and in two patients given ceftazidime plus 
amikacin; i.e. these patients then received ceftazidime plus telcoplanln. 
The Initial Infections are detailed In TABLE 2. Presenting bacteraemla was 
detected In 25 cases and seven Isolates were resistant to at least one of the 
drugs given Initially (TABLE 3). There were 12 cases of proven or presumed 
Gram-positive Infection. Two patients with persistent bacteraemla due to 
coagulase-negative staphylococci also had a tunnel Infection related to the 
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Hickman catheter and a response was achieved In one. There was also one 
case of new bacteraemla due to coagulase-negatlve staphylococci which 
failed to respond. Skin and /or soft tissue Infection was diagnosed In the 
remaining nine cases of which none were confirmed mlcroblologlcally. 
Seven p a t i e n t s responded (78%) of which one died of pulmonary 
haemorrhage associated with a fungal Infection 18 days zifter slopping 
teicoplanln. 
TABLE 2. Definition of the initial infection 
Infection category 
Fever of undetermined origin 
Lower respiratory tract 
infection 
Skin and soft tissue infection 
Other 
Bacteraemia without focus 
of infection 
Total 
Initial 
CAZ a 
19 
5 (2) 
6 (4) 
1 О) 
11 
42 (7) 
experimental regime 
CAZ+AMI PIP+AMI 
2 (1) 
1 О) 
2 (1) 
5 (3) 
2 
4 
6 
Total 
21 
7 
7 
3 
15 
53 
CAZ, ceftazidime; AMI, amikacin; PIP, piperacillin; ( ), number of cases with 
bacteraemia; a patients given the comparative regimen of ceftazidime plus 
teicoplanin are excluded. 
Teicoplanln was given empirically in 41 cases: 23 with persistent fever only 
and 18 with persistent fever following Initial Gram-positive bacteraemia. 
The organisms had been cleared In all of 10 cases in which blood cultures had 
been repeated. An overall response was achieved In 15 of 41 cases (37%) and 
there was no difference between patient groups (TABLE 4). The duration of 
fever after the addit ion of teicoplanln was significantly shorter for 
respondéis (4.9 ± 1.2 vs 14.2 ± 2.8 days; P<0.01) but the granulocytopenic 
period was comparable (22.8 ± 5.2 vs 31.2 ± 6.8 days; P>0.05). The number of 
the granulocytopenic days after stopping therapy was also shorter for 
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responders but the difference was not significant ( 6.8 ± 6.0 vs 12.2 ± 5.7 
days; P>0.05). The development of a probable lower respiratory tract 
Infection was the main reason for failure occurring In 20 of 30 cases (67%) all 
of whom were given telcoplanln empirically (TABLE 5). 
TABLE 3. Initial bacteraemia 
Bacteria Number Eradicated Persisted Unevaluable 
Staphylococcus 
aureus 
Coagulase-negative 
staphylococci 
Streptococci 
Polymicrobial 
6 
5 
8 
6 
3 (1) a 
2 
5 (2)c 
3 ( 1 ) d 
3 (1)3 
2 (1) b 1 (1) ъ 
3 
3 
( ) a Resistant to piperacillin; b initially susceptible, became resistant to 
ceftazidime; c resistant to amikacin; ^ Enterococcus faecalis resistant to 
ceftazidime 
The aetiology of the lung Infiltrates was established In only six cases (30%); 
two Aspergillus fumigatus, one Candida albicans and one cytomegalovirus 
infection were detected at autopsy, Legionella pneumophila was cultured In 
the bronchial-alveolar lavage material In one survivor and A. fumigatus was 
found repeatedly in the sputum of the another. One patient out of 14 cases 
with a lung Infiltrate of unknown origin died. Other reasons for failure were 
established in four cases (13%): pseudomembranous colitis due to 
Closírídíum difficile in one patient who died and three cases with tunnel 
infection which improved only after the Hickman catheter had been 
removed. Thus failure was not explained In six cases (20%) of whom all 
survived. 
Serum concentrations were consistent and adequate (FIGURE 1) and did 
not correspond with outcome. By the fourth day of therapy, a peak 
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concentration of 30.4 ± 5.0 mg/1 was reached, and this level was maintained 
thereafter. 
TABLE 4. Outcome of therapy 
Reason for addition of teicoplanin 
Proven or presumed Gram-positive infection: 
persistent or new Gram-positive 
bacteraemia 
skin and soft tissue infection 
Empirical 
persistent fever only 
persistent fever and initial Gram-positive 
bacteraemia 
Total 
No. 
12 
3 
9 
41 
23 
18 
53 
% Response 
67 
33 
78 
37 
39 
33 
43 
Liver and kidney function were evaluated In all cases and transient liver 
function disturbances were noted In 14 patients (26%); eight receiving 
ceftazidime, five ceftazidime plus amphotericin В at 0.5 mg/kg/day and one 
teicoplanin alone. There was a rise In alkaline phosphatase In four cases, 
alkaline phosphatase plus bilirubin In one case, transaminases In six and 
bilirubin In three cases. Thirty seven patients received ceftazidime and eight 
were given amphotericin B; liver function disturbances were observed In 19% 
and 65% respectively. Two patients were given only teicoplanin and liver 
function disturbance was observed In one. A rise In serum creatinine was 
observed in one patient receiving concomitant amphotericin В and 
ceftazidime. A complete sequence of audiograms were obtained in 15 patients 
and in one case given teicoplanin and ceftazidime a difference of 20 dB at 
8000 Hz was recorded. The audiogram remained normal in the others. A skin 
rash was observed in one patient receiving ceftazidime and ciprofloxacin, but 
therapy was continued without further complications. 
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TABLE 5. Reasons for failure to respond to teicoplanin 
Reason for failure 
Lower respiratory tract infection 
A. fumiga tus 
С. albicans 
L pneumophila 
cytomegalovirus 
unknown 
Other 
pseudomembranous colitis 
caused by CI. difficile 
tunnel infection 
Unknown 
Total 
Empirical 
addition 
3 (2 died) 
1 (1 died) 
1 
1 (1 died) 
14 (1 died) 
1 (1 died) 
5 
26 (6 died) 
Proven/ 
presumed 
Gram-positive 
infection 
3 (1 died) 
1 
4 (1 died) 
DISCUSSION 
Of the 203 febrile, granulocytopenic patients Included In this evaluation 
during the period 1985-1988 32% (65) were given teicoplanin as first 
modification of Initial empirical antimicrobial therapy. Of the 53 who were 
évaluable, 23 responded favourably. Thus only 23 of 203, or 11% of the total 
patients benefitted from this intervention and did not require further 
changes in therapy. The antibiotic was shown to be effective In patients with 
proven and presumed Infection by Gram-positive bacteria. All but two cases 
with skin and soft tissue Infection responded to teicoplanin; both 
nonresponders had tunnel Infection which improved only after removal of 
the Hickman catheter. This corresponds with data reported by other authors 
(19). Teicoplanin was most often added to the Initial regimen empirically 
because of persistent fever and/or presenting bacteraemia due to Gram-
positive bacteria. Since the initial regimens used at the time were marginally 
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active against staphylococci and streptococci in uiiro it was our practice to 
assume t h a t the bacteria might not be cleared if the symptoms and signs 
persisted. However, it is worth noting that 56% of strains were eradicated 
from the blood at the time therapy was changed, although this knowledge was 
not available until one or two days later. 
40-
30· 
с 
2 20 
Peak 
Trough 
ι о 
Day of therapy 
FIGURE 1. Serum concentrations of teicoplanin. 9, Peak; O, trough. 
There is as yet no general consensus about the management or the definition 
of persistent fever (20, 21). However, it does not seem likely that teicoplanin 
per se altered outcome in these patients In any way since there was no 
difference in terms of teicoplanin concentrations, the day of addition, or in 
the duration of therapy or of granulocytopenia. In fact our study shows that 
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adding telcoplanln empirically appears to benefit only one-third of the 
patients. This approach may postpone more appropriate treatment, e.g. 
antifungal treatment, since two-thirds of the non-responders developed a 
lung infìltrate which was diagnosed in 4 1 % at the time the glycopeptlde was 
begun. It was disappointing that the aetiology of lower respiratory tract 
Infection could not be determined In the majority of the cases, although lung 
infection was the main cause of death. The problems associated with 
diagnosing the presence and cause of Infection in granulocytopenic patients 
remains largely unsolved. Certainly careful follow-up and the use of 
diagnostic tools such as bronchoalveolar lavage offer some improvement in 
allowing therapy modifications to be as specific a s possible (22). 
Currently in our centre around 60% of presenting bacteraemias at the 
onset of fever are caused by Gram-positive cocci. Patients might therefore 
gain more benefit from adding telcoplanln ab initio (23, 24) If there is a very 
strong suspicion of involvement of Gram-positive bacteria for example 
clinical signs of a catheter-related infection. Rubin et al. (25) concluded that 
specific t reatment for Gram-positive infections need only be added on 
indication. Indeed their data Indicate that only seven percent of all febrile 
granulocytopenic patients gain benefit from specific t reatment aimed at 
Gram-positives. This figure is comparable with our estimate, suggesting that 
giving the drug as part of the initial empirical regimen would be unnecessary 
in as many as nine out of ten cases. 
In conclusion, telcoplanln was shown to be a safe drug which, when given 
once dally, resulted In adequate serum concentrations. It does not appear to 
have a useful role when given empirically as a modification to deal with 
persistent fever, but is effective in patients with presumed or proven Gram-
positive infection. 
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ABSTRACT 
In a prospective randomized study, 120 febrile, granulocytopenic patients, 
received as initial therapy ceftazidime with or without telcoplanln. At the 
onset of fever, patients had no obvious Infectious focus. For 103 assessable 
episodes, initial bacteremias were detected in 18 of 51 patients (35%) given 
ceftazidime and 20 of 52 patients (38%) given the combination; 13 and 17 
bacteremias caused by Gram-positive bacteria occurred In these groups, 
respectively. There was no difference In terms of the final response (25 of 51 
patients [49%] treated with ceftazidime alone versus 33 of 52 patients [63%] 
given the combination), and the morbidity was comparable for both 
treatment groups. The duration of fever and of total antibiotic therapy was 
similar in both groups. Initial therapy was modified in 26 patients (51%) 
treated with ceftazidime, with 20 surviving the Infection, and in 19 patients 
(37%) treated with the combination, with 15 surviving. Persistent fever was 
the main reason for changing treatment, and no patient died of a Gram-
positive infection. Subsequent infective events occurred in 16 patients (31%) 
given ceftazidime and In 25 patients (48%) given the combination. Lung 
Infiltrates developed in 12 and 13 patients, respectively, but more new 
infections occurred in the combination group. Allergic skin reactions were 
also more frequent In this group. Thus, while telcoplanln provides simple, 
reliable, and safe t reatment of patients with presumed Gram-positive 
infection, it is not useful when given empirically to this patient population. 
and treatment may result in more infective complications and adverse 
events. 
INTRODUCTION 
The Incidence of Gram-positive Infections has increased In the last few years 
as a result of combination of several factors (1, 2). Selective oral prophylaxis 
has reduced incidence of Gram-negative infections (3, 4) while bacteremia 
caused by coagulase-negatlve staphylococci has Increased, partly as a result 
63 
of the greater use of indwelling intravenous catheters (5, 6). Intensification of 
cytostatic therapy h a s resulted in extensive damage to the mucosa . 
particularly of the mouth; consequently bacteremia caused by 'viridans' 
group streptococci h a s assumed greater prominence (7, 8). Thus, agents 
specific for Gram-positive bacteria, particularly vancomycin, are often 
added to the initial regimen whenever fever persists (9) or are Included In the 
Initial empiric regimen (10). Skin reactions and ototoxicity are well known 
side effects of vancomycin, and nephrotoxicity is more likely to occur when 
the drug is given concurrently with an aminoglycoside (11). Teicoplanln Is a 
new glycopeptide antibiotic with activity a n d s t r u c t u r e similar to 
vancomycin, but it can be given once daily with a minimal risk of toxicity 
(12, 13). In a previous study, we assessed the utility of adding teicoplanln 
empirically for persistent fever (14). The results showed that only one-third 
of patients responded. However, the addition was effective in 67% of patients 
with proven or presumed Gram-positive infection and in 78% of those with 
skin and soft tissue infections (SSTIs). We estimated from these data that 
only 11% of a general population of febrile, granulocytopenic patients might 
benefit from addition of this antibiotic. Therefore, a prospective randomized 
s tudy was designed to address the quest ion of whether combining 
teicoplanln with ceftazidime for initial empiric therapy might be more 
effective. To keep the study population as homogeneous as possible, we 
excluded patients with an infective focus, such a s a lung Infiltrate, at the 
onset of fever, since these appear to comprise a different risk-group (15-17). 
PATIENTS AND METHODS 
The study was designed to compare the efficacy and toxicity of ceftazidime 
with or without teicoplanln as empiric therapy for febrile, granulocytopenic 
patients. The investigation received the approval of the Medical Ethics 
Committee of the University of Nijmegen (1987-11270. February 1988). 
Pat ients were eligible for this s tudy if they were 14 years or older, 
granulocytopenic (granulocyte counts expected to fall to <0.5 χ 109/1) and 
64 
febrile (single axillary temperature >38.5 "С or at least two readings of >38 0 C 
taken 2-4 hours apart) with no obvious focus of Infection. In addition, all 
gave Informed consent. They were randomized only once during the same 
granulocytopenic phase, had received no other parenteral antibiotics before 
starting therapy, and were nursed In reverse-barrier isolation. The majority 
of patients had received oral antimicrobial prophylaxis prior to onset of 
fever: 43 patients (72%) allocated to receive a single drug and 48 patients 
(80%) allocated to receive the combination. The majority of patients in both 
groups were given either ciprofloxacin or co-trimoxazole plus Colistin. 
Pretreatment procedures 
Clinical history taking and examination, hematological and biochemical 
profiling, and chest rontgenography were done before t reatment. Ten 
milliliters of blood were obtained for culture from two separate veins, and 
another 10 ml of blood was obtained from a Hickman catheter when present. 
Isolates were identified by standard technics, and antibiotic susceptibilities 
were determined by disc dilTusion In accordance with the criteria of the 
National Committee for Clinical Laboratory Standards (18). Patients were 
examined dally, and biochemical and hematological profiles were obtained 
once and three times weekly, respectively. Audiometry was performed with a 
portable audiometer (ST-10; Bosch) at frequencies of 0.25, 0.5, 1. 2, 3, 4, 6 and 
8 kHz, when possible, at the beginning and after more than seven days of 
treatment. Evaluation was done only when both measurements were 
available, and a hearing loss of 20 dB or more was considered to be 
significant. 
Definition of infection 
Failure to culture organisms from blood was defined as FEVER OF UNKNOWN 
ORIGIN (FUO), while BACTEREMIA was documented when at least one blood 
sample yielded growth for all organisms, except skin commensals namely, 
coagulase-negatlve staphylococci and coryneforms, for which two or more 
positive samples were required. The development of a focus, a new episode of 
bacteremia, or fever were considered a SUBSEQUENT INFECTIVE EVENT. Any 
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subsequent Infective event that occurred during treatment was defined as a 
SUPERINFECTION, while one that occurred after the cessation of treatment 
was defined as a NEW INFECTION. Fever of longer t han 72 hours was 
considered to be PERSISTENT. LOWER RESPIRATORY TRACT INFECTION (LRTI) 
was diagnosed when an infiltrate not attributable to a noninfectious cause 
was detected with a chest rontgenograph. Positive culture of bronchial 
alveolar lavage and organisms detected histologically In material obtained 
at autopsy established a PROVEN INFECTION, whereas sputum which yielded 
organisms not considered as normal upper respiratory commensal flora 
constituted PRESUMED INFECTION. A SSTI comprised erythema. Induration. 
and tenderness of skin and/or soft tissue. 
Treatment 
Ceftazidime was given In a short infusion of 2 g every eight hours while 
teicoplanln was administered as an Intravenous dosage of 800 mg in two 
divided doses on the first day and 400 mg once daily thereafter. Modifìcation 
by addition or substitution was permitted in cases in which marked clinical 
deterioration occurred, a resis tant pathogen had been isolated, the 
presenting bacteremia persisted, or a superinfection was diagnosed. A change 
in therapy was not mandatory in cases of persistent FUO, but the clinician 
was free to change the therapy if he or she Judged it necessary. Treatment 
could be altered earlier than 72 hours only if a pathogen was resistant or 
there was marked clinical deterioration. Therapy was continued until the 
patient was free of symptoms, signs, and fever for at least four days if still 
granulocytopenic or for two days If not. 
Clinical evaluation and outcome 
The outcome of therapy was classified at the end of therapy, as follows: 
RESPONSE. The patient survived the infection, and all signs and symptoms 
disappeared without any change In the initial therapy. 
RESPONSE AFTER THERAPY MODIFICATION. The patient survived the 
infection, but defervescence and resolution of all signs and symptoms of 
infection was achieved only after modification of the empiric regimen. 
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FAILURE. The patient died because of infection, regardless of whether 
therapy was modified. 
UNASSESSABLE. Patients were unassessable if they were not 
granulocytopenic, violated protocol, had a proven non-bactertal etiology at 
the onset of fever, died from a cause unrelated to infection, or received fewer 
than two doses of antibiotic therapy. 
The occurrence of new infective complications and adverse events at the 
end of the granulocytopenic period was also documented. 
Bacteriological evaluation and outcome 
Negative blood cultures during treatment were considered as evidence of 
ERADICATION. In the case of a clinical cure with no follow-up cultures, the 
case was assumed to be bacteriologically cleared, whereas continued 
Isolation of the original pathogen(s) constituted PERSISTENCE. 
Telcoplanln levels 
After starting therapy with telcoplanln serum was obtained on days 2, 4 and 
7 one hour after injection (peak levels) and Immediately before the next dose 
(trough levels). Drug levels were assayed using an agar diffusion method with 
a spore-suspension of Bacillus subtílís. Samples and standards ranging from 
4 to 64 mg/1 were assayed in duplicate, and the resultant zones of inhibition 
were calculated by interpolation from the standard curve. 
Statistics 
All means and proportions are given with their respective 95% confidence 
Intervals, and the differences between treatment group parameters were 
analyzed by the Student t -test. Categorical data were analyzed by means of 
X^-test with Yates correction, unless the number In any category was less 
than five. In which case Fisher exact test was used. Given the non-Gaussian 
nature of the data, the conventional significance level of five percent was 
replaced by the more stringent level of one percent. 
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RESULTS 
Both groups of 50 patients were similar in terms of sex, age and underlying 
disease, with more than 70% of cases being treated for leukemia (TABLE 1). 
TABLE 1. Clinical and demographic data 
Number of patients 
Male/female 
Age (yr) 
mean ± 95% confidence interval 
range 
Underlying disease 
Acute leukemia 9 
Chronic myeloid leukemia 3 
Other hematological diseases 
Solid tumors 
Total number of assessable episodes 
Number (%) of patients 
with the following 
no of granulocytes χ 10 9 /l 
< 0.1 
0.1-0.5 
> 0.5 
Duration of granulocytopenia (days) b 
Days to onset of fever after patient became 
granulocytopenic^ 
Ceftazidime 
5 0 
3 4 / 1 6 
38.7 ± 3.4 
1 6 - 6 9 
2 8 
7 
8 
7 
51 
40 (78%) 
10 (20%) 
1 (2%) 
22.1 ± 4.0 
4.0 ± 1.0 
Ceftazidime 
+ teicoplanin 
5 0 
2 4 / 2 6 
40.4 ± 3.5 
1 7 - 6 9 
2 9 
8 
4 
9 
5 2 
43 (83%) 
7 (13%) 
2 (4%) 
20.3 ± 2.8 
6.2 ± 1.5 
a
 Seventy percent of patients treated with ceftazidime and 74% of patients treated 
with ceftazidime plus teicoplanin were leukemic 
k ± 95% confidence interval 
There were nine unassessable episodes In the ceftazidime group. Two patients 
died of cerebral hemorrhage, and another died within six h o u r s off 
admission due to Escherichia coli sepsis. Four patients were ineligible: two 
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were not granulocytopenic, one presented had a lung infíltrate, and another 
had an infected postoperative wound. There were also two protocol 
violations (one patient who was randomized for the second time during the 
same pancytopenic phase and one for whom therapy was s topped 
prematurely). In the combination group, eight episodes were deemed 
unassessable. One patient died of lung hemorrhage, one had been treated 
with other antibiotics before randomization and one never became 
granulocytopenic. The remaining cases were protocol violations (two 
pat ients who were randomized for the second time during the same 
pancytopenic phase and three for whom therapy was stopped prematurely). 
Therefore 51 febrile episodes in the ceftazidime group and 52 In the 
combination group were assessable. Both treatment groups were comparable 
in terms of granulocytes at entry, the onset of fever and the total period of 
granulocytopenia. On days 2, 4 and 7 peak teicoplanin serum concentrations 
were 28.7 ±4.1 ,30.5 ±3.4 and 29.3 ±3.9 mg/liter and trough levels were 9.2 ± 
1.2, 10.7 ± 1.8 and 12.1 ± 1.4 mg/liter, respectively. 
Bacteremia was detected in 18 (35%) and 20 pat ients (38%) in the 
monotherapy and combination group, respectively (TABLE 2), the majority of 
cases being caused by Gram-positive bacter ia . There were three 
polymicrobial episodes in the ceftazidime group, one involving a resistant 
Enierococcus Jaecalis isolate. There was also one episode involving a 
res is tant Enterobacter cloacae Isolate. The remaining isolates were 
susceptible to ceftazidime. All episodes occurring in the combination group 
were susceptible to the regimen, including one polymicrobial episode of 
bacteremia. 
Clinical outcome 
Twenty-five patients (49%) in the monotherapy group, of whom seven had 
initial bacteremia, responded to the initial regimen without modification, as 
compared with 33 patients (63%), of whom 10 had initial bacteremia, in the 
combination group (FIGURE 1). Approximately half of the patients in each 
group became afebrile within 72 hours after therapy was started, and the 
majority responded before granulocyte recovery (TABLE 3). Both groups were 
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comparable In terms of the duration of fever, antibiotic therapy, and the 
duration of both total granulocytopenia and granulocytopenia following 
defervescence. 
TABLE 2. Bacteremia at onset of fever 
Organism No. of patients treated with the 
following and harboring the 
indicated organism 
(no. with proven persistent 
bacteria): 
Gram-negative 
Pseudomonas aeruginosa 
Escherichia coli 
Enterobacter cloacae 
Morganella morgan! 
Aeromonas hydrophila 
Haemophilus influenzae 
Gram-positive 
Staphylococcus aureus 
Coagulase-negative staphylococci 
Stomatococcus mucilaginosus 
Streptococcus mitis 
Streptococcus sanguis 
Streptococcus salivarius 
Viridans' group streptococci 
Streptococcus bovis 
Group G streptococci 
Enterococcus faecalis 
Anaerobic (Fusobacterium sp.) 
Polymicrobial 
Ceftazidime 
1 
1 
1 (1) 
1 
1 
1 
3 
2 
1 
2 
1 
3 a 
Ceftazidime 
+ 
teicoplanin 
1 
1 
2 
4 (1) 
2 
3 
2 
1 b 
a
 Coagulase-negative staphylococci plus S. bovis, coagulase-negative staphylococci 
plus E. faecalis resistant to ceftazidime, and S. sanguis plus a nonidentified strain of 
'viridans' group streptococci. 
b
 Staphylococcus hominis plus two nonidentified strains of coagulase-negative 
staphylococci 
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TABLE 3. Therapy with and without modifications 
Drug 
Ceftazidime 
Without modification 
With modification 
Ceftazidime + teicoplanin 
Without modification 
With modification 
No. of 
episodes 
25 
26 
33 
19 
No. (%)of patients 
showing deferves-
cence within 72 h 
14 (56) 
6 (23) 
17 (51) 
4 (21) 
Fever 
3.5 ± 0.8 
14.6 ± 3.8 
3.8 ± 0.9 
13.6 ± 3.3 
Duration3 of: 
Antibiotic therapy 
7.3 ± 0.8 
22.3 ±7,0 
7.6 ± 0.8 
17.4 ± 2.3 
Granulocytopenia 
16.8 ± 3.4 
29.0 ± 6.9 
19.6 ± 3.7 
21.9 ± 3.6 
No. (%) of patients 
showing defervescence 
for >2 days before 
granulocyte recovery 
21 (84) 
10 (38) 
24 (73) 
7 (37) 
a
 Days (mean ± 95% confidence interval) 
^ 
Initial therapy was modified In 26 patients (51%) treated with ceftazidime 
and in 19 patients (37%) treated with the combination. Eleven cases in the 
monotherapy group and 10 in the combination group had bacteremia. 
Ceftazidime 
51 assessable episodes 
died 
response after 
modification 
Ceftazidime 
+ teicoplanin 
52 
25 response 33 
FIGURE 1. Flow chart for outcome of therapy 
Twenty patients (39%) in the monotherapy group and 15 (29%) in the 
combination group responded after modification of the therapy; eight and 11 
patients, respectively, did so after the first modification. Of ceftazidime-
treated patients given teicoplanin as first modification, only seven of 15 
(47%) responded without further changes in therapy. Both treatment groups 
were comparable In terms of duration of fever, and antibiotic therapy, and 
the duration of both total granulocytopenia and and granulocytopenia 
following defervescence. Interestingly, patients in both groups, who had 
initial Gram-positive bacteremia were febrile for similar durations: 7.8 ± 3.0 
for those given monotherapy versus 9.8 ±4 .1 days for those given teicoplanin 
initially, whether or not therapy was modified. The infective episode 
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resolved in about half of cases after the recovery of marrow function, 
regardless of the antimicrobial regimen Six patients (12%) in the 
monotherapy group and four patients (8%) in the combination group died 
Only one patient, treated Initially with ceftazidime alone, died In shock five 
days after onset of the Infection with the resistant E.cloacae Isolate All 
other deaths in both treatment groups occurred seven or more days after the 
onset of the original infection (TABLE 4). 
TABLE 4. Deaths 
Drug 
Ceftazidime 
Ceftazidime 
+ teicoplanm 
Initial infection 
E cloacae 
RJO 
FUD 
M Morgana 
'vindans' group 
streptococci 
R D 
RJO 
FUD 
FUD 
FUD 
S bows 
'vindans' group 
streptococci 
Cause of death 
E cloacae sepsis 
Colitis caused by С difficile 
LRTI caused by A fumigatus 
LRTI, cause unknown 
LRTI caused by A fumigatus 
Disseminated С albicans 
infection 
LRTI, cause unknown 
Shock0 
LRTI, cause unknown^ 
LRTI, Cause unknown 
Disseminated H capsulatum 
infection 
Disseminated С albicans 
infection 
Day of 
death3 
5 
7 
18 
25 
34 
45 
13 
13 
16 
17 
17 
30 
a
 Day after empiric therapy was begun, ^ New infection 
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Bacteriological outcome 
The clinical response rate for episodes caused by Gram-poslttve bacteria was 
lower for ceftazidime than for the combination, since only four out of 13 
patients (31%) and nine out of 18 patients (50%), respectively, were not given 
additional antibiotics. However, the Gram-positive bacteria were eradicated 
by ceftazidime alone In all 10 assessable episodes and by combination in 16 
out of 17 assessable episodes (94%), i.e., before a possible modification. One 
coagulase-negative staphylococcus persisted during treatment with the 
combination. Consequently, therapy was modified for six patients in the 
ceftazidime group and eight patients In the combination group after the blood 
cultures had become sterile. Four Gram-negative rods were eradicated in the 
monotherapy group, but the resistant E.cloacae isolate persisted. In the 
combination group, both Gram-negative rods were eliminated. 
Modifications of Initial regimens 
Treatment was changed significantly earlier in the ceftazidime group 
(P<0.01), and of the 17 patients in this category, 15 were given telcoplanin as 
the first modification (TABLE 5). However, the average time to the addition of 
drugs other than telcoplanin was virtually the same as the point of the first 
modification in the combination group (7.9 ± 2 . 9 versus 7.4 ±2 .2 days, 
respectively). There was no significant difference in the average number of 
modifications or in the number of single modifications. 
CLINICAL DETERIORATION. For three patients given ceftazidime initially, 
therapy was changed within 72 hours because of clinical deterioration. Two 
became hypotensive, one of these two Improved after modification with 
telcoplanin and erythromycin, and the other died of pneumonia caused by 
Aspergillus fumigatus. The third patient was referred to earlier. She died of 
sepsis caused by E. cloacae, despite the addition of amikacin. 
SUPERINFECTION. Monotherapy was modified as a direct result of 
superinfection In six patients. Two patients had LRTIs of unknown cause, 
and one of these two died. A patient had a superinfection caused by 
-Aspergillus fumigatus; was treated with amphotericin B, and survived 
despite ensuing polymicrobial bacteremia caused by Staphylococcus aureus 
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and coagulase-negative staphylococci. A culture-negative Hickman tunnel 
infection occurred In the fourth patient; additional t rea tment with 
telcoplanln proved unsuccessful, and the catheter had to be removed. Two 
patients developed abdominal complications which turned out to be fatal In 
one case of enteritis, despite the addition of telcoplanln. At autopsy, 
Clostridium difficile and its toxin were detected in fecal material, bu t there 
was no convincing evidence of pseudomembranous colitis. 
TABLE 5. Modifications of therapy 
No. of patients for whom 
the following was the reason for first 
modification: 
Clinical deterioration 
Superinfection 
Persistent fever 
Day of first modification3 
Average no. of modifications3 
No. of patients for whom 
the following drug(s) was 
used for modification: 
Antifungal agents 
ß-lactams 
Macrolides or lincosamides 
Aminoglycosides 
Metronidazol 
Acyclovir 
Glycopeptides 
Ceftazidime 
3 
6 
17 
4.9 ± 1.1 
2.5 ± 0.5 
14 
8 
1 1 
3 
2 
7 
21 
Ceftazidime 
+teicoplanin 
8 
1 1 
8.0 ± 1.4Ь 
1.5 ± 0.7 
10 
7 
5 
3 
1 
3 
1 
3
 mean ± 95% confidence interval 
ь
 P< 0.001 
Eight superinfections led to modification in the combination group. One 
patient died of disseminated Candida albicans infection. Another died of 
Hisiqplosma capsulatum Infection which had spread from the lungs to the 
brain. There were three LRTIs of unknown origin, one with a fatal outcome. 
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Culture-negative SSTT, enteritis due to Campylobacter Jejuni and a new FUO 
were the reasons for modiflcation In the remaining three cases. 
PERSISTENT FEVER A persistent fever was the principal reason for the 
first t h e r a p y change for both t reatment groups (17 pat ients in the 
monotherapy group and 11 in the combination group). For seven patients in 
the monotherapy group and nine in the combination group, superinfection 
occurred after modification. In the monotherapy group, four culture-negative 
LRTIs and three microbiologically documented LRTIs occurred: one caused by 
Legionella pneumophila and followed by late-onset bacteremia caused by E. 
cloacae, one (fatal) caused by A. Jumigatus, and one caused by С albicans. In 
the combination group, there were two cases of late-onset bacteremia due to 
coagulase-negative staphylococci and one LRTI caused by E. cloacae. The 
etiologies of four LRTIs and two SSTIs could not be established. 
New Infections and fever 
After stopping therapy, one patient In the monotherapy group developed a 
LRTI of unknown origin. In contrast, eight cases of subsequent infection 
occurred after combined therapy was stopped (Fisher's exact test; P<0.05). 
Pneumonia caused by L. pneumophila developed In one patient, and an LRTI 
of unknown origin was diagnosed in a patient who died. A third patient with 
an LRTI developed bacteremia due to Enterobacter aerogenes. There were also 
three patients with new FUOs and another patient died In shock presumed to 
be septic, although no causative pathogen was isolated. The last patient 
developed a tunnel Infection which subsided after removal of his Hickman 
catheter. 
Subsequent infective events 
Sixteen patients initially given ceftazidime alone experienced 29 subsequent 
Infective events throughout the granulocytopenic period, as compared with 
25 patients In the combination group, who experienced 36 further Infective 
events [χ2 =5.28 : 0.01<P<0.02). LRTIs accounted for 12 (41%) versus 13 (36%), 
FUOs accounted for seven (24%) versus 13 (36%) and SSTIs accounted for one 
versus four events In the monotherapy and the combination groups, 
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respectively. There were also four bacteremlc episodes and one case of brain 
abscess in each group. Abdominal complications and sinusitis represented 
the remainder. 
Adverse events and safety evaluation 
An Increase of 50% or more in serum creatinine levels was seen in three 
patients treated with monotherapy and in four treated with the combination. 
Normal kidney function was restored after the cessation of therapy in two 
and three patients, respectively. 
A greater-lhan-threefold rise in alkaline phosphatase, bilirubin, and /o r 
of transaminase levels was found in 10 patients treated with monotherapy 
and in six treated with the combination. These changes were reversible after 
the cessation of therapy in five and three patients, respectively. 
Two patients in the ceftazidime group experienced a n allergic skin 
reaction, as did eight in the combination group (Fisher's exact test; P<0.05) 
The rash appeared to be related to the study drugs in neither patient treated 
with monotherapy and in five patients t reated with the combination 
(Fisher's exact test; P<0.05). One case was probably caused by ceftazidime, 
since subsequent administration of the drug as sole treatment resulted in the 
reappearance of the rash. Teicoplanin appeared to be responsible for the 
exanthema in another case, since further therapy with ceftazidime alone was 
uneventful. It was not possible to determine which of the drugs was 
responsible in the remaining three cases. 
Patients given ceftazidime alone were thrombocytopenic (<20xl0 ^/liter) 
for 22.5 ± 4.6 days, and those given both drugs were thrombocytopenic for 
19.9 ± 5.2 days. The requirement for thrombocytes during treatment with 
teicoplanin was similar to that during treatment with ceftazidime alone 
(mean numbers of thrombocyte transfusions, 8.4 ± 3.3 and 7.8 ± 2 .1 , 
respectively). 
Complete audiograms were obtained for 29 patients treated with the 
combination, and no changes were recorded between the measurements 
obtained before and during the treatment. 
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Pooled data from both treatment groups 
Of 103 febrile granulocytopenic episodes, 12 (11.7%) resulted In death and 58 
(56%) were managed successfully with either of the Initial regimens alone. 
Thirty-eight percent of episodes were accompanied by bacteremia, 79% being 
due to Gram-posltlve bacteria. Forty-four percent of cases experienced one or 
more subsequent Infective events on average 7.4 ±1.4 days after onset of 
Initial fever with 75% developing between four and nine days. One In four 
patients developed subsequent Infection due to LRTI. Fever persisted for five 
or more days In 38% and its mean duration was similar for cases with initial 
FUO or Gram-positive bacteremia (7.3 ± 1.9 versus 9.7 ± 3.9 days, 
respectively; P>0.1) but patients who developed an LRTI were febrile 
significantly longer (17.5 ±4.1 days; P<0.01). 
Patients who responded without modification were granulocytopenic for a 
significantly shorter period than were those who responded after 
modifications: 18.3 ± 2.6 versus 26.1 ± 4.5 days, respectively (P<0.01). 
However, the periods of thrombocytopenia (<20 χ 10 9/1) were essentially the 
same. Of patients responding to Initial therapy, 53 ± 13% defervesced within 
72 hours compared with only 2 ± 4% of those responding to modified therapy 
(P<0.01). Those given initial therapy only were febrile for 3.8 ± 0.2 days, and 
those who needed additional antibiotics were febrile for 11.7 ± 0.7 days 
(P<0.01). The latter were also less likely to respond before granulocyte 
recovery (49 ± 15% versus 78 ± 11% , respectively [P<0.01]) and more likely 
to have a subsequent Infective event (71 ± 13% versus 22 ± 11% , respectively 
[P<0.01]). 
DISCUSSION 
This study was designed to Investigate the utility of adding teicoplanln to 
ceftazidime at the outset for the initial therapy of a FUO or bacteremia 
occurring during granulocytopenia, patients with infective foci being 
excluded. The study populations were similar in all essential details, 
Including those concerning granulocytopenia and oral antimicrobial 
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prophylaxis. Almost 40% of episodes were accompanied by bacteremia, the 
majority of cases being caused by Gram-posltlve cocci. 
More patients given the combination responded to therapy without 
modification than did those given ceftazidime alone. However, there were 
more instances of new Infection In the combination group, two of these 
resulting In death. Most deaths occurred seven or more days after empiric 
therapy was begun and all after modifications of one sort or another. The 
Initial Infection was responsible for one death, despite early modification 
with amikacin. The patient had persistent bacteremia due to E. cloacae, an 
organism likely to present problems to any patient given ceftazidime as the 
only anti-Gram-negative antibiotic If, as In this case, the strain is resistant 
or possesses a derepressible ^-lactamase. Clinical deterioration might have 
been prevented In the two cases with bacteremia caused by 'viridans' group 
streptococci had they been treated Initially with both ceftazidime and 
teicoplanln. Therapy was changed more often and earlier in the ceftazidime 
group, mainly because of what was regarded as being persistent fever. This 
change might have been due to genuine lack of efllcacy were it not for the fact 
that the proportion of patients with persistent fever was similar In both 
groups. Since only a minority of patients with a serious infection will 
defervesce within 72 hours (19), fever sustained for at least four or perhaps 
five days might In fact provide a more appropriate decision making point. 
The durations of fever were similar In both treatment groups. Including 
patients who had Initial Gram-positive bacteremia, and the majority of the 
cases of bacteremia were cleared before eventual modifications were made. 
Thus the response rate was dependant on whether the clinician perceived 
it to be necessary to modify the Initial treatment rather than on there being 
clear reasons for doing so. The modifications were done earlier in the 
monotherapy group because the clinician was inclined to augment the antl-
Gram-positive spectrum of ceftazidime more readily than for the 
combination, given that infection was more likely caused by these bacteria 
than by Gram-negative bacteria. Indeed, the day on which a drug other than 
teicoplanln was added to ceftazidime was comparable to the day on which 
the first modification was done in the combination group. In the light of 
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these facts, the larger number of modifications made to monotherapy does 
not reflect a lack of efficacy but rather an element of uncertainty on the part 
of the clinician. This phenomenon Is not peculiar to our study but has been 
encountered before. In both our center and others, but usually the exact 
reasons for changing the therapy have not been stated (20). These 
observations tend to support the conclusion tha t the strategy for 
management is influenced by the choice of initial therapy insofar as the 
clinician h a s the option of adding a specific anti-Gram-positive bacterial 
agent to ceftazidime alone but Is obviously denied this option when the 
patient has already started taking that agent. To avoid this bias, a study such 
as this one would have had to have been blinded and placebo controlled. This 
solution would be both complicated and expensive, but if the results of 
treatment are liable to be influenced strongly by observer effects, then the 
benefits outweigh the costs. 
Patients given therapy modifications were granulocytopenic significantly 
longer than were those responding to the initial regimens. Furthermore, they 
were febrile longer, experienced more infective events, and received more 
therapy. They were also more likely to die, and infections tended to resolve 
only after granulocyte recovery. These differences had more impact on 
outcome than had initial therapy, but apart from persistent fever, there is 
little to aid the clinician In defining this group prospectively. Nevertheless, 
these patients clearly represent a different risk group, possibly because of 
their longer period of granulocytopenia. It is clear that those who continue to 
have fever beyond the Initial therapy period are likely to develop further 
Infective complications, whereas those who respond early are not. Patients 
who remain persistently febrile or develop a second fever usually do so 
because of subsequent infection unrelated to the presence of initial 
bacteremia. Diagnosis and treatment, are difficult and the fact that most 
complications occur within nine days off the start of the Initial therapy 
demonstrates a clear need for sustained clinical attention. Currently, around 
30 to 40% of leukemic patients fall into this category (21). 
Our repeated failure to isolate bacteria in these patients suggests another 
etiology, especially In cases where a lung infiltrate developed. These were 
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associated with persistent fever and a mortality of 4 1 % and were mostly of 
fungal etiology (in cases that were documented). Pat ients with lung 
infiltrates also remained febrile for a longer period t h a n those with either 
initial bacteremia or a FUO. Thus, the presenting Infection did not appear to 
be prognostic for either further infective complications or the ultimate 
outcome. 
More pat ients treated Initially with ceftazidime and teicoplanln t h a n 
with monotherapy developed a subsequent Infection during the whole 
granulocytopenic phase, mainly a SSTI and a second FUO. The difference 
could not be explained by the duration of granulocytopenia or total fever or 
by the total n u m b e r of the antimicrobial drugs given as modification. 
However, subsequent Infective events developed more frequently In patients 
treated with two drugs Initially t h a n in patients treated with monotherapy 
modified by one drug, suggesting that the initial t r e a t m e n t of a 
granulocytopenic patient with more than one antibiotic may be complicated 
by a higher risk of subsequent infection. 
Concentrations of teicoplanln in serum were within the expected range 
and there were few Inter-patient variations (12). There was neither evidence 
of major telcoplanln-related toxicity nor evidence of any obvious adverse 
effects on the bone marrow recovery In terms of return of thrombocytes and 
leukocytes or with regard to ototoxicity. Notwithstanding the greater number 
of allergic skin reactions attributable to the combination, teicoplanln still 
appears to offer a safe alternative to vancomycin when an antl-Gram-
posltlve bacterial agent is required. 
The results of our study showed that the addition of teicoplanln at the 
outset to ceftazidime did not markedly alter the final outcome in febrile 
granulocytopenic pat ients . We acknowledge t h a t to detect reliably a 
difference of 15%, we would have needed about 200 assessable episodes in 
each randomization group (β=0,8, α=0.05). Such a study would have taken at 
least four years to accomplish In our centre and was therefore not feasible. 
Nevertheless, our results suggest that if such a difference does exist, it Is 
likely to be small and therefore of questionable clinical relevance. Our 
selection criteria were broad, since Initial Gram-positive bacteremia was 
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detected in only about 30% of episodes. Thus, at least 70% of cases of a 
general population of febrile, granulocytopenic patients will be overtreated 
when a glycopeptlde antibiotic is given initially. The prevalence of infection 
caused by Gram-positive bacteria, such as In cases of line-associated 
infections, should be one of the determinants in deciding whether to add a 
specific agent at the outset. The mortality and morbidity associated with 
postponing the administration of a glycopeptlde mus t also be taken into 
account. In our patient population, these were relatively low, as was also the 
case in other studies (9, 21), but the risk of superinfection was higher in the 
two-drug treatment group. This risk indicates that one should only add a 
specific agent when required, although others have argued to the contrary 
(10, 22). Each centre must know Its own epidemiology and make its own 
decision In the light of the published data. 
In conclusion, our results show that the addition of telcoplanln to Initial 
empiric therapy is unnecessary in pat ients with presumed bacteremia 
without specific signs and symptoms of Gram-positive infections. Its use 
may also lead to more Infective complications and adverse events. However, 
when indicated, the drug is both effective and relatively safe. 
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ABSTRACT 
In a prospective randomized study, 90 granulocytopenic febrile patients 
presenting with a localized Infection were treated empirically with 
ceftazidime alone or In combination with amikacin (1.5 g/day). Two-thirds 
had received selective oral antimicrobial prophylaxis before therapy. The 
treatment groups were comparable in terms of the depth and duration of 
granulocytopenia as well the distribution of the Infection categories and rate 
of bacteremia. There was no difference with respect to the final response: 
53% for the monotherapy group versus 48% for the combination group, and 
both regimens appeared to be equally safe. The duration of fever, clinical 
symptoms, antibiotic therapy, and granulocytopenia were comparable for 
both treatment groups and approximately 90% of patients survived the 
Infection. Only one patient given monotherapy required amikacin. It Is 
concluded that aminoglycosides are not necessary for the empiric treatment 
of infectious complications In granulocytopenic patients if antibacterial 
prophylaxis has been given beforehand. 
INTRODUCTION 
Empiric antibiotic treatment of the febrile granulocytopenic patient is a 
generally accepted strategy, the goal of which is to prevent early morbidity 
and mortality due to Infection. A combination of an aminoglycoside with a 
JÎ-lactam Is traditionally recommended in order to provide extensive 
coverage (1, 2). The availability of antibiotics with a very broad spectrum of 
activity has recently provoked considerable discussion as to the necessity of 
such combinations under all circumstances (3, 4). Indeed, trials of empiric 
therapy in unselected febrile neutropenic patients have failed to establish 
any superiority of multiple-drug regimens over a single agent with similar 
broad spectrum activity such as ceftazidime (4-7). Combinations are aimed 
particularly at Gram-negative bacteria, and the lack of superiority of these 
regimens may be due to the fact that Gram-positive cocci now account for a 
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greater proportion of Infections, particularly those of the blood stream (3). 
Nevertheless, Gram-negative organisms may still remain the most likely 
cause of focal infection, particularly that of the lung (8-10). It seemed 
worthwhile to address specifically whether or not the addition of an 
aminoglycoside to ceftazidime would be of benefit in the empiric treatment 
of febrile, granulocytopenic patients with a focus of Infection at the onset of 
fever. The study was designed as a prospective randomized trial and was 
approved by the ethics committee (CEOM 1986-919). 
PATIENTS AND METHODS 
Patients were eligible If they were 14 years or older, febrile (axillary 
temperature £38.5 0C) with signs of a local infection, granulocytopenic (<1.0 χ 
109/1, expected to fall to <0.5 χ 10^/1) and had given Informed consent. 
Patients without an initial focus of infection were recruited to other 
contemporaneous protocols (11, 12). Those eligible for the current study were 
randomized only once during the same granulocytopenic phase and had 
received no other parenteral antibiotics before starting therapy. All were 
nursed In reverse isolation and given a diet of low microbial content. All but 
11 patients In each group had received selective oral antibacterial and 
antifungal prophylaxis. The diagnostic procedures have been described 
previously (12) 
When a patient was eligible, the attending physician opened a sealed 
envelope containing the prescribed treatment. These envelopes had been 
generated using a computer and were to be opened following a strict 
numerical sequence. Ceftazidime was given In a short Infusion of 2 g and 
amikacin as a 30-min Infusion of 500 mg. Both drugs were administered 8-
hourly. Treatment could be modified If the presenting Infection progressed or 
was thought not to have been caused by bacteria, if a subsequent Infective 
event such as superinfection or new fever occurred, or the clinical response 
was Inadequate. Antimicrobial treatment was continued until the patient 
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was free of symptoms, signs, and fever for at least four days If still 
granulocytopenic or for two days If not. 
Definition of Infection 
Classification of the presenting infection was based on clinical and 
microbiological data obtained at onset of infection. BACTEREMIA was defined 
as being at least one blood sample positive for all organisms except for 
coagulase-negative staphylococci and 'vlridans' streptococci, for which two 
or more positive samples were required (13). LOWER RESPIRATORY TRACT 
INFECTION (LRTI) was diagnosed when an infiltrate was detected 
radiologically. An Infection was considered proven when a positive culture 
from bronchial alveolar lavage (BAL) was obtained or when microorganisms 
were detected histologically in material obtained at autopsy, and was 
presumed If sputum culture yielded organisms not considered as normal 
upper respiratory commensal flora. SKIN OR SOFT TISSUE INFECTION (SSTI) 
comprised erythema. Induration, and tenderness of the skin or soft tissue. 
UPPER RESPIRATORY TRACT INFECTION (URTI) included clinical (and 
radiological) signs of sinusitis, pharyngitis or tonsillitis. Dysuria. with a 
positive urinary culture was considered as URINARY TRACT INFECTION (ΙΓΠ). 
The development of a new focus, bacteremia, or fever were considered to be 
subsequent infective events. 
All Isolates were identified by standard laboratory techniques and 
antibiotic susceptibility was determined by means of disk diffusion 
according to the National Committee for Clinical Laboratory Standards (14). 
A strain was considered resistant to the combination If it was resistant to 
both antibiotics. 
Clinical evaluation and definition of outcome 
The outcome of therapy was classified at the end of therapy as follows: 
RESPONSE: the patient survived the infection, and all signs and symptoms 
disappeared without any change of Initial therapy. 
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RESPONSE AFTER THERAPY MODIFICATION: the patient survived the 
infection, but defervescence and resolution of all signs and symptoms of 
Infection occurred only after modification of the empiric regimen. 
FAILURE: the patient died due to infection whether or not therapy was 
modified. 
UNASSESSABLE: patients who were not granulocytopenic, or whose fever 
was proven to have a nonbacterial etiology at the onset, or whose death was 
unrelated to Infection. 
All possible adverse events were documented. 
Statistics 
All means are given with their respective 95% confidence intervals and the 
differences between treatment group parameters were analyzed by the 
Student-1 test. Categorical data were analyzed by means of χ^ with Yates 
correction. 
RESULTS 
Details of patients are shown in the TABLE 1. In total, 45 febrile episodes 
occurred in 40 patients given ceftazidime alone and 42 patients given the 
combination. More cases given the combination were leukemic, but there 
was no difference In the intensity of antitumor therapy. 
Nine of 45 episodes given monotherapy were unassessable: granulocytes 
remained above 0.5 x 10^/1 in three cases, two were randomized a second 
time during the same granulocytopenic episode, one patient was already 
receiving parenteral antibiotics at entry, and therapy was stopped after 24 
hours due to rash In another. In addition, one patient died due to cerebral 
hemorrhage and another patient was given antifungal therapy within 24 
hours of entry for presumptive mycotic pneumonia. She died on day 13 of 
Aspergillus fumigatus infection confirmed at autopsy. Twelve of 45 cases 
treated with combination were unassessable: eight never became 
granulocytopenic below 0.5 x 109/1, one was given amphotericin В 
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Intravenously at the start of empiric therapy, and another died due to 
progression of non-Hodgkln's lymphoma. One patient was never given 
amikacin at all and the drug was started four days after entry to another 
case. Thus 36 episodes treated with monotherapy and 33 episodes from the 
combination group were assessable for clinical and microbiological 
evaluation. These episodes were comparable In terms of granulocyte count at 
the onset of Infection, the total duration of granulocytopenia (<0.5 χ 10^/1), 
and onset of fever after becoming granulocytopenic. 
TABLE 1. Clinical and demographic data 
Number of patients 
Male/female 
Age: mean (years) 
95% confidence interval 
Range 
Underlying disease 
Leukemia 
Other malignancies 
Total number of episodes 
Chemotherapy treatment: 
Antileukemic therapy 
Other chemotherapy 
No therapy 
Assessable episodes 
Granulocytes at onset of fever 
< 0.1 
0.1-0.5 
> 0.5 
Duration of granulocytopenia < 
(No. 
0.5 
X 109/l) 
(days)* 
Onset of fever after granulocytopenia (days)* 
Ceftazidime 
40 
17/23 
42.9 
5.0 
16-83 
22 
18 
45 
32 
11 
2 
36 
19 (53%) 
9 (25%) 
8 (22%) 
22.5 ± 4.7 
9.1 ± 5.7 
Ceftazidime 
+ Amikacin 
42 
32/10 
45.4 
5.2 
15-82 
35 
7 
45 
35 
4 
6 
33 
21 (64%) 
6 (18%) 
6 (18%) 
26.0 ± 7.7 
5.7 ± 4.5 
* ± 95% confidence interval 
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Failures of therapy. 
Three patients died while receiving ceftazidime. The first died on the third 
day of therapy; he had presented with both septicemia due to Escherichia coli 
and LRTI of unknown etiology. The second patient presented with Initial 
bacteremia due to Streptococcus sanguis after bone marrow transplantation. 
She developed a skin Infection and lung Infiltrate for which she was treated 
Intravenously with erythromycin, amphoter icin B, and acyclovir, in 
addition to ceftazidime, but she died of pneumonitis 26 days after Initial 
infection despite Intensive care. Both s t ra ins were fully susceptible to 
ceftazidime. The third patient presented with pneumococcal pneumonia, 
peritonitis due to E. coli, and polymicrobial bacteremia (Streptococcus 
pneumoniae + E. coli + Closírídíum sporogenesi. He died on the second day of 
therapy despite the addition of parenteral ampiclllln, and no susceptibility 
data were available. Extensive pneumonia and perforation of the stomach 
were found at autopsy. 
Two patients, who received the combination of ceftazidime and amikacin 
without further modifications died. One died in shock after three days 
treatment having presented with a urinary tract infection due to a susceptible 
E. coli although blood cultures were sterile. The other patient also presented 
with urinary tract symptoms, but cultures. Including those from blood, were 
negative. On the second day of therapy, he developed LRTI presumed to be due 
to Staphylococcus aureus, which was cultured only from sputum and was also 
susceptible to ceftazidime. He died three days later. Two patients with 
refractory leukemia died in respiratory failure. In one case the patient died 
10 days after onset, having failed to respond to the addition of teicoplanln, 
erythromycin, and amphotericin B. all given intravenously. Multiple 
Infiltrates due to A. fiimigatus were found at autopsy, together with extensive 
pulmonary hemorrhage. The other patient died seven days after starting 
empiric therapy. He had presented with LRTI of unknown origin, which did 
not respond despite the addition of vancomycin, erythromycin and 
amphotericin B. No autopsy was performed. 
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Responden 
Infection of the lower respiratory tract comprised the largest single category 
of Infection, followed by URTI and SSTI. (TABLE 2). 
TABLE 2. Categories of infection in relation to outcome of therapy-survivors 
only. 
Ceftazidime Ceftazidime + amikacin 
Total Without With Total Without With 
modification modification modification modification 
Number 
of 
episodes 
LRTI 
URTI 
SSTI 
UTI 
aOthers 
33 (5) 
13 (2) 
8 (1) 
6 
2 (1) 
4 (1) 
19 (4) 
6 (1) 
6 (1) 
2 
1 (1) 
4 (1) 
14 (1) 29 (3) 16 (2) 
7 (1) 
2 
4 
1 
13 (2) 
6 
8 
2 (1) 
5 
4 
5 (1) 
2 (1) 
13 (1) 
8 (1) 
2 
3 
( ) Number in parentheses is number associated with Gram-negative infection 
a
 Three cases of gingivitis and one case of sterile peritonitis with bacteremia due 
to E. coli 
However, microbiological documen ta t i on was achieved in only 
approximately one-third of cases: 11 of 33 survivors (33%) In the ceftazidime 
group and 10 of 29 cases (35%) in the combination group (TABLE 3). Gram-
negative infection was established In ftve cases in the ceftazidime group and 
In three cases cases In the combination group. Infection due to S. aureus was 
recorded only once In the ceftazidime group, compared with four cases in the 
other group. All s t rains were susceptible to the study drugs, with the 
exception of the EnterococcusJaecalis Isolated in the ceftazidime group and 
one coagulase-negatlve staphylococcus In the other group. 
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Overall, response without modification was achieved in 19 cases (53%) 
given the monotherapy and 16 (48%) treated with the combination. 
TABLE 3. Microbiological documentation of infection in survivors. 
Initial focus Etiology Bacteremia Outcome 
Ceftazidime 
LRTI a 
LRTI 
LRTI 
LRTI 
LRTI 
SSTI 
SSTI 
UTI 
UTI 
Abdomen 
Pharyngitis 
Not established 
Xanthomonas maltophilia 
Not established 
Haemophilus influenzae 
Enterococcus faecalis 
Staphylococcus 
Not established 
Not established 
Not established 
Not established 
E. coli 
aureus 
Streptococcus mitis 
СЫ
Ь
 staphylococci 
CN staphylococci 
None 
None 
S. aureus 
CN staphylococci 
Escherichia coli 
CN staphylococci 
E. coli 
E. coli 
RM 
RM 
RM 
R 
R 
R 
RM 
R 
RM 
R 
RM 
Ceftazidime 
+ amikacin 
LRTI 
LRTI 
LRTI 
SSTI 
SSTI 
SSTI 
SSTI 
UTI 
Sinusitis 
Pharyngitis 
£. coli 
S. aureus 
Not established 
Not established 
Not established 
Not established 
Not established 
E. coli + Proteus 
mirabilis 
Not established 
S. aureus 
CN staphylococcus+ 
E. faecalis 
S. aureus 
CN staphylococci 
CN staphylococci 
S. aureus 
S. aureus 
E. coli 
None 
S. mitis 
S. aureus 
RM 
RM 
R 
R 
R 
RM 
R 
R 
RM 
R 
R, Response without modification; RM, response after modification 
a
 LRTI were presumed due to the stated organism since only sputum samples had 
been obtained, b CN coagulase-negativo 
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Of the 15 patients In each group with Initial LRTI, six (40%) responded to 
monotherapy alone and Ave (33%) to the combination without modification. 
In contrast, 13 of 21 patients (62%) with other Infections responded to 
ceftazidime and 11 of 18 (61%) to the combination. 
Therapy was modified In 14 survivors (42%) after 5.0 ±1 .0 days in the 
monotherapy group compared with 13 episodes (45%) after 5.6 ±1.2 days In 
the combination group. Progression of initial infection was the reason for 
modification in seven cases in both treatment groups. Four patients who had 
received monotherapy had failed to defervesce within three days compared 
with two patients given the combination. A subsequent infective event was 
the reason for altering therapy In three cases in the monotherapy group, 
compared with four cases In the combination group. The etiology was not 
established in any Instance at this time. Antibiotic resistance did not play 
any role in the decision to alter therapy. 
On average, there were 1.9 ± 0.7 modifications per patient in the 
ceftazidime group and 2.1 ± 0.8 modifications in the combination group. 
although half were given only one additional antibiotic. Glycopeptides were 
given to nine and seven patients and antifungals to five and eight patients 
given monotherapy and the combination respectively. Only one patient 
treated Initially with ceftazidime alone was given amikacin as first 
modification. A low proportion of responders from both treatment groups 
became afebrile within 72 hours (TABLE 4) and fever lasted an average of one 
week. However, the majority of patients in both groups became afebrile 
before granulocytes recovery. Treatment groups were also comparable in 
terms of the duration of symptoms, antibiotic therapy and total 
granulocytopenia. 
Subsequent Infective events 
Overall, subsequent Infective events I.e.. superinfection and new episodes of 
fever, occurred In seven of 33 cases 21%) in the monotherapy group (1 second 
fever, 5 LRTI, 1 SSTI) compared with 11 of 29 cases (40%) In the combination 
group (3 second fever, 4 LRTI. 4 SSTI). The etiology was confirmed in only one 
case. This patient had Initially responded to ceftazidime, but one week later 
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fever recurred. The LRTI became worse and A. fumigatus was cultured from 
three consecutive sputum samples. He was treated successfully with 
Intravenous amphotericin В . 
TABLE 4. Clinical parameters in survivors. 
Total number 
Defervescence within 72 h 
Duration of fever* 
Defervescence at least 2 days 
before granulocyte recovery 
Duration of symptoms* 
Duration of antibiotic therapy* 
Duration of granulocytopenia* 
Ceftazidime 
33 
10 (30%) 
6.8 ± 1.6 
28 (85%) 
9.0 ± 3.0 
13.0 ± 3.5 
21.4 ± 3.6 
Ceftazidime 
+ amikacin 
29 
7 (24%) 
10.0 ± 2.7 
24 (83%) 
7.3 ± 2.2 
16.9 ± 6.8 
27.2 ± 9.0 
* Mean number of days ± 95% confidence interval 
Adverse events 
Two patients In the ceftazidime group experienced a rise in serum creatinine 
of more than 50% above pretreatment values. Both patients had been given 
multiple modifications. Including glycopeptldes and parenteral 
amphotericin B, before adverse reactions occurred. Renal dysfunction was 
not observed in any case treated with the combination. Liver transaminases 
rose to greater than three times the norm In two cases In the monotherapy 
group and four In the other group. The disturbance was probably due to 
ceftazidime in two cases since normal function was restored after 
discontinuation of the drug. One patient in each group developed a skin rash, 
which was probably related to ceftazidime. 
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DISCUSSION 
This trial was designed to address the question of whether or not the initial 
addition of amikacin would reduce the morbidity and mortali ty of 
granulocytopenic patients presenting with localized infections. Our results 
failed to show any significant benefit for the addition of the aminoglycoside 
ab initio. We readily acknowledge that we did not accrue a sufficient number 
of subjects In order to reduce the type-II error. However, our experience 
suggests that even were we to have done so, it is unlikely that we would have 
been able to show a significant advantage, for two main reasons. First, 
microbiological documentation was achieved in a minority of cases, and if 
bacteremia is excluded, the cause of the infection was identified only in 19% 
of all assessable cases, a figure similar to that reported by the EORTC (3). 
These data highlight an ongoing problem in diagnosing the cause of infection 
in granulocytopenic patients. Second, we encountered only 11 episodes of 
Infection due to Gram-negative bacteria, there being only one Instance of 
proven Gram-negative pneumonia. This may have been due to the fact that 
two-thirds of pa t ien t s had been given selective oral antimicrobial 
prophylaxis, which has been shown to be effective In reducing Gram-negative 
bacteremia If not other Infections due to these organisms (15, 16). 
However, even if a difference in efficacy does exist, it is likely to be small 
since treatment groups were comparable in almost every respect, including 
the categories of infection. The larger number of leukemic patients in the 
group treated with amikacin did not lead to a major Imbalance since the 
chemotherapy given resul ted in a similar grade and dura t ion of 
granulocytopenia, the principal infective risk factor (17). Mortality was the 
same In both treatment groups, being 10% Including those cases with lung 
infiltrates. The overall response was also similar and neither was there any 
evidence of a more rapid response in terms of the duration of fever or 
symptoms. Only 30% of survivors from both treatment groups became 
afebrile within 72 hours , which corresponds with the higher risk group, 
described by Pizzo, namely patients who are granulocytopenic for longer 
than 14 days (17). The outcome achieved In our patient population was in fact 
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very similar to that reported for cases without an Infectious focus at onset of 
fever (11, 12) and was also comparable to the results reported by the National 
Cancer Institute (4) 
There was also no difference In the rate of modification, the reasons for 
modifying therapy , which were m a d e on clinical r a the r t h a n 
microbiological grounds, or in the use of glycopeptides and antifungal drugs. 
Amikacin was in fact added to ceftazidime in only one case; thus, 32 of the 33 
pa t ien t s were managed successfully wi thout any aminoglycosides 
whatsoever. 
The dose of amikacin used in this s tudy was 50% higher t han is 
conventional and did not result in an Increase in side effects. Higher doses of 
this and other aminoglycosides appear necessary due to the greater volume of 
distribution and the higher clearance rate (18). We did not measure levels in 
this study since we had previously shown 1.5 g amikacin/day to result in a 
peak which ranged from 26.2 to 42.5 mg/1 and averaged at 34.7 mg/1, while 
the corresponding trough levels ranged from 7.9 to 16 mg/1 and averaged at 
12.6 mg/1 (11). 
We therefore conclude that aminoglycosides are not necessary for the 
empiric treatment of infectious complications in granulocytopenic patients 
if antibacterial prophylaxis has been given beforehand. 
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ABSTRACT 
Three hundred episodes of neutropenia were reviewed for the occurrence of 
potential sites of Infection. Ninety sites (30%) were Identified at the onset of 
fever independent of initial bacteraemia which was encountered In 104 
episodes (35%) predominantly involved Gram-positive cocci. A further 90 
sites were recorded involving mainly the lower respiratory tract (58%) and 
skin and soft tissue (18%). These changes evolved significantly later (mean 
of 5.1 and 4.3 days respectively) than did other foci which mainly presented 
at the onset of fever (P<0.01). However, the infectious aetiology was 
established In only 54 cases overall, with fungi being responsible for 25 of 45 
cases of lower respiratory tract Infections with a known microbiological 
aetiology. The mortality associated with the Initially diagnosed fever of 
unknown origin, initial bacteraemia and presenting focus of infection was 
13%, 11% and 14%, respectively, while that associated with the development 
of a subsequent focus was 28%, with lung Infiltrates carrying the worst 
prognosis. Therefore rather than being seen as a final solution for possible 
Infectious complications, empiric therapy provides an opportunity for daily 
review of the patient thereby Increasing the likelihood of both explaining 
Initial fever and diagnosing subsequent infection. 
INTRODUCTION 
Intensive chemotherapy for malignant disease increases the risk of infection 
by inducing both mucosal damage and compromised immunity particularly 
neutropenia. Pyrexia Is often the only sign of infection due to the lack of 
granulocytes but there is no reliable way of distinguishing fever of infectious 
origin from that due to other causes. Consequently, therapy with broad-
spectrum antibiotics is begun as soon as there is an elevation In the body 
temperature, typically in excess of 380C, in order to reduce infection-related 
morbidity and mortality (1, 2). While fever is explained microblologically 
and clinically in about 60% of cases, no explanation is found for the 
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remainder (3, 4). Nevertheless, the majority of patients will respond to 
antimicrobial therapy favourably within a few days suggesting occult 
Infection. Where fever persists , however, there is a tendency to add 
antibiotics on a trial and error bas is (5) ra ther t han exploiting the 
opportunity provided by the empirical phase In continuing at tempts to 
identify the origin of fever. Clearly, defining the aetiology would permit 
appropriate therapy to be given thus avoiding any unnecessary, and possibly 
hazardous, medication. 
Febrile neutropenic patients do not comprise a homogeneous population. 
Certain risk groups can already be delineated at the onset of fever, for 
example lower respiratory tract infection (3, 6-8), but there are few data to 
Indicate the frequency with which Infections become manifest subsequently. 
This reflects the difficulty In distinguishing infection clinically from other 
processes particularly where the lung is concerned, and mlcroblologlcally 
when a body site Is normally colonised with commensal flora which Includes 
potential pathogens such as the 'viridans' streptococci in the oral cavity. 
There Is also seldom any opportunity of procuring appropriate samples 
safely and the value of any microbiological data obtained is often limited by 
lack of sensitivity and specificity (9). Nevertheless, it seems Important as a 
first step to at least establish the frequency with which sites of potential 
infection occur during neutropenia despite such constrains since th is 
information might prove valuable In deciding when to adjust empiric 
therapy. If at all. We therefore reviewed 300 febrile, neutropenic episodes 
experienced by 210 patients who had been treated at our Institute with 
Intensive chemotherapy during the years 1985-1988 to determine the 
occurrence of potential sites and assess their Impact on the eventual 
outcome. 
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PATIENTS AND METHODS 
Eligibility 
Case histories were obtained of each patient that had met Identical entry 
criteria for three consecutive ongoing randomised trials of empirical therapy 
for fever occurring during neutropenia. Those for which no focus was 
detectable at the onset of fever were entered Into two sequential studies where 
the first 90 had been treated initially with either a combination of amikacin 
and piperacillin or ceftazidime (10) while the next 120 had received either 
ceftazidime alone or in combination with telcoplanln (11). A further 90 cases 
h a d presented with a presumed focus of infection for which either 
ceftazidime had been given either alone or in combination with amikacin 
(12). Patients had been nursed in reverse-barrier isolation and 70% had 
received selective oral antimicrobial prophylaxis with either co-trimoxazole 
and Colistin or ciprofloxacin In a ratio of approximately 2:1. 
Diagnostics procedures 
P r e t r e a t m e n t eva luat ion h a d included relevant history, phys ica l 
examination, haematologlcal and biochemical profiles, chest X-ray and 
cultures of blood and any clinically suspicious lesions. Patients had been 
examined daily, with haematologlcal and biochemistry profiles being 
obtained three times a week and at least once weekly, respectively. Blood 
cultures had been taken dally for as long fever persisted and also before any 
change in antimicrobial therapy had occurred. Follow-up chest X-rays had 
been made only when clinically Indicated, or whenever fever had persisted 
for at least six days. 
Oral mucositis was only considered to constitute a potential UPPER 
RESPIRATORY INFECTION If there was evidence of necrosis, gingivitis or 
herpetic lesions. Cellulitis or the presence of erythema, induration, and 
tenderness or warmth was considered as INFECTION OF SKIN OR SOFT Ή58υΕ. 
PULMONARY INFILTRATES whether or not accompanied by respiratory signs 
and symptoms such as cough or dyspnoea were deemed infectious in the 
absence of an alternative explanation. URINARY T R A C T I N F E C T I O N was 
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defined by frequency and dysuria or by the culture of more than I O 5 colony 
forming units per milliliter of a single organism from urine that had been 
adequately collected. 
Whenever possible, an attempt h a d been made to demonstrate any 
potential pathogens from sites presumed to be Infected. Microbiological 
confirmation required culture of specific pathogens such as Sireptococcus 
pneumoniae or Legionella species. Infection was considered proven due to 
Staphylococcus aureus. Gram-negative rods and Candida species when the 
organism had been recovered from blood or tissue, whereas their aetiologic 
role was regarded as uncertain when they were recovered from secretions 
such as sputum. Mycotic Infection of the lung was considered proven when 
examination of t issue showed fungal elements, b u t full Identification 
required isolation of the fungus. Oral candidiasis was diagnosed on the basis 
of direct smear and culture. All other normal commensal flora cultured from 
mouthwashes, faeces and superficial swabs of the skin were discounted. 
Isolates were identified by means of standard laboratory techniques and 
the susceptibility of bacteria to antibiotics was determined by agar diffusion 
according to the NCCLS guidelines (13). 
Definitions 
Neutropenia was defined as a granulocyte count of < 0.5 χ 10 9/1. Fever was 
defined as an axillary temperature > 38.0 0C sustained for 2-4 hours, or single 
temperature >38.5C'C In the absence of an obvious non-infectious cause. 
FEVER was considered to be OF UNKNOWN ORIGIN when no focus had been 
identified and microbiological evaluation had failed to yield any potential 
pathogen. BACTERAEMIA was defined as the occurrence of at least one positive 
blood culture of any organism with the exception of coagulase-negative 
staphylococci for which two Identical positive cul tures were necessary. 
Initial bacteraemla entailed recovery of any organism from blood within two 
days of starting therapy while late bacteraemla was reserved for any episode 
which first occurred after this time. 
A potential focus of infection which developed more t h a n two days after 
the onset of fever was classified as a subsequent event. 
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Death was attributed to infection when it occurred as a direct consequence 
of either the presenting or subsequent presumed infective event. 
Statistical methods 
All m e a n s and proportions are given with their respective s t a n d a r d 
deviation. Categorical data were analysed by m e a n s of χ 2 with Yates 
correction except when the number in any category was less than five In 
which case Fisher's exact test was employed. 
RESULTS 
The casenotes of 92 female and 118 male patients were reviewed. Their mean 
age was 43.5 ± 15.3 years and ranged from 16 to 83 years and the majority 
(89%) had been treated for haematological malignancy (TABLE 1). Fever 
developed Just over a week after the onset of neutropenia at which time the 
majority of pat ients had a granulocyte count of < 0 . 5 x l 0 9 / l . The total 
duration of neutropenia was on average about three weeks. 
Potential sites of Infection were identified in 90 of 300 febrile episodes 
(30%) at onset of fever of which 28 (31%) were accompanied by positive blood 
cultures (FIGURE 1). Initial bacteraemla without an infectious focus was 
detected In 76 (25%) while no explanation for fever was found in the 
remainder. A second potential focus of Infection was identified In 15 of 90 
episodes with a presenting site of Infection (17%) while one developed de novo 
In 71 of 210 episodes without an Initial focus (34%; P<0.005). These foci 
developed In 36 out of 104 cases which h a d presented with Initial 
bacteraemla (35%) compared with 50 out of 196 cases In which blood cultures 
had been initially negative (26%; R>0.1). Late bacteraemla was detected In 17 
of 300 cases (6%). 
Overall, bacteraemla was detected In 114 of 300 episodes (38%) of which 
104 were recovered at the onset of fever (TABLE 2). Two episodes of 
bacteraemla were encountered In seven cases. Gram-positive bacteria 
predominated with 'v ir idans ' s treptococci a n d coagulase-negatlve 
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staphylococci in both initial and late bacteraemlas. The three cases of 
fungaemia all occurred later during the course of fever. 
TABLE 1. Clinical data on febrile episodes. 
Number of febrile episodes 300 
Underlying disease related to episodes 
Acute myeloid leukaemia 
Acute lymphoblastic leukaemia 
Myelodysplastic syndrome 
Chronic myeloid leukaemia 
Lymphoma 
Other haematological malignancies 
Solid tumors 
Number of episodes with granulocytes count < 0.5 χ 109/l 
at onset of fever 
Onset of fever after onset of neutropenia (days) 
range 
mean ± standard deviation 
Number of episodes assessable for total duration 
of neutropenia 
Reason for unassessable 
Persistent neutropenia 
Granulocytes count at death < 0.5 χ 109/l 
No neutropenia 
Insufficient data 
Duration of neutropenia (days) 
range 
mean ± standard deviation 
139 
48 
12 
24 
31 
12 
34 
262 
0-74 
7.9 ± 10.2 
22.2 
224 
10 
33 
20 
13 
2-90 
± 12.3 
In total 180 foci developed during 161 episodes of which lung Infiltrates 
accounted for majority of both initial and subsequent foci (TABLE 3), 
comprising 58% of cases. Skin and soft tissue lesions were the second most 
frequent site (18%), followed by the upper respiratory tract (12%). Foci 
emerged steadily with time (FIGURE 2) with more than 90% becoming 
manifest within 14 days after onset of fever. Lung infiltrates appeared after a 
mean of 5.1 ± 5.8 days ( range 0-21) , and skin and soft tissue lesions after 
4.3 ± 7.3 days (range 0 - 32) from onset of fever while other foci were already 
apparent at its onset. Overall, 30% of foci were confirmed microbiologically. 
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Four of nine presumed urinary tract Infections were proven by significant 
bacterlurla: two cases were caused by E. colt, one by E. coli together with 
Proteus mirabilis, and another by Klebsiella pneumoniae and Enterococcus 
faecalis. 
TABLE 2. Microorganisms cultured in blood 
Microorganism Initial Late 
Gram-negative 
Pseudomonas aeruginosa 
Klebsiella pneumoniae 
Escherichia coli 
Enterobacter cloacae 
Enterobacter aerogenes 
Morganella тогдапіі 
Aeromonas hydrophila 
Haemophilus influenzae 
Gram-positive 
Staphylococcus aureus 
Coagulase-negativo staphylococci 
Stomatococcus mucilaginosus 
Streptococcus mitis 
Streptococcus sanguis 
Streptococcus salivarius 
'Viridans' group streptococci 
Group G streptococci 
Streptococcus bovis 
Streptococcus faecalis 
Anaerobic 
Mycotic 
Candida albicans 
Candida tropicalis 
Polymicrobial 
Total 
16 
1 
2 
7 
2 
1 
1 
2 
74 
14 
21 
2 
18 
10 
1 
5 
1 
1 
1 
2 
12 
104 
(1) 
(4) 
d) 
(6) 
3 
1 
1 
1 
9 
8 
1 
3 
2 
1 
2 
17 
( ) Resistant to empirical regimen 
109 
focus at Init ial subsequent late 
onset bacteraemia focus bacteraemia (died) 
0 
3 
0 
25 
0 
12 
1 
49 
5 
28 
2 
41 
6 
3 2 * 
3 
93 
(1 ) * 
(3) 
(3 ) * 
(6) 
(7 ) * 
(1) 
(13) 
(1) 
(3) 
FIGURE 1. Flow chart showing number of cases with and without presenting 
focal infection, initial bacteraemia at onset of fever and occurrence of the 
subsequent focus or bacteraemia. 'Second subsequent focus developed in one 
case 
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TABLE 3. Initial and subsequent clinical foci. 
Site 
Pulmonary complications 
Skin and soft tissue lesions 
Other sites 
upper respiratory tract 
urinary tract 
abdominal complications 
central nervous system 
Otitis media 
Total number 
Initial 
42 
17 
19 
8 
2 
1 
1 
90 
Subsequent 
63 
16 
3 
1 
4 
3 
90 
Total 
105 
33 
22 
9 
6 
4 
1 
180 
E 
Ü 
100-
9 0 -
8 0 -
7 0 -
6 0 -
5 0 -
4 0 -
3 0 -
2 0 -
10-
0 - l i l i l í 
7 14 
Days after onset of fever 
21 
FIGURE 2. The rate of development of different foci. Infections of the lower 
respiratory tract infection ( · ) and skin and soft tissue (Δ) develop more 
slowly than do those involving other sites (O) 
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Three out of six abdominal Infections were attributed to bacteria with a 
single case of peri tonit is due to E. coli, a n d one case each of 
p s e u d o m e m b r a n o u s colitis due to Closiridium difficile and enterit is 
involving Campylobacter Jejuni 
TABLE 4. Microbiological aetiology of lung infiltrates. 
Cause Total 
number 
Bacterial 
Pseudomonas aeruginosa 
Escherichia coli 
Xanthomonas maltophilia 
Morganella morganii 
Enterobacter cloacae 
Enterococcus species 
Gram-negative rods 
Haemophilus influenzae 
Staphylococcus aureus 
Legionella pneumophila 
Mycotic 
Aspergillus fumigatus 
Candida albicans 
Candida tropicalis 
Geotrichum candidum 
A. fumigatus + C. albicans 
G. candidum + C. tropicalis 
Unspecified 
Polymicrobial 
S. aureus + Klebsiella oxytoca 
+ Streptococcus pneumoniae 
S. aureus + С tropicalis 
Streptococcus faecalis +Torulopsis glabrata 
+ C. albicans 
L pneumoniae + A. fumigatus 
Unknown 
Total 
19 
3 
2 
2 
5 
2 
22 
1 1 
4 
2 
2 
1 
1 
1 
4 
1 
1 
1 
1 
60 
105 
(5) 
(2) 
(1) 
(2) 
(10) 
(6) 
(3) 
(2) 
(1) 
(1) 
(17) 
( ) Proven infection 
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Sinusitis due to Xaníhomonas maltophüia was diagnosed but no pathogen 
was implicated In the remaining 21 cases of upper respiratory tract 
complications. There were two cases of meningitis of which one was due to 
herpes zoster and two cases with brain abscess. Bacteria and fungi were 
equally represented in pulmonary infiltrates (TABLE 4). According to the 
definitions employed, the aetiology was considered to be proven in 17 cases 
(16%) with pulmonary infiltrate of which 10 were due to fungi, five to 
bacteria and two to a combination of fungi and bacteria. Coexistent 
bacteraemla with the same organism as that cultured from spu tum or 
bronchoalveolar lavage occurred in eight cases whereas a different 
organisms were Isolated in 16 cases. 
Development of a subsequent focus led to therapy modifìcation In 75 of 90 
cases (83%) and in 30 of 63 cases (48%) with a subsequent pulmonary 
infiltrate amphotericin В was the first drug which was added. 
Seven patients died for reasons that were clearly unrelated to infection: 
six due to major haemorrhage and one to veno-occlusion complicating acute 
graft-versus-host disease. The remaining 38 patients died of infection. 
Twenty nine patients had developed respiratory insuffîciency while seven 
patients succumbed to septic shock. The patient with pseudomembranous 
colitis died as did the patient who had herpes zoster meningitis. On average, 
death occurred 14.4 ±11 .0 days (range 1-44 days) after onset of fever with 
34% of patients dying within one week. 
Bacteraemla did not influence mortality since 11% of episodes with 
positive blood cultures but without a presenting focus of Infection culminated 
in death compared to 13% of the patients with Initially diagnosed FUO and 
14% of the cases with a presenting focus of infection (FIGURE 1). In contrast, 
20.5% of episodes with a potential site of infection (initial a n d / o r 
subsequent) ended in death compared with four percent of those who never 
developed a focus (P<0.0001). A site which developed during the course of 
fever was associated with a mortality of 28% which contras ts with a 
mortality of 12 % in cases where a potential focus of infection was already 
present at the onset of fever and in whom no subsequent focus developed 
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(P<0.05). Pulmonary Infiltrates carried a mortality of 28% which was 
significantly higher than deaths associated with other sites (7%; P<0.005). 
DISCUSSION 
In reporting clinical trials it is conventional to account for fever that 
develops during neutropenia In terms of microbiologically documented 
infection with or without bacteraemla, clinically diagnosed infection and 
unexplained fever at the onset of the event (14, 15). However half of the foci 
only developed after the starting empiric therapy. These might be due to 
inadequate coverage of the causative pathogen, a new pathogen, latent 
Infection which only becomes apparent with the return of the granulocytes, 
failure to recognize an infectious process earlier or due to an non-infectious 
cause. Secondary foci, mainly localized in the lung, have a poor prognosis as 
almost one In every three patients died. Moreover, only the potential sites of 
Infection appeared to have any impact on the eventual outcome suggesting 
bacteraemla to be an independent event. Whether or not pulmonary 
Infiltrates or Indeed any other focus represent infection seems almost a moot 
point. Microbiological diagnosis is notoriously unreliable due to the 
difficulties in procuring adequate samples . Discrimination between 
infection and colonisation is by no means straightforward particularly for 
opportunistic pathogens which comprise the commensal flora such as 
Candida albicans. 
The assumption that every clinical focus is a potential site of infection 
does not seem unreasonable since the majority will respond to antimicrobial 
therapy. For pulmonary Infiltrates, the Issue is somewhat clearer since fungi 
rather than bacteria were more frequently diagnosed in the present study. 
This is not unexpected since fungi are most frequently found at post mortem 
(16). This poses a particular dilemma since earlier diagnosis Is difllcult to 
make and the possibilities for effective treatment are limited. (17, 18) 
It seems obvious that pat ients who respond suboptimal to empiric 
antibiotic therapy may benefit more from early diagnosis and adequate 
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microbiological documentation of pulmonary infiltrates than from blind 
addition of more antlbacterials. Therefore greater attention should be paid to 
symptoms suggestive of respiratory tract infection by means of dally 
physical examination and periodic chest X-rays In neutropenic patients with 
continuing fever. Certainly, a given intervention is more likely to be effective 
when it is begun during the initial stages of infection where the Inoculum is 
relatively low, rather than later when the infection is firmly established and 
has begun to disseminate. Therefore at the first sign of pulmonary infiltrate 
such as a dry cough, the lung should be thoroughly investigated by culture and 
microscopic examination of secretions whether expectorated as sputum or 
retrieved following broncho-alveolar lavage. Negative results should not be a 
deterrent in considering fungal infection. 
Potential sites of infection will almost certainly be discovered earlier if 
diagnosis is more regularly and vigorously pursued. The diagnostic yield 
might be further improved by making more use of modem imaging 
techniques (19, 20). Little correlation was found between pathogens isolated 
from the blood and those from the organs involved. Moreover, the organisms 
isolated from blood are rarely pathogenic for the lung which accounted for 
most of the localized infections. 
Patients with neoplastic disease, particularly those with prolonged 
neutropenia, frequently have multiple concurrent and subsequent 
infections, including bacterial as well as non-bacterial Infections. 
Furthermore the non-infectious complications such as tissue damage due to 
chemotherapy or irradiation, haemorrhage and drug-related adverse events 
which result in similar symptoms and signs should be considered. The main 
goal of empirical therapy is to prevent early death due to sepsis (21). However, 
in view of the changing spectrum of infection in cancer patients it is unlikely 
that such a scheme will suffice for the entire neutropenic episode (2, 22). In 
the present study, fever alone was the first and only sign of possible infection 
in 70% of all episodes, whereas a clinical focus was Identified in 30% of 
cases. The latter were mainly localised in the lung and skin and soft tissue. 
Bacteraemla, whether or not associated with a focus, was found in 38% of 
episodes, and was mainly due to 'viridans' streptococci and coagulase-
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negative staphylococci. These data concur with those previously published (2, 
23). Subsequent foci developed In one-quarter of cases, leaving the fever 
unexplained In almost a third of all cases at the end of the febrile, 
neutropenic episode. Only when therapy is adapted to meet changing clinical 
circumstances will its value be maintained In pat ients with prolonged 
neutropenia. Antibiotic modifications should be based, as far as is possible, 
on objective grounds so as to avoid over-treatment (5), which can lead to 
complications including allergy, fever, toxicity and fungal infection (11). 
Inadequate diagnosis is clearly responsible for suboptimal treatment in 
many Instances resulting In unnecessary morbidity if not mortality. 
Therefore the empirical period should not be regarded as time to 'wait and 
see', but rather as an opportunity to achieve a definitive diagnosis. 
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ABSTRACT 
The relationship between the roentgenographlc pattern and symptoms, 
signs, etiology and outcome was Investigated In 200 lung Infiltrates which 
developed In patients with hematological malignancies. Focal Infiltrate was 
detected In 151 cases of which 46 percent were confined to the anatomical 
borders, mainly In the lower lobes. A diffuse pattern was observed In 37 cases 
while the remainder showed a mixed pattern. Most cases presented with 
cough while dyspnoea was more often a symptom of diffuse infiltrates. A 
microbiological cause was established for 84 Infiltrates of which 38 percent 
involved fungi. Anatomical Infiltrates were usually due to bacterial infection 
especially when patients were no longer granulocytopenic while other focal 
infiltrates were more frequently associated with mycosis. Progressive 
Infiltrates were more likely to lead to death than were those which remained 
stable or improved. The chest roentgenogram remains a useful diagnostic 
tool in helping discriminate between different types of infection and for 
monitoring therapy In patients with hematological malignancies. 
INTRODUCTION 
Pulmonary complications occur in about 30 percent of patients with 
hematological malignancies (1-4). As a consequence of granulocytopenia, 
clinical symptoms are usually absent, physical signs are muted and sputum 
is seldom produced (5). This may lead to the false conclusion that no 
infection is present unless other diagnostic aids are employed. There Is also a 
reluctance to employ Invasive diagnostic techniques such as open lung 
biopsy because of profound thrombocytopenia and even when undertaken, 
the information is seldom useful In directing therapy (6, 7). Since infection is 
responsible for the majority of pulmonary complications emerging during 
neutropenia (8), patients are managed empirically, first with broad spectrum 
antlbacterlals, and. If there Is no response, other agents such as ampho­
tericin В are added (9,10). Antimicrobial therapy may be further augmented 
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to cover other possible Infective agents such as Pneumocystis carinii. 
Nevertheless, between 30-50 percent of patients die (11, 12). Moreover, when 
therapy Is escalated In this way, the Infection may have already progressed to 
such a n advanced stage that successful t reatment with an appropriate 
regimen becomes unlikely. 
Roentgenologic examination of the chest is often performed as part of the 
clinical work-up at the onset of fever (13, 14). However, some authors doubt 
its utility since positive findings are seldom present at this stage (15). 
Moreover, investigations which correlate radiography with clinical and 
microbiological findings are scarce. Therefore, in order to identify any 
relationship that might occur between the roentgenographlc pattern, clinical 
signs and symptoms and Infection, we reviewed a series of roentgenograms 
taken in all patients who had been admitted with hematologic malignancy to 
our hospital during 1985-1989. 
P A T I E N T S A N D M E T H O D S 
Patients 
Chest roentgenograms made In 304 patients with hematological malignan-
cies during the study period 1985-1989 were reviewed retrospectively by a 
radiologist (F.H.) and a hematologist (I.N.). Patients with hematological 
malignancies who were treated with bone marrow ablative chemotherapy or 
who were given a bone marrow transplant were eligible for this retrospective 
analysis. All granulocytopenic patients had been nursed In reverse isolation. 
The majority had also been given either co-trlmoxazole or qulnolone as 
prophylaxis (16, 17). Patients had been treated empirically with ceftazidime 
unless allocated to alternative treatment according to standardized protocols 
of which the results have been published previously (2-4). 
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Roentgenogram and microbiological assessment 
Chest roentgenograms were made routinely when the hematological 
malignancy was first diagnosed, when fever developed, and whenever 
clinical signs and symptoms of pulmonary infiltrate occurred. Persisting 
pulmonary Infiltrates or hypoxemia were indications for bronchoalveolar 
lavage. Sputum was routinely examined for the presence of bacteria and 
fungi, while specimens from a bronchoalveolar lavage were also Investigated 
for the presence of cytomegalovirus, Pneumocystis carinii, herpes and 
specific respiratory viruses. 
FIGURE 1. Diffuse infiltrate. The reticulo-nodular appearance is characte-
ristic of diffuse pulmonary infiltrates. Pneumocystis carinii and herpes 
simplex virus were demonstrated both in bronchoalveolar lavage and at post 
mortem examination. 
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Definitions 
DIFFUSE Infiltrates were characterized by nodular, reticular or retículo-
nodular lesions which were distributed throughout both lung fields (FIGURE 
1), whereas FOCAL Infiltrates comprised alveolar consolidations confined by 
anatomy to a particular segment of the lung or an entire lobe (FIGURE 2). 
FIGURE 2. Focal anatomical infiltrate. The pulmonary infiltrate is confined to 
the left lower lobe. Legionella pneumophila was isolated from bronchoalveolar 
lavage. 
Irregular peripheral lesions which were not confined to any particular 
anatomical region were also regarded as being focal (FIGURE 3), while 
roentgenograms which displayed a combination of these patterns were 
classified as being mixed. 
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FIGURE 3. Focal non-anatomical infiltrate. Multiple lesions are present in the 
upper and lower left lobes, with pleural effusion on the right side. Aspergillus 
fumigatus was cultured from sputum. 
Granulocytopenia was defined as a granulocyte count of < 0.5 χ 10 ^/i. Fever 
was deñned as a single axillary temperature of > 38.5 0C or a temperature of 
>38 0C sustained for at least two hours. 
Recovery of specific pathogens such as Sírepíococcus pneumoniae, 
Haemophilus influenzae or Legionella species from a single sample of either 
sputum or bronchoalveolar lavage, or the demonstration of microorganisms 
in tissue, was considered sufficient proof of infection although complete 
identification required positive culture. The etiology was presumed to be of 
bacterial origin whenever cultures yielded growth of any organism which 
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was not a specific pathogen, while mycotic Infection was presumed when 
fungi were recovered. Viral etiology was established by culture or the 
demonstration of early antigen for CMV, while Pneumocysits carinii was 
diagnosed microscopically. 
Analysis 
Casenotes were reviewed for the occurrence of fever and any pulmonary signs 
and symptoms including cough. Categorical data were analyzed by means of 
χ
2
 -tests. All means are given with their respective standard deviation. 
RESULTS 
Of 340 patients admitted to our hospital during the study period, records of 36 
(11 percent) were incomplete and therefore could not be assessed. Two 
hundred pulmonary Infiltrates developed In 152 patients whose sex, age and 
underlying diseases are given In TABLE l. 
TABLE 1. Demographic data of the patients with infiltrate 
Number of patients 152 
Male/Female 91/61 
Age (years) 
Range 16-79 
Mean 41.5 
Standard deviation 15.8 
Underlying disease 
Acute myeloid leukemia 72 
Acute lymphoblastic leukemia 3 2 
Myelodysplastic syndrome 1 8 
Chronic myeloid leukemia 1 7 
Malignant lymphoma 9 
Other 4 
The roentgenographic appearance at presentation was diffuse In 37 cases 
(18.5 percent), anatomical In 92 cases (46 percent), non-anatomical In 59 
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cases (29.5 percent) and mixed In the remainder. Seventy percent of 
anatomical Infiltrates (64/92 ) were localized In a lower lobe compared with 
22 percent (13/59) of nonatomlcal Infiltrates. Non-anatomical Infiltrates 
were localized more frequently In an upper lobe than were anatomical 
Infiltrates: 47 percent (28/59) uersus 14 percent (13/92) respectively 
(P<0.0001). Granulocytopenia was not associated with any particular 
radiological pattern and neither the stage of the underlying disease nor the 
type of chemotherapy (TABLE 2). 
TABLE 2. Radiological pattern in relation to stage of disease, chemotherapy and 
granulocytopenia. 
Stage of disease 
Active 
Remission 
BMT 
Chemotherapy 
with ARAC <1000* 
with ARAC>1000* 
other " 
Granulocyte count 
< 0.5 χ 109/l at onset 
yes 
no 
Total 
Total 
108 
37 
55 
83 
37 
25 
135 
65 
200 
Diffuse 
15 
7 
15 
1 1 
8 
3 
26 
11 
37 
Anatomical 
53 
15 
24 
37 
17 
14 
60 
32 
92 
Nonanatomical 
32 
13 
14 
27 
1 1 
7 
41 
18 
59 
Mixed 
8 
2 
2 
8 
1 
1 
8 
4 
12 
* (ARAC, Cytosine arabinoside, dosage of less (<) or more (>) than 1000 
mg/m2/day, respectively. 
"Bone marrow transplantation recipients excluded 
Symptoms and signs 
Cough accompanied most pulmonary Infiltrates (TABLE 3), while dyspnoea 
presented significantly more often In cases with a diffuse infiltrate (P<0.05). 
The number of patients with dyspnoea increased to 86 percent (32/37) during 
the course of diffuse Infiltrates compared with 52 percent (48/92) with an 
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anatomical Infiltrate (P<0.005), and 49 percent (28/59) with a non-
anatomical appearance (P<0.005). All other respiratory symptoms were 
equally common. At least one sign or symptom was observed In all but eight 
cases with a non-anatomical infiltrate although auscultatory signs were 
present at onset In only one quarter of cases. 
TABLE 3. Presenting symptoms and signs associated with lung infiltrates. 
PAIIbRN: 
Symptoms 
/signs 
Cough 
Dyspnoea* 
Chest pain 
Hemoptysis 
Auscultatory 
changes 
No symptoms 
Fever 
DIH-USE 
n=37 
19 
*1 5 
5 
8 
36 
% 
(51) 
(41) 
(14) 
(22) 
(97) 
ANATOMICAL 
n=92 
60 
22 
19 
3 
20 
86 
% 
(65) 
(24) 
(21) 
(3) 
(22) 
(93) 
NON-ANATOMICAL 
n=59 
32 
*1 0 
14 
1 
1 1 
8 
56 
% 
(54) 
(17) 
(24) 
(2) 
(19) 
(14) 
(95) 
MIXED 
n=12 
5 
3 
1 
6 
12 
% 
(42) 
(25) 
(8) 
(50) 
(100) 
*P<0.05 
Infectious etiology of Infiltrates and Its relation to roentgenographlc pattern 
Infection was proven In 43 cases and presumed In 41 cases. In total, there 
were 39 bacterial, 32 mycotic, seven viral, one case of Pneumocystis carinii, 
and five cases with polymicrobial Infection (TABLE 4). Overall, 68 percent of 
focal anatomical Infiltrates were associated with bacterial Infection while 
54 percent of focal non-anatomical Infiltrates Involved mycotic infection 
(P<0.05; TABLE 5). Thirty six percent (8/22) of anatomical Infiltrates which 
developed during granulocytopenia were related to mycotic Infection compa-
red with only seven percent of those which occurred in non-granulocytopenic 
patients (1/15 : P<0.05). Overall, 40 percent (6/15) of diffuse infiltrates were 
associated with a mycotic and 33 percent (5/15) with viral Infection. Two-
thirds of the diffuse infiltrates (6/9) which developed during 
granulocytopenia were fungal whereas a viral Infection was responsible for 
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all six infiltrates that occurred In non-granulocytopenlc patients of which 
one each was combined with Pneumocysils corfriU and Candida albicans. No 
microbiological cause was Identified In the remainder. 
TABLE 4. Microbiological etiology of infiltrates. 
INFECTIOUS CAUSE 
BACTERIAL 
Pseudomonas aeruginosa 
Pseudomonas apatia 
Escherichia coli 
Xanthomonas maltophilia 
Klebsiella oxytoca 
Enterobacter cloacae 
Haemophilus influenzae 
Staphylococcus aureus 
Streptococcus pneumoniae 
Enterococcus faecalis 
Legionella pneumophila 
Haemophilus influenzae + Streptococcus pneumoniae 
Enterobacter cloacae + Staphylococcus aureus 
MYCOTIC 
Aspergillus fumigatus 
Aspergillus fumigatus + Candida albicans 
Candida albicans 
Candida tropicalis 
Unspecified 
VIRAL 
Cytomegalovirus 
Herpes simplex virus 
PNEUMOCYSTIS CARINII 
POLYMICROBIAL 
Pneumocystis carinii + Herpes simplex virus 
Aspergillus fumigatus + Cytomegalovirus 
Aspergillus fumigatus + Candida albicans 
+ Klebsiella oxytoca 
Candida albicans + Cytomegalovirus 
Candida tropicalis + Staphylococcus aureus 
TOTAL 
Presumed 
19 
2 
1 
1 
2 
3 
7 
2 
1 
12 
4 
2 
4 
2 
7 
5 
2 
3 
1 
1 
1 
41 
Proven 
20 
1 
1 
9 
4 
3 
2 
20 
1 1 
4 
5 
1 
2 
1 
1 
43 
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TABLE 5. Relation of infectious etiology to radiological pattern 
Pattern Total Bacterial Mycotic Viral Miscellaneous 
number 
Anatomical 37 25 (68%) 9 (24%) 1 (3%) 2 (5%)c, d 
Non-anatomical 26 9 (35%) 14 (54%) 1 (4%) 2 (7%)a, / 
Diffuse 15 2 (13%) 6 (40%) 5 (33%) 2 (14%)b, e 
Mixed 6 3 (50%) 3 (50%) 
Miscellaneous: a Pneumocystis carinii, b Pneumocystis carinii + Herpes simplex 
virus, с Aspergillus fumigatus + Cytomegalovirus, d Aspergillus fumigatus+Candida 
albicans + Klebsiella oxytoca, e Candida albicans + Cytomegalovirus, f Candida 
tropicalis + Staphylococcus aureus 
Outcome 
Overall 34 percent of infiltrates (67/200) culminated in the patient's death. 
The mortality rate was 54 percent (20/37) for patients with a diffuse infiltrate 
compared with 25 percent (23/92) for those with an anatomical infiltrate 
(P<0.005). The mortality of non-anatomical infiltrates was 34 percent 
(20/59) which was also significantly higher t h a n t h a t of anatomical 
infiltrates (P<0.005). In the 38 patients who underwent autopsy mycosis was 
proven in 53 percent while in the remainder no obvious infection was found. 
The chest roentgenogram was first repeated an average of 6.2 ± 6.0 days (range 
1 - 41) ) after onset of the infiltrate in 178 cases. 
Four percent (2/47) of patients who showed improvement died, as 
compared with 51 percent (36/71) in whom there was evidence of 
roentgenographic deterioration (P<0.005) while 27 percent (16/60) with an 
unchanged picture died. 
D I S C U S S I O N 
Pulmonary infiltrates affected half the patients included in this study 
confirming that pulmonary complications pose a significant problem in 
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individuals undergoing t rea tment for hematologic malignancy (18). 
Moreover mortality was high and, when autopsy was performed, mycosis 
accounted for half the cases supporting the general Impression that fungal 
infection comprises a major threat to survival (19). There were no 
pathognomonic signs and symptoms of pulmonary disease. Rather, fever 
accompanied more than 90 percent of episodes and there were only minor 
respiratory complaints at onset, cough being the most common symptom. 
Furthermore, auscultatory changes were found In only 23 percent of cases, 
t hus their absence does not exclude the possibility of pulmonary infiltrate. 
Signs and symptoms, when present, were not associated with any particular 
type of infiltrate although dyspnoea tended to accompany diffuse infiltrates. 
An Infectious etiology was established in 42 percent of cases as noted by 
others (20). The diagnostic yield of microbiological investigations was low 
probably because spu tum is rarely produced (5), and the sensitivity and 
specificity of these techniques is known to depend, among other things, upon 
prior antimicrobial therapy and the nature of the pulmonary disease In this 
patient population (8). Other diagnostic tools, such as bronchoalveolar 
lavage and open lung biopsies do not contribute significantly In the search 
for an etiology (21, 22). Moreover, the results of these invasive procedures do 
not substantially Influence therapy (7) and given the techniques presently 
available, further improvement in microbiological diagnosis seems 
unlikely. Hence, any clues which point to the probable etiology of lung 
Infiltrates would be desirable, especially if they allowed more appropriate 
therapy for the Individual patient. This is of particular relevance to fungal 
Infection where survival depends upon early Institution of therapy (23-25). 
Against this background, a readily available, non-invasive technique such 
as the chest roentgenogram assumes greater Importance, If it can help to 
discriminate between different types of Infection. 
Three basic roentgenographic pa t t e rns were observed which, in 
conjunction with granulocytopenia, appeared to assist In distinguishing 
bacterial and fungal infection. Focal infiltrates respecting the normal 
anatomical borders were usually due to bacterial Infection especially when 
the patients were not granulocytopenic while non-anatomical Infiltrates 
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were more frequently associated with mycosis. These findings are In concert 
with those of others (18, 26-28). In contrast, diffuse Infiltrates were more 
suggestive of a fungal Infection In granulocytopenic patients, while viral 
(CMV) or Pneumoqjstis carinii infection were more likely in patients with 
adequate neutrophils. 
Focal infiltrates were most often encountered, which is in agreement with 
data from the literature (18, 26) and about three-quarters of anatomical 
infiltrates involved the lower lobes. This might be an underestimate If 
posteroanterior radiograms are obtained at the bedside since this may 
preclude optimal assessment. 
A chest roentgenogram Is one of the most reliable and accessible means of 
detecting pulmonary complications. However, optimum use of this 
diagnostic tool can only be obtained by making serial roentgenograms which 
are necessary for the correct classification of the roentgenographic pattern, 
the discrimination between different types of Infection and for monitoring 
therapy. 
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ABSTRACT 
Thirty seven of 104 allogeneic bone marrow recipients transplanted during 
the period 1985-1989 developed 51 lung Infiltrates during the follow-up 
period. Conditioning with anthracycllnes was associated with a higher 
incidence of early infiltrates, mucosit is a n d 'viridans' streptococcal 
bacteremia. Microbiological etiology of early infiltrates was established less 
frequently t h a n of the later infiltrates (P<0.01). Chronic graft-versus-host 
disease (GVHD) was diagnosed in 3 3 % patients and was associated with a 
higher Incidence of pulmonary complications. Focal infiltrates occurred 
more often than diffuse infiltrates independent of granulocytopenia. Three -
quarters of all patients had respiratory symptoms prior to the radiological 
diagnosis with focal infiltrates being more often accompanied by coughing 
(P<0.05), while diffuse infiltrates were presented with dyspnoea (P<0.05). 
Chest X-rays were delayed when cough was the only symptom although 
mortality did not seem adversely affected. All cases of proven bacterial and 
mycotic infection were associated with focal infiltrates while all but one case 
with CMV and Pneumocystis carinii infection presented with a diffuse 
infiltrate. Granulocytopenia, the development of an infiltrate within 100 
days after BMT and a diffuse radiological p a i t e m were identified a s 
Independent unfavorable risk factors with prognostic values of 72 %, 72% a n 
68%, respectively. These factors together with careful evaluation of clinical 
signs and symptoms helped define a group of patients who deserve special 
attention. Moreover, knowledge of the radiological pattern together with the 
clinical picture often provide the only useful clue to selecting appropriate 
therapy. 
INTRODUCTION 
Pulmonary complications can emerge at any time post-transplant and are 
associated with significant morbidity a n d mortality (1, 2). Diffuse 
interstitial pulmonary infiltrates occur in 25-60% of pat ients, mainly 
during the early and mid-гесо ету phase a n d result in death due to 
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respiratory failure in 50-70% of cases (3). Cytomegalovirus (CMV) is 
responsible for about half of cases (4) in which important risk factors for the 
development of pneumonitis Include age, positive pre-transplanl CMV 
serology, acute GVHD and its prevention other than cyclosporin A (5). The 
etiology of the remaining diffuse infiltrates Is often obscure and may Include 
undetected CMV, other respiratory viruses, Pneumocystis carinii, GVHD as 
well as pulmonary damage due to chemotherapy and irradiation. The 
incidence of focal infiltrates, apart from those associated with chronic GVHD 
(6, 7) Is poorly documented during the first 100 days after BMT. Therefore we 
decided to review the case records and chest X-rays obtained from 104 
consecutive patients who had received bone marrow depleted of lymphocytes 
using counterflow centrifugation (8). An attempt was made to relate the 
radiological appearance with etiology and particular attention was paid to 
the Impact of lung infiltrates on morbidity and mortality. 
PATIENTS AND METHODS 
Patients 
The clinical and radiological data of 104 consecutive recipients of allogeneic 
bone marrow grafts during the period from January 1985 to October 1989 
were reviewed retrospectively. All relevant data were collected from the day 
of transplant until at least 6 months post-BMT, unless death or relapse of the 
underlying disease Intervened. The follow-up period was divided into two 
phases: a granulocytopenic and post-granulocytopenic episode. The details of 
conditioning regimens have been described previously (9). Briefly, the 
majority of patients was conditioned with cyclophosphamide together with 
anthracyclines followed by total body Irradiation with a corrected mean 
total lung dose of 770 ± 50 cGy. All but five donors were HLA-A,-B, and DR-
identical. mixed lymphocyte culture-negative siblings. Cyclosporin A alone 
was used for immunoprophylaxls In all but seventeen patients who received 
methotrexate (8). 
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Patients were nursed In single rooms with filtered air under positive 
pressure throughout the transplantation period. A single-lumen Hickman 
catheter was Inserted before conditioning. All patients were given acyclovir 
400 mg every 6 hours and 90 were given antimicrobial prophylaxis based on 
oral ciprofloxacin and amphotericin-B (10). Co-trimoxazole was given twice 
weekly for Pneumocystis carinii prophylaxis (11). All blood products were 
obtained from randomly selected volunteers who were not screened for CMV. 
Pulmonary radiological pattern 
Chest X-rays were made after insertion of the central venous line, when 
unexplained fever persisted and whenever respiratory signs and symptoms 
occurred. Persisting pulmonary infiltrates or hypoxemia were Indications 
for bronchoalveolar lavage. Sputum, If produced, was routinely examined for 
the presence of bacteria and fungi, while Investigations of bronchoalveolar 
lavage specimens were extended to Include cytomegalovirus, Pneumocystis 
carinii, herpes and other specific respiratory viruses. 
DIFFUSE infiltrates were characterized by nodular, reticular or reticulo-
nodular lesions which were distributed throughout both lung fields whereas 
FOCAL Infiltrates comprised either alveolar consolidations restricted to a 
particular lung segment or an entire lobe or Irregular peripheral lesions 
which were not confined to any particular anatomical region. 
Définitions 
Granulocytopenia was defined as a granulocyte count of <0.5 χ 10 9/1 and 
severe thrombocytopenia by a thrombocyte count of <20 χ 1 0 ^ / 1 . 
Engraftment was considered to have occurred when peripheral leukocytes 
were maintained above 1.0 χ 10^/1 and was confirmed by the presence of 
donor cells (12). Acute graft-versus-host disease (GVHD) was graded according 
to the criteria of Glucksberg et al (13) and chronic GVHD was classified as 
either limited or extensive as described by Shulman et αϊ (14). Fever was 
defined as a single axillary temperature of >38.5 "С or a temperature of >38 0 C 
sustained for at least two hours. Bacteremia was diagnosed when at least one 
10 ml blood sample yielded growth of any organism, except for coagulase-
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negative staphylococci and skin coryneforms, for which two or more positive 
samples were required. 
The growth of specific pathogens such as Streptococcus pneumoniae, 
Haemophilus inßuenzae or Legionella species from either spu tum or 
bronchoalveolar lavage was considered to be sufficient to prove bacterial 
Infection. If Staphylococcus aureus or Gram-negative rods were cultured 
from only one sample, the etiology was regarded as being uncertain. Mycotic 
infection was considered proven If hyphae were identified in t issue but 
definitive diagnosis required positive cultures. Viral disease was considered 
p r o v e n w h e n i n t r a n u c l e a r i n c l u s i o n s w e r e d e m o n s t r a t e d 
histopathologlcally and /o r the virus was recovered from lung tissue. The 
detection of CMV early antigen and isolation of virus from samples obtained 
by means of bronchoalveolar lavage was regarded as evidence of possible 
disease a s was a four fold rise in antibody titer. Pneumocystis carinii 
Infection was diagnosed when the organism was seen in material obtained 
from bronchoalveolar lavage or at autopsy. 
Statistics 
All means and proportions are given with their respective 95% confidence 
Intervals and categorical data were analyzed by means of x2-tests with Yates 
correction except when the number In any category was less than five in 
which case Fisher's exact test was employed. 
RESULTS 
The demography of the patients is depicted in TABLE 1. One hunderd-four 
patients were followed up for an average of 503 ±104.4 days. Thirty seven 
patients (36%) developed one or more lung infiltrates during the whole 
period, 29 (78%) within the first six months. Cardlomegaly with pulmonary 
oedema was found In two cases, pneumothorax related to the Insertion of the 
Hickman catheter occurred In six and there were three cases with pleural 
effusion. 
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TABLE 1. Patients characteristics 
Follow-up period (days) 
Range 
Mean 
95% confidence interval 
Male (%) 
Age (years) 
Range 
Mean 
95% confidence interval 
Underlying disease (No. of patients) 
Acute leukemia 
Chronic myeloid leukemia 
Myelodysplastic syndrome 
Lymphoma 
Other 
CMV serology prior to BMT (No. of cases) 
Recipient+ Donor+ 
Recipient+ Donor-
Recipient- Donor+ 
Recipient- Donor-
Conditioning regimen (No. of patients) 
TBI + Cyclophosphamide + Anthracycline 
TBI + Cyclophosphamide 
Other 
Assessable for acute GVHD (No. of patients) 
Acute GVHD total 
Grade I 
Grade II 
Grade III 
Grade IV 
Assessable for chronic GVHD (No. of patients) 
Chronic GVHD total 
Limited 
Extended 
Number of deaths 
Infiltrate 
no 
(n-67) 
12 - 1902 
661.6 
122.1 
60 
13-51 
31.1 
2.2 
37 
16 
7 
3 
4 
25 
8 
11 
23 
43 
20 
4 
65 
13 
5 
5 
2 
1 
61 
16 
14 
2 
8 
Infiltrate 
yes 
(n-37) 
4 - 1782 
462.9 
183.3 
59 
16-47 
31.1 
3.0 
15 
10 
3 
5 
4 
15 
7 
5 
10 
28 (15) 
6 
3 (1) 
35 
* 1 2 
3 
8 
1 
20 
* * 1 1 
7 
4 
* * * 2 2 
TBI Total body irradiation, ( ) Number of infiltrates which occurred within two 
weeks post-transplant 
*P>0.05, **P<0.05, *"P<0.0001 
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Sex, age, underlying disease and pre-BMT CMV serology in both the 
recipients and the bone marrow donors were similar for pat ients who 
acquired a lung infiltrate and for those without. 
The conditioning regimen did not Influence the development of lung 
Infiltrates overall, but early (1. e. within two weeks of transplant) pulmonary 
complications occurred in 15 out of 71 patients (21%) who had been given 
anthracycllnes but in only one of 33 patients (3%) who had not received these 
drugs (P<0.05). "Viridans' streptococcal bacteremia was detected during the 
first week post transplant In 43 out of 71 patients (61%) conditioned with 
anthracycllnes, as compared with nine out of 29 patients (31%) who were not 
(P<0.01). Likewise, severe mucositis occurred during granulocytopenia in 54 
out of 71 (76%) and In three out of 33 cases (9%; P<0.0001), respectively . 
One-quarter of patients developed acute GVHD which was graded II-IV In 
68% of cases. Lung Infiltrates developed slightly more often In the patients 
with acute GVHD bu t the difference did not reach statistical significance 
(0.1>P>0.05). Chronic GVHD was diagnosed In a third of patients of whom 
4 1 % developed a lung infiltrate which was more than twice the rate observed 
for those who were free of this complication (17%; P<0.05). Twenty two of 37 
patients (59%) with an Infíltrate died compared with eight out of 67 of those 
who had no pulmonary complications (12%; P<0.0001). 
Occurrence of lung Infiltrates In relation to granulocytopenia 
Fifty one lung infiltrates were documented. Besides those which occurred 
early, two patients developed an infiltrate during granulocytopenia as a 
result of graft rejection 47 and 66 days after BMT respectively (TABLE 2). 
Those infiltrates that developed after granulocytopenia occurred between 23 
and 405 days post t ransplant . Focal infiltrates predominated and a 
microbiological etiology was established In around half of cases whether or 
not the patient was granulocytopenic. Diffuse Infiltrates that occurred during 
granulocytopenia remained unexplained while a microbial cause was 
confirmed in three-quar ters of those that occurred later. None of the 
Infiltrates occurring during granulocytopenia were related to bacteria, 
whereas the converse was true for those tha t developed after marrow 
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recovery. Therefore, excluding the two pat ients with graft-failure, a 
microbial etiology was established in four of 16 cases (25%) with an early 
infiltrate compared with 20 of 33 (61%) cases when infiltrates appeared later 
(P<0.05). 
TABLE 2. Occurrence of lung infiltrates in relation to granulocytopenia. 
Granulocytopenia 
Yes No 
Total number of infiltrates 
Radiological pattern 
Focal 
Diffuse 
Cause of infiltrate 
Bacterial 
Mycotic 
CMV 
Pneumocystis carinii 
Polymicrobial 
Unknown 
18 
13 
5 
4 
1 
1 
12 
(6) 
33 
25 
* 8 
12 
1 
4 
1 
1 
13 
(14) 
(6) 
( ) Number of infiltrates of proven cause 
* One cases with diffuse plus focal infiltrate initially 
Respiratory symptoms and signs In relation to radiological pattern. 
Clinical signs and symptoms (TABLE 3) preceeded the radiological diagnosis 
of an Infiltrate in 29 out of 38 cases (76%) with focal lesions and in 10 out of 
13 cases (77%) with diffuse infiltrates. Subjective complaints were already 
present for 17.3 ±11 .9 days in patients with focal lesions and for 13.7 ± 13.7 
days In those with diffuse abnormalities before a definitive radiological 
diagnosis was made (ns). Cough accompanied focal Infiltrates but not diffuse 
infiltrates (P<0.05) which were more likely to be associated with dyspnoea 
(P<0.05). Other signs and symptoms occurred less frequently and showed no 
correlation with the type of Infiltrate. Chest X-rays were made within five or 
six days of dyspnoea or signs and symptoms other t han coughing first 
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appearing whereas radiological examination was delayed by two till three 
weeks when cough was the only symptom. 
TABLE 3. Respiratory symptoms and signs in relation to radiological pattern. 
Symptoms/signs Focal Diffuse 
n=38 n=13 
Cough * 33 (33) 8 
Dyspnoea * 21 (8) 11 
Chest pain 11 (4) 1 
Hemoptysis 1 1 
Auscultatory changes 12 (9) 6 
None 1 
( ) Presenting symptoms, * P<0.05 
Relationship of radiological pattern and etiology 
In total 34 of 38 initial focal infütrates remained unchanged, while in four 
additional diffuse lesions developed. The etiology of 53% of focal infiltrates 
was established of which the clear majority (60%) was related to bacteria 
(TABLE 4). Thirty focal infiltrates (79%) were localized in a lower lobe and 
bacteria were responsible for 11 of 15 proven cases (73%) compared with only 
one of 5 cases involving an upper lobe. One of four cases with A. Jwnigatus 
infection presented in the right lower lobe, two affected both an upper and 
lower lobe while the last case developed a diffuse infiltrate as a result of 
coincident CMV infection having presented with consolidation of the left 
upper lobe. Both infiltrates associated with candidiasis were localized 
initially in the left lower lobe. Seven of the eight cases associated with CMV 
developed a diffuse infiltrate either initially (five cases) or later. One diffuse 
infiltrate was due to P. carinii alone and another to this organism together 
with with herpes simplex virus while the etiology was not established for the 
remainder. 
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(7) 
(7) 
( 1 ) 
TABLE 4. Relation of radiological pattern and etiology. 
Etiology 
BACTERIAL 
Haemophilus influenzae 
Streptococcus pneumoniae 
Streptococcus pneumoniae 
+ Haemophilus influenzae 
Streptococcus pneumoniae 
+ Staphylococcus aureus 
MYCOTIC 
Aspergillus fumigatus 
Candida albicans 
PNEUMOCYSTIS CARINII 
CMV possible 
POLYMICROBIAL 
Aspergillus fumigatus + CMV 
Pneumocystis carinii 
+ Herpes simplex virus 
Candida albicans + CMV 
UNKNOWN 
TOTAL 
Focal 
7 
2 
2 
1 
3 
1 
1 
1 
1 
1 
18 
38 
(1) 
(1) 
(1) 
(1) 
(4) 
Diffuse 
5 
1 
7 
13 
(1) 
( 1 ) * 
(2) 
( ) Number of patients who developed either a diffuse infiltrate after presenting 
with a focal infiltrate or the contrary. 
'One case with initial diffuse + focal infiltrate 
Factors which Influenced outcome of Infiltrates 
Twenty pulmonary infiltrates culminated in respiratory failure and death 
(39%) and the radiological pattern at presentation was an important 
prognostic factor since eight out of 12 diffuse infiltrates (67%) proved fatal 
compared with 12 out of 38 focal inllltrates (32%; P<0.05). One case could not 
be assessed because of the simultaneous appearance of focal and diffuse 
lesions. Granulocytopenia was also a poor prognostic factor since 13 of 18 
infiltrates (72%) which developed during granulocytopenia proved 
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ultimately fatal compared with seven out of 31 Infiltrates (23%) which arose 
after marrow recovery (P<0.005). Finally, 16 out of 26 patients (62%) died 
after developing a lung Infiltrate within 100 days after BMT, as compared 
with four out of 24 cases (17%) which developed later (P<0.001). Each factor 
was Independent, the prognostic value being 68% for diffuse pattern and 72% 
for both granulocytopenia and onset within 100 days post t ransplant . 
Combining them In pairs or all together did not alter the prognostic value 
(74%). 
DISCUSSION 
A third of all allogeneic bone marrow recipients developed one or more lung 
Infiltrates after transplant, the majority within the first six months. There 
was no association between age, sex and underlying disease and the 
occurrence of respiratory disease. However, the addition of anthracycllnes to 
the condit ioning regimen resul ted In more pu lmonary Infiltrates 
Immediately after transplant. Tissue damage as evidenced by mucositis was 
also more extensive and this coincided with 'vlrldans' streptococcal 
bacteremia. However, the majority of these pulmonary complications might 
be explained by alveolar damage caused by cytostatic drugs and irradiation 
(15, 16), since a microbial cause was only established In one out of four cases 
none of which Involved bacteria. 
Substantial acute GVHD affected 17% of patients who had all received T-
cell depleted grafts and compares favorably to the 39-82% reported for 
patients receiving unmanlpulated grafts (17, 18). The total number of lung 
Infiltrates associated with acute GVHD was only marginally higher than in 
those who remained free of this complication. In total 17 diffuse Infiltrates 
occurred which were clinically compatible with pneumonitis and therefore 
might have been due to CMV (4). The diagnosis was almost certain In seven 
cases according our criteria. However there was little likelihood of CMV 
disease in the remaining cases since five infiltrates were seen In recipients 
with negative CMV serology prior to BMT In whom primary infection was 
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Improbable (5, 19) and neither early antigen nor a rise in antibody titre was 
observed In the other five cases. Although lower than the Incidence observed 
in other series (4), the number of patients affected was comparable to that 
recently published by Wlngard and colleagues (5). This group also reported a 
decrease in pneumonitis, even In CMV positive recipients, as a result of the 
greater use of cyclosporin A. Prophylaxis with acyclovir, which we gave to all 
our patients, may have also played a role (20). 
Chronic GVHD also constituted a risk factor for the development of 
pulmonary complications as has been noted before (21). A large proportion of 
those for which a microbial etiology was established (65%) Involved the 
encapsulated bacteria S. pneumoniae and H. influenzae reflecting Impaired 
opsonisatlon (22) as a result of IgG deficiency (23) and also poor 
reticuloendothelial function of the liver and spleen (24). 
Despite the frequent use of bronchoalveolar lavage, a microbial etiology 
was established in only 25% of the early Infiltrates in contrast to 63% in the 
infiltrates which occurred more than four weeks after BMT. There were no 
bacterial infections during the early granulocytopenic phase after BMT 
which is In agreement with the data of others who report 80% of pneumonitis 
occurring during the first 20 days after BMT to be of unknown origin (4). This 
may be due to the effectiveness of ciprofloxacin in eliminating Gram-
negative bacteria. It also suggests that the etiology of the pulmonary 
abnormalities may be due to causes other than infection such as hemorrhage 
(25, 26) as well as chemotherapy and Irradiation as mentioned before. Focal 
infiltrates began more often In the lower lobes and were more common in our 
population than were diffuse abnormalit ies independent of 
granulocytopenia. This has already been noted by others (27) and must be 
taken into consideration since it is rarely possible to optimally investigate a 
febrile, granulocytopenic patient radiological^ because they are confined to 
bed or kept in isolation. Although the numbers were small, both bacterial 
infection and candidiasis presented in the lower lobes, while three of the four 
cases of A. fwnigatus infection involved an upper lobe. The association of 
focal infiltrates with bacterial and mycotic infection and diffuse infiltrates 
with viral disease or Pneumocystis carinii has been previously reported (15, 
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25). However the radiological appearance Is unlikely to be sufficiently 
specific to allow distinction to be made between mixed Infection, pulmonary 
hemorrhage and localized leukemic Infiltrates. Signs and symptoms 
provided some Indication of the type of Infiltrate since those that were 
localized were more often associated with coughing while diffuse Infiltrates 
presented with dyspnoea. The latter led to prompter chest X-ray investigation 
while coughing was largely ignored as being of minor Importance. Although 
this did not appear to Influence mortality, it was clearly erroneous since 
knowledge of the radiological pattern together with the clinical picture often 
provide the only useful clue to selecting appropriate therapy when efforts to 
achieve the microbiological diagnosis have either failed or were never 
possible. Moreover, neither the choice of therapy nor the final outcome 
appear to be markedly Improved by bronchoalveolar lavage and lung biopsy 
In granulocytopenic patients (28). 
Granulocytopenia, the development of any infiltrate within 100 days after 
BMT and diffuse radiological pattern were all identifled as being unfavorable 
independent prognostic factors. The inability to diagnose lung infection may 
be partially compensated for by using these to define a group of patients who 
deserve special clinical attention. Such factors together with coughing of any 
description should alert the clinician to the possibility of incipient lung 
infection and this alone may well translate to a significant improvement in 
outcome. 
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CHAPTER 10 
SUMMARY 
SAMENVATTING 

SUMMART 
The Introduction of this thesis provides a short survey on the actual prob-
lems of infectious complications in granulocytopenic patients with 
haematological malignancies who are being treated for their disease. The 
concept of empiric treatment Is still valid, but the possible options have 
changed during the last decade due to the availability of new antibiotics and 
altered patterns of Infection as a result of the increasing use of central venous 
devices, prophylactic antibacterlals and more aggressive antltumour 
therapy. 
CHAPTER 3. In the first prospectively randomised study the efficacy and 
toxicity of the combination of piperacillin plus amikacin was compared with 
ceftazidime alone. The study population consisted of 69 assessable febrile 
granulocytopenic patients with a presumed bacteraemia without a clinical 
focus of infection at the onset of fever. Both regimens appeared to be equally 
effective as initial treatment since response without modification was 
achieved In 44% of the cases given the combination compared with 66% of 
the patients treated with ceftazidime; ultimately 90% of the patients in each 
group survived the granulocytopenic episode. Persistent fever was the most 
frequent reason, i.e. In 90% of the cases, for changing the initial therapy. 
During antibacterial treatment an Infectious focus emerged in 21 (30%) 
patients, the lung being the most prominent site. The microbiological 
aetiology was established In eight of these 21 cases; one was of bacterial 
origin, whilst the remaining seven were due to fungal Infection. Therapy with 
ceftazidime proved to be more safe, as use of the combination of piperacillin 
and amikacin was associated with higher serum creatinine (P<0.001) and 
lower potassium levels (P<0.001) In comparison with the single agent 
regimen. 
CHAPTER 4. During a phase II study teicoplanln at a dose of 400 mg per day 
after a starting dose of 800 mg was added to the initial therapy of 65 out of 203 
febrile granulocytopenic episodes. At the end of the observation period 43% 
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of the cases évaluable for outcome had responded. Responders and non-
responders were comparable in terms of starting telcoplanin treatment, 
duration of therapy and granulocytopenia, the number of granulocytopenic 
days after therapy was stopped, and peak and trough levels of the drug. 
Telcoplanin was given most often because of persistent fever or Initial Gram-
posltive bacteraemla and only one third of these cases responded. Two-third 
of the non-responders had developed a pulmonary Infiltrate of which the 
aetiology could not be established In the majority of cases. On the other hand, 
when telcoplanin was administered for proven or presumed Gram-positive 
Infections, 67% of the cases showed a successful outcome. All 10 Initially per-
sisting Gram-positive organisms were eradicated by telcoplanin. Patients 
with skin and soft t issue infections achieved a 78% response rate. The 
development of a lung infiltrate was the most common reason for failure to 
respond although In most instances the aetiology could not be determined. 
Serum levels of telcoplanin were as expected with a peak and trough 
concentration on the fourth day of 30.4 ± 5.0 mg/1 and 9.8 ± 1 . 7 mg/1, 
respectively. There was no correlation between the levels obtained and the 
final outcome. Hearing loss of 20 dB at 800 Hz was noted in one out of 15 cases 
and transient liver or kidney disturbances attributable to the drug were 
observed in 4% of the cases. It was concluded that therapy with telcoplanin 
therapy was safe, but its use was only effective in infections with a high 
probability of being due to Gram-positive bacteria. 
CHAPTER 5. The, in contrast to piperacillin, promising results obtained with 
telcoplanin In Gram-positive infections fostered the next prospectively 
randomised study. Ceftazidime alone was compared with a combination of 
telcoplanin plus ceftazidime as empiric regimen in 120 granulocytopenic 
patients without an obvious focus of Infection at the onset of fever. Gram-
positive bacteraemla was detected In 25% of the assessable patients treated 
with ceftazidime and In 33% of the cases given the combination. There was 
no statistically significant difference In terms of final response. Ceftazidime 
alone was successful in 49% of the cases and response without modification 
was registered In 63% of the cases treated with the combination. Duration of 
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fever and of total days of antibiotic therapy were similar In both groups. 
Persistent fever was the main reason for modification of the initial 
treatment. Ten patients died as a result of the originell infection, whereas two 
patients died due to new Infection. Development of a localised Infection. 
notably In the lower respiratory tract, was cause of death In 10 out of 12 
patients. In neither group a fatal case of Gram-positive Infection was 
observed. The patients treated with the combination showed more new 
infections and allergic reactions. It was concluded that In the patient 
population investigated the need for a glycopeptlde ab Initio is at least 
doubtful, but that teicoplanln provides a simple, reliable, and safe treatment 
in case of proven Gram-positive infection. 
CHAPTER 6. In the third prospectively randomised study the value of an 
aminoglycoside as part of the empiric regimen In febrile granulocytopenic 
patients with signs and symptoms of a localised infection at the onset of 
fever was evaluated. In 90 of these patients the efficacy and safety of 
ceftazidime alone was compared with that of ceftazidime plus amikacin (1.5 
g/day). The treatment groups were comparable In terms of the depth and 
duration of granulocytopenia as well as the distribution of the Infection 
categories and rate of bacteraemla. The microbiological cause of the localised 
infections was Identified In 20% of all assessable cases only. There was no 
difference with respect to the final response: 53% for the monotherapy group 
versus 48% for the combination group and both regimens appeared to be 
equally safe. The duration of fever, clinical symptoms, days on antibiotic 
therapy and granulocytopenia were comparable for both treatment groups 
and 93% of the patients survived the infection. Only one patient Initially 
given monotherapy required addition of amikacin and therefore it was 
concluded that aminoglycosides are probably not an essential part of the 
empiric regimen in granulocytopenic patients with an infectious focus at the 
onset of fever. 
CHAPTER 7. In a retrospective analysis of 300 febrile episodes occurring in 
210 patients, localised Infection was Identified at the onset of fever In 30% of 
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the cases . Initial bacteraemla, predominantly involving Gram-positive 
cocci, was encountered in one-third of episodes independent of the presence 
of focus. A subsequent localised infection developed during one-third of 
episodes, involving mainly the lower respiratory tract and skin and soft 
tissue. These infections evolved significantly later than did other foci which 
mainly presented at the onset of fever. However, the aetiology was 
established in only 30% of the cases overall with fungi being responsible for 
56% of the lower respiratory tract infections. The mortality associated with 
initially diagnosed 'fever of unknown origin', with Initial bacteraemla 
without a focus of infection at the onset of fever and with initial infectious 
site of infection was 13%, 11% and 14%, respectively, while that associated 
with the development of a subsequent focal infection was 28% with 
pulmonary Infiltrates carrying the worst prognosis. 
CHAPTER 8. The relation between the radiological pattern on the chest X-ray 
and symptoms, signs, aetiology and outcome in 200 cases of lung infiltrates 
was analysed retrospectively. Focal infiltrates. Irrespective of anatomical 
localisation, accounted for the majority of cases. Cough was the most 
frequent symptom in all types of Infiltrates while dyspnoea was prominently 
associated with a diffuse infiltrate. At presentation auscultatory changes 
were recorded in 23% of the cases. Proven and probable aetiology could be 
established in 84 cases. Mycotic infections were responsible for two-third of 
the diffuse infiltrates in the granulocytopenic pat ients , whereas all 
Infiltrates in the non-granulocytopenic pat ients were of viral origin. 
Anatomical infiltrates were caused by bacterial infections in the majority of 
cases, but this relation was more evident in patients with a normal number 
of granulocytes. Mortality was high In the patients with diffuse infiltrates. 
Overall, a favourable outcome was noted for patients in whom improvement 
of the radiological abnormalities was seen on the first follow-up chest X-ray. 
Progression of the initial infiltrate influenced the prognosis negatively. In 
conclusion, a radiological pat tern in combination with clinical findings 
such as the granulocyte count offers a useful key for the possible aetiology of 
a pulmonary Infiltrate and knowledge may be helpful In the design of a 
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therapeutic strategy in pat ients with haematological malignancies and 
infections in the lower respiratory tract. 
CHAPTER 9. During the follow-up period after allogeneic bone marrow 
transplantation 37 out of 104 patients transplanted between 1985 and 1989 
developed 51 lung infiltrates. Conditioning with additional anthracyclines 
was associated with a high incidence of early infiltrates, mucositis and 
bacteraemla by Viridans' streptococci. The microbiological aetiology of 
early infiltrates was more difficult to be established than that of infiltrates 
which occurred later during the course of granulocytopenia (P<0.01). This 
may suggest a non-infectious aetiology of a part of the early pulmonary 
abnormalities. During both the early and late period after bone marrow 
transplantation focal infiltrates were more frequently detected than diffuse 
infiltrates. Focal infiltrates presented more often with cough, whereas 
dyspnoea was the leading clinical symptom in diffuse infiltrates. The 
importance of cough as the only symptom of a possible pulmonary infection 
appeared frequently to be underestimated and therefore there was usually 
some time lost before a chest X-ray was made. Bacterial and mycotic infec-
tion were associated with focal infiltrates whilst infections of other origin 
tended to present as a diffuse infiltrate. Chronic graft-versus-host disease 
was diagnosed in 33% of the patients and this entity was associated with a 
h igher incidence of pu lmonary compl ica t ions . Granulocytopenia , 
development of a n infiltrate within 100 days after BMT, and diffuse 
radiological pa t te rn were identified as independent unfavourable r isk 
factors. In conclusion, knowledge of the risk factors and a careful evaluation 
of clinical signs and symptoms is useful to define a group of patients who 
deserve special at tention including radiological examination. A given 
radiological pattern together with the clinical picture may provide a useful 
key to select an appropriate treatment in these cases. 
CONCLUSION. Neither an aminoglycoside nor an glycopeptlde appear to be 
an unequivocal part of an empiric regimen in the febrile granulocytopenic 
patient since ceftazidime given as a single agent proved to be at least as 
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effective as various combinations and was associated with a lower rate of 
adverse events and subsequent Infections. Suboptimal response. Independent 
of the starting regimen, was observed when a focus of Infection developed. 
Pulmonary Infiltrates, of which the microbiological origin can only be 
established In a minority of cases, carried a dismal prognosis. Sequential 
chest X-rays with assesment of the radiological pattern and evolution of the 
granulocytes count appear to be a useful tool for the selection of the 
appropriate therapeutic strategy. 
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SAMENVATTING 
De Inleiding van dit proefschrift geeft een kort overzicht van de huidige 
problemen van infectleuze complicaties bij granulocytopenische patiënten 
die voor kwaadaardige bloedziekten behandeld worden. Een empirische 
behandeling Is nog steeds gangbaar. Dankzij het voorhanden zijn van nieuwe 
antibiotica en als gevolg van het toenemende gebruik van centraal veneuze 
lijnen, profylactische antimicrobiële therapie en agressievere antitumor-
behandeling die een veranderd infectiepatroon tot gevolg hadden, is de 
behandelingskeuze gedurende de laatste tien jaar veranderd. 
HOOFDSTUK 3. De eerste prospectieve, gerandomiseerde studie vergelijkt de 
werkzaamheid en toxiciteit van de combinatie piperacilllne plus amikacin 
met ceftazidim alleen. De onderzochte populatie bestond uit 69 evalueerbare 
granulocytopenische patiënten met koorts en een veronderstelde bacteriëmie 
zonder een klinische haard van infectie bij aanvang van de koorts. De beide 
behandelingen bleken gelijkwaardig voor wat betreft h u n effectiviteit als 
Initiële therapie, omdat succes zonder modificatie werd bereikt in 44% van 
de gevallen die behandeld werden met de combinatie, vergeleken met 66% 
van de patiënten die ceftazidim kregen. Uiteindelijk heeft 90% van de 
patiënten de granulocytopenische periode overleefd. De meest voorkomende 
reden om de initiële therapie te veranderen was aanhoudende koorts; 
hiervan was sprake in 90% van de gevallen. Een haard van infectie, meestal 
gelokaliseerd in de longen, werd gevonden bij 21 patiënten (30%). Een 
microbiologische oorzaak werd vastgesteld bij acht van deze 21 gevallen; één 
ervan was bacterieël, terwijl de overige zeven te wijten waren aan een 
schimmelinfectle. De therapie met ceftazidim bleek veiliger te zijn dan die 
met de combinatie, daar het gebruik van de laatste vaker gepaard ging met 
een hoger serum krealinlnegehalte (P<0.001) en en met een lager kallum-
gehalte (P<0.001), in vergelijking tot de monotherapie. 
HOOFDSTUK 4. Gedurende een fase 11-studie werd teicoplanin In een dosis 
van 400 mg per dag, na een beglndosls van 800 mg, aan de initiële therapie bij 
65 van de 203 granulocytopenische episoden met koorts toegevoegd. Aan het 
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einde van de observatieperiode had 43% van de gevallen die evalueerbaar 
waren op de behandeling gereageerd. Responders en nlet-responders waren 
vergelijkbaar voor wat betreft het begin van de behandeling en de 
granulocytopenic, de duur van de behandeling en van de granulocytopenic, 
het aantal granulocytopenlsche dagen nadat de behandeling was gestopt en de 
top- en dalsplegels van het medicament. Telcoplanln werd heel vaak gegeven 
vanwege aanhoudende koorts of Initiële Gram-posltleve bacterlëmle en 
slechts eenderde van deze gevallen reageerde. Tweederde van de nlet-
responders hadden een longinfiltraat ontwikkeld, waarvan de aetlologle In 
de meeste gevallen niet kon worden vastgesteld. Werd telcoplanln toegediend 
bij bewezen of veronderstelde Gram-posltleve Infecties, dan was In 67% van 
de gevallen sprake van een positief resultaat. Alle 10 initieel persisterende 
Gram-positieve bacteremiën verdwenen door telcoplanln. Achtenzeventlg 
procent van de patiënten met infecties van de huid en de weke delen reageerde 
positief. De meest voorkomende ooizaak van een falende behandeling was de 
ontwikkeling van een longinfiltraat, alhoewel in de meeste gevallen de 
aetlologle niet kon worden vastgesteld. De telcoplanln top- en dalsplegels 
waren, zoals werd verwacht, op de vierde dag respectievelijk 30.4 ± 5.0 mg/l 
en 9.8 ±1.7 mg/l. Er werd geen relatie gevonden tussen de bloedspiegels en het 
uiteindelijke resultaat. Gehoorverlies van 20 dB bij 800 Hz werd 
waargenomen in één van de 15 onderzochten gevallen en voorbijgaande 
lever- of nierfunctiestoomissen, die toe te schrijven waren aan het 
medicament, werden waargenomen in vier procent van de gevallen. 
Geconcludeerd wordt dat therapie met telcoplanln veilig is, maar het gebruik 
ervan is alleen effectief bij infecties die naar alle waarschijnlijkheid worden 
veroorzaakt door Gram-positieve bacteriën. 
HOOFDSTUK 5. De veelbelovende resultaten die behaald werden met 
telcoplanln bij Gram-positieve infecties, vormden de basis voor de volgende 
prospectieve, gerandomiseerde studie. Ceftazidim alleen werd vergeleken met 
de combinatie van ceftazidim plus telcoplanln als empirisch regime bij 120 
granulocytopenlsche patiënten die geen duidelijke infectiehaard bij het begin 
van de koorts hadden. Gram-positieve bacteriëmie werd gevonden bij 25% 
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van de evalueerbare patiënten die behandeld waren met ceftazidlm en bij 
3 3 % van de gevallen die de combinatie hadden gekregen. In het behaalde 
resultaat werd tussen beide behandelingsgroepen geen statistisch significant 
verschil vastgesteld. Ceftazidlm alleen had succes In 49% van de gevallen, de 
combinatie in 6 3 % . Koortsduur en totaal aanta l dagen antibiotische 
behandeling waren In belde groepen vergelijkbaar. Aanhoudende koorts was 
de belangrijkste reden om de initiële behandeling te modificeren. Tien 
patiënten stierven als gevolg van de oorspronkelijke infectie, en twee 
patiënten overleden t. g. v. een nieuwe infectie. Ontwikkeling van een 
gelokaliseerde Infectie, vooral In de onderste luchtwegen, was doodsoorzaak 
bij 10 van de 12 patiënten. Een fatale afloop a. g. v. Gram-positieve Infectie 
werd bij beide groepen niet waargenomen. De patiënten die behandeld waren 
met de combinatie, vertoonden echter meer nieuwe Infecties en allergische 
reacties. Geconcludeerd wordt dat bij de onderzochte patiëntenpopulatie de 
behoefte a a n initiële behandel ing met een glycopeptide tenmins te 
twijfelachtig Is, maar dat teicoplanln een eenvoudige, betrouwbare en veilige 
behandeling biedt daar waar een Gram-positieve infectie bewezen is. 
HOOFDSTUK 6. De waarde van aminoglycoside als onderdeel van hel 
empirische regime bij granulocytopenlsche patiënten met tekenen van een 
gelokaliseerde Infectie bij het begin van de koorts, werd bestudeerd In de 
derde prospectieve, gerandomiseerde studie. De werkzaamheid en de 
toxiciteit van ceftazidlm alleen, werd vergeleken met die van ceftazidlm plus 
amikacin (1.5g/dag) bij 90 patiënten. De behandelingsgroepen waren 
vergelijkbaar voor wat betreft ernst en duur van granulocytopenic, verdeling 
v a n infec t ieca tegor ieën en voorkomen van bac t e r i ëmle . E e n 
microbiologische oorzaak van de gelokaliseerde Infecties kon slechts In 20% 
van de evalueerbare gevallen worden vastgesteld. Er was geen verschil In het 
uiteindelijke succespercentage: 53% in de monotherapiegroep en 48% In de 
combinatiegroep. De beide regimes waren even veilig. De duur van de koorts. 
de klinische symptomen, het aantal dagen van de antibiotische behandeling 
en de d u u r van granulocytopenie waren vergelijkbaar voor beide 
behandelingsgroepen. Drieënnegentig van de patiënten overleefde de Infectie. 
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Amikacin werd toegevoegd aan de ceftazldlm monotherapie bij slechts één 
patiënt. Daarom kan worden geconcludeerd dat amlnoglycoslden naar alle 
waarschijnlijkheid niet essentieel zijn bij de empirische behandeling van de 
granulocytopenlsche patiënten met een haard van Infectie aanwezig bij de 
aanvang van de koorts. 
HOOFDSTUK 7. Bij een retrospectieve analyse van 300 koortsperioden die 
zich voorgedaan hebben bij 210 patiënten, bleek in 30% van de gevallen een 
gelokaliseerde Infectie aantoonbaar te zijn bij het begin van de koorts. De 
Initiële bacteriëmle, vooral veroorzaakt door Gram-posltleve coceen, werd 
gevonden In eenderde van de episoden onafhankelijk van de aanwezigheid 
van een infectiehaard. Een latere gelokaliseerde infectie ontwikkelde zich in 
éénderde van de gevallen en betrof vooral de onderste luchtwegen, de huid 
en/of weke delen. Deze soort van infecties heeft zich significant later 
voorgedaan dan de Infecties van andere lokalisaties die meestal aanwezig 
waren bij het begin van de koorts. De ooizaak werd echter slechts vastgesteld 
In 30% van de gevallen; schimmels waren verantwoordelijk voor 56% van de 
infect ies in de onde r s t e luch twegen . Mortal i te i t v a n initieel 
gediagnostlseerde 'koorts van onbekende oorzaak', van initiële bacteriëmle 
zonder aanwezigheid van een Infectieuze haard en van Initiële haard van 
infectie, was respectivelljk 13%, 11% en 14%, terwijl de mortaliteit die 
gepaard ging met de ontwikkeling van een daarop volgende Infectieuze haard 
28% bedroeg. Longinflltraten hadden daarbij de slechtste prognose . 
HOOFDSTUK 8. Retrospectieve analyse vond plaats van de relatie tussen 
beeld van longafwijkingen op de thorax-foto, klachtenpatroon, klinische 
tekenen van luchtweginfectie en de uiteindelijke prognose van 200 
longinfll traten. Focale Infiltraten vormden, onafhankelijk van de 
ana tomische lokalisatie, de meerderheid. Hoesten was het meest 
voorkomende symptoom bij alle typen van Infiltraten; kortademigheid ging 
bijna altijd gepaard met diffuse Infiltraten. Auscultatoire afwijkingen 
werden s lechts in 2 3 % van de gevallen gevonden. De bewezen of 
waarschijnlijke oorzaak van de longafwijkingen kon in 84 gevallen worden 
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opgespoord. Schlmmellnfectles waren verantwoordelijk voor tweederde van 
de diffuse Infiltraten gediagnostlseerd tijdens granulocytopenic, terwijl alle 
Infiltraten in de niet-granulocytopenische patiënten van virale origine 
bleken te zijn. De anatomisch begrensde Infiltraten werden In meerderheid 
veroorzaakt door bacteriële Infectie. Deze relatie bleek meer uitgesproken te 
zijn bij patiënten met een normaal aantal granulocyten. Diffuse Infiltraten 
gingen gepaard met hoge mortaliteit. BIJ patiënten bij wie een verbetering 
van de radiologische afwijkingen op de eerste controle thorax-foto werd 
gezien hadden significant beter behandelingsresultaat. Progressie van het 
Initiële infiltraat beïnvloedde de prognose negatief. Concluderend: een 
radiologisch patroon in combinatie met de klinische bevindingen, zoals het 
granulocyten aantal, biedt een bruikbare aanwijzing voor een mogelijke 
oorzaak van een longlnfiltraat. Deze kennis kan van nut zijn bij de keuze 
van een therapeutisch beleid bij patiënten onder behandeling voor 
kwaadaardige bloedziekten met Infecties van de onderste luchtwegen. 
HOOFDSTUK 9. Zevenendertig van de 104 patiënten die een allogene 
beenmergtransplantatie ondergingen in de periode van 1985 tot 1989, hebben 
tijdens de vervolgperiode na de transplantatie 51 longinflltraten 
ontwikkeld. De 'conditionering' vooraf aan de transplantatie, waarbij 
anthracyclines werden toegediend, ging gepaard met een hoog aantal vroege 
Infiltraten, mucosit is en 'viridans' streptococcenbacteriëmie. De 
microbiologische oorzaak van de vroege Infiltraten was moeilijker op te 
sporen dan de oorzaak van de Infiltraten die later, na het stijgen van het 
granulocytenaantal, optraden (P<0.01). Dit kan wijzen op een nlet-
infectieuze oorzaak van de vroege longafwijkingen. Tijdens de vroege en ook 
gedurende de latere periode na de beenmertransplantatle, werden de focale 
Infiltraten vaker gezien dan de diffuse. De focale Infiltraten manifesteerden 
zich meestal met hoesten, terwijl kortademigheid het belangrijkste 
klinische symptoom was bij de diffuse Infiltraten. Het belang van hoesten als 
enig symptoom van een mogelijke infectie van de onderste luchtwegen blijkt 
vaak te zijn onderschat zodat een thorax-foto meestal pas na enige tijd werd 
gemaaktt. Bacteriële en schimmelinfecties gingen gepaard met focale 
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inflltraten, terwijl Infecties van andere origine resulteerden In een diffuus 
Inflltraat. Chronische 'graft-versus-hosf ziekte werd gedlagnostlseerd bij 
33% van de patiënten, en deze aandoening ging gepaard met een hogere 
frekwentle van longcomplicatles. Granulocytopenie, ontwikkeling van een 
Inflltraat binnen 100 dagen na de beenmergtransplantatie en een diffuus 
patroon van het inflltraat werden geïdentificeerd als onafhankelijke 
ongunst ige risicofactoren. Conclusie: kenn is van de risicofactoren, 
zorgvuldige beoordeling van het klinische klachtenpatroon en tekenen van 
luchtweginfectie, zijn bruikbaar voor het afbakenen van de groep patiënten 
die speciale aandacht verdient, ook wat het radiologisch onderzoek betreft. 
Een bepaald patroon van de longafwijkingen op de thorax-foto, samen met 
het klinische beeld, kan een nuttige aanwijzing opleveren bij het kiezen van 
een doeltreffende behandeling In deze gevallen. 
CONCLUSIE. Noch een aminoglycoside, noch een glycopeptide blijkt een 
noodzakelijk onderdeel te zijn van een empirisch regime voor de 
granulocytopenlsche patiënt met koorts. Ceftazidim alleen heeft bewezen 
tenminste even effectief te zijn als de verschillende combinaties. De 
behandel ing met monotherapie alleen ging gepaard met minder 
bijwerkingen en minder daarop volgende Infecties. Longlnflltraten waarvan 
de microbiologische aetiologie slechts In een minderheid van de gevallen kon 
worden vastgesteld, hebben een slechte prognose. Vervolg thorax-foto's aan 
de hand waarvan het radiologisch patroon in de tijd wordt beoordeeld, samen 
met het verloop van het granulocytenaantal , lijken een bruikbare 
hulpmiddel om een doeltreffend therapeutische beleid te bepalen. 
164 
DANKWOORD 
De lijst van namen van diegenen die direct of indirect betrokken waren bij 
het ontstaan van dit proeschrift kan nooit volledig zijn. Daarom wil Ik graag 
In eerste instantie allen bedanken die mij bij mijn onderzoek hebben 
gesteund, maar toch niet met naam en toenaam zullen worden genoemd. 
Ik bedank alle patiënten die aan de gerandomiseerde studies hebben 
meegedaan, de verpleging en medische staf van de afdeling bloedziekten, alle 
betrokken analisten van de afdeling medische microbiologie. Dr J Galama en 
zijn medewerkers voor de assistentie bij het beoordelen van het virologlsch 
onderzoek, het radiodiagnostisch archief voor de hulp bij het opsporen van 
de fotomappen, het secretariaat van de afdeling bloedziekten voor h u n inzet 
bij het zoeken naar de statussen en het bewaken van mijn sein. Prof Dr A. 
Verbeek en Dr J . Boezeman voor hun statistische adviezen, en Anneke de 
Pauw voor het verrichten van de audiogrammen. In het bijzonder: 
Ben de Pauw, ik ben Je dankbaar dat Je mij in dit onderwerp wist te 
Interesseren en me kon blijven motiveren. Niet altijd zijn wij even 
vriendelijk tegen elkaar geweest maar wij weten wat wij aan elkaar hebben. 
Met je feilloos gevoel voor wat wel en wat niet belangrijk is hielp je mij 
uitstekend. 
Peter Donnelly, een eerlijke wetenschapper die onaardig tegenover 
zichzelf en zo inspirerend is voor een ander, bedankt voor je eindeloze hulp 
en samenwerking. 
Frans Heystraten, Ik ben Je erkentelijk dat Je bereid was met een rustige 
glimlach duizenden röntgenfoto's met mij te bekijken en altijd tijd voor mij 
had. 
Bert Verbruggen en alle analisten van het Centraal hematologisch 
l a b o r a t o r i u m , b e d a n k t da t ju l l i e m e t zoveel gevoel voor 
verantwoordelijkheid de voortgang van het stollingsonderzoek hebben veilig 
gesteld, ook als ik er niet was. 
Tenslotte mijn gezin. Cees Smale, Petra en Bart, bedankt voor Jullie geduld 
en hulp. 
165 

CURRICULUM VITAE 
Irena Nováková werd op 29 maar t 1944 geboren te Cesky Brod, 
Tsjechoslowaklje. In 1961 behaalde zij het diploma van de 'Elfjarige' lagere 
en middelbare school (Atheneum). Vervolgens studeerde zij geneeskunde aan 
de Karls Universiteit In Praag. Na het behalen van hel artsexamen (Juni 1967) 
begon zij met de opleiding Algemene Heelkunde In het ziekenhuis in Cesky 
Brod (opleider Dr M. Sálek). In Januari 1968 stapte zij over naar de opleiding 
Interne Geneeskunde in ditzelfde ziekenhuis (opleider Dr J . Wlesner). Vanaf 
april 1969 werd de opleiding voorgezet bij de afdeling Interne Geneeskunde 
vim het St. Radboud ziekenhuis te Nijmegen (opleider Prof Dr С Majoor). In 
juni 1971 heeft zij de bevoegdheid verkregen om de geneeskunde in Nederland 
uit te oefenen. Te Leldschendam werd de eed afgelegd ten overstaan van de 
Hoofdinspecteur van de Volksgezondheid. In October 1973 volgde de 
Inschrijving In het specialistenregister en werd zij aangesteld als staflid van 
de afdeling Algemene Interne Geneeskunde van het St. Radboud ziekenhuis In 
Nijmegen. In 1975 werd zij aangesteld tot staflid van de afdeling Bloedziekten 
van hetzelfde ziekenhuis, eerst voor 0.5 later voor 0.8 aanstelling, met als 
primaire t a a k bloedstolling. In 1986 is zij betrokken geraakt bij het 
onderzoek bij granulocytopenische patiënten met koorts. In 1987 startte zij 
met het werk aan dit proefschrift. 
167 

Stellingen behorende bij het proeschrift: 
DIAGNOSTIC AND THERAPEUTIC 
ASPECTS OF INFECTION IN THE 
GRANULOCYTOPENIC PATIENT 
I. R O. Nováková 
1. Goede behandel ing van granulocytopenische pa t iën ten met 
persisterende koorts is alleen optimaal in een team-verband, waarbij 
hematoloog en/of oncoloog bijgestaan wordt door een empatische 
microbioloog, radioloog en longarts. 
2. Blinde modificatie van het reeds ingestelde antlmicrobiële regime met 
een breed spectrum dient vaker als ondersteuning van een onzekere 
behandelaar dan als een doeltreffende behandeling van de patient. 
3. Behandeling met meer dan één breed spectrum antibioticum verhoogt 
de kans op superinfectie, die vaak door schimmels en gisten wordt 
veroorzaakt. 
4. Telcoplanin is bij de neutropenische patient een effectief en veilig 
alternatief voor vancomyclne in si tuaties waar een glycopeptide 
geïndiceerd is. 
5. De wetenschap dat vooruitzien onmogelijk is zonder een goede kennis 
van het verleden, zou ertoe moeten bijdragen dal de onderwaardering 
van retrospectieve analyse ten opzichte van prospectieve studies moet 
worden opgewaardeerd. 
6. Het maken van een thorax foto is een onontbeerlijk onderdeel van het 
onderzoek bij een granulocytopenische patient, die koorts heeft. 
Bovendien neemt de waarde toe, indien een vergelijking mogelijk is met 
foto's die ervoor en ema zijn gemaakt. 
7. Longlnflltraten die ons taan tijdens de eerste 14 dagen na de 
beenmergtransplantatie zijn meestal niet van Infectleuze origine, maar 
een uiting van weefselbeschadiging door chemotherapie, radiotherapie 
of bloedingen en kunnen worden verergerd door een onzorgvuldig 
vochtbeleid. 
8. Verlaging van afweer en vitaliteit kunnen bij mensen en bomen tot 
vergelijkbare bedreigende gevolgen leiden: schimmellnfecties en padde-
stoelengroel. 
9. Hemofilie is geen ziekte, maar een afwijking. Mensen die met h u n 
hemofilie moeten leren omgaan zijn vaak goed op de hoogte van de aard 
van hun afwijking en moeten daarom door de behandelende arts als een 
gelijkwaardige gesprekspartner worden beschouwd.. 
10. Het wetenschappelijk potentieel In een land als Tsjecho-Slowaklje is 
hoog, al ontbreken de middelen. Een goede wetenschappelijke 
uitwisseling zou dat land in enkele jaren op het huidige westerse niveau 
brengen. 
11. Men 1ère niet alleen begrijpen, doch ook het begrepene uitspreken. 
Comentos 
12. Een criticus is een man zonder benen die les geeft in hardlopen. 
Channlng Pollock 
13. Dertiende stelling: 
Carpe dlem (Pluk de dag). 
Horaüus 
Nijmegen, 26 Januari 1993 
Irena Nováková 
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